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Supervisor:  Eric V. Anslyn 
 
Differential arrays, composed of receptors that are capable of generating unique 
patterns of responses, have been shown to be useful for discrimination of molecular 
analytes. Herein, differential arrays have been developed and utilized for the 
discrimination of small molecule and multivalent biological analytes using cross-reactive 
receptors. A variety of carboxylate-binding guanidinium-based receptors were tested for 
their ability to discriminate carboxylate enantiomers. Lanthanide complexes showed the 
most promising enantiodifferentiation. A dynamic receptor for multivalent biological 
analytes was developed using self-assembling components designed to target cancer cell 
lines in a cross-reactive manner. Using this differential array, cancer cell lines of different 
tissue origin were classified using principal component analysis. The receptors in the 
array responded to targets as hypothesized but also behaved in a cross-reactive manner 
that allowed for analyte differentiation. The classification response of the array was 
reproducible. Boronic acid receptors and receptor arrays were also developed for 
discrimination of cell surface glycans. In this work, the success of cross-reactive 
receptors with designed components in differential sensing for small molecules as well as 
complex multivalent analytes is demonstrated.  
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Chapter 1: Small Molecule Sensing 
1.1 INTRODUCTION  
In an effort to understand the natural world from the perspective of atoms and 
molecules, scientists have developed a variety of techniques to separate, identify, and 
quantify chemicals. Wet laboratory and instrumental techniques exist for both qualitative 
analysis to identify chemical components and quantitative analysis to ascertain the 
amount of a chemical component. These techniques either use direct determination of a 
chemical via its physical properties, such as its absorbance of light using UV/visible 
spectroscopy, or transformation of a chemical to indicate its presence and/or amount, 
such as oxidation using Tollens’ reagent in the silver mirror test for aldehydes. 
As indicated above, the interaction of molecules with one another is important to 
qualifying and quantifying a particular chemical. Beyond such analysis, chemists also 
strive to understand the manner in which molecules interact with one another in order to 
manipulate those interactions to some end, such as synthesis of new molecules via the 
creation of covalent bonds. Non-covalent interactions such as ion pairing, dipole-dipole, 
dipole-induced dipole, hydrogen bonding (H-bonding), van der Waals and London 
dispersion forces, pi-interactions, and hydrophobic interactions, as well as reversible 
covalent bonds are important to molecular recognition.1 Designed receptors often 
combine several of these forces for the detection of molecular analytes. 
1.1.1 Designed Receptors for Small Molecules 
Inspired by nature, researchers have designed synthetic receptors based on 
molecular recognition in biological systems. In 1894, Emil Fischer introduced the “Lock-
and-Key” model to describe enzyme-ligand interactions2: 
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I would like to say that enzyme and glucoside have to fit together like lock and 
key in order to exert a chemical effect on each other. 
He later expounded: 
The geometrical structure exerts such a profound influence on the playing of the 
chemical affinities, that it appeared legitimate to me to compare the interacting 
molecules with key and lock. 
This had led to the hypothesis, that there must be a similarity in the molecular 
configuration between the enzymes and their object of attack, if reaction is to take 
place. To make this thought more perspicuous, I have used the picture of lock and 
key. 
Enzymes interact with substrates with high specificity and selectivity; in Fischer’s 
analogy, an enzyme behaves as a lock that will only fit a particular ligand key that is 
complementary to the lock’s structure.  
Artificial receptors for molecular recognition, also known as hosts, can be tailored 
to particular target analytes, also known as guests, using the lock-and-key principle. Such 
hosts are designed and synthesized to possess complementary structures to a particular 
target guest in order to bind with high specificity and selectivity. Complementarity in 
“geometrical structure” and similarity in “molecular configuration” are the molecular 
features of the host that allow for attractive, reversible interactions with the guest, and a 
researcher can manipulate such interactions through host structure design. 
Using molecular recognition as an analytical technique to identify or quantify an 
analyte requires that the host/guest interaction results in a signal to indicate that binding 
between the species has occurred. When binding results in a measurable change to the 
physical properties of one or both binding partners, transduction of the binding event can 
be achieved using spectroscopic, electrochemical, or calorimetric techniques. Signal 
transduction is achieved by observing changes to the portions of the host or guest directly 
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involved in recognition or by synthetically appending the host structure with a component 
that can generate an optical or electrochemical signal.  
For example, shifts in the ppm values of nuclear magnetic resonance (NMR) 
signals due to changes in the electronic environment upon molecular interaction can be 
used as a direct signal of a binding event. Furthermore, identification of the atoms 
involved in a binding interaction can be determined from the structural information 
provided by the NMR spectrum. A recent report by RoyChowdhury et al. explored the 
anion binding properties of indole- and urea-based receptors of different cleft size (Figure 
1.1).3 Titration of selected monoanions with the indole receptor monitored by 1H-NMR 
led to broadening and downfield shifts of the aromatic and aliphatic -NH protons. This 
was explained by anion recognition through H-bonding, resulting in a change of electron 
distribution of the bound species and the observed proton shifts. In contrast to the indole 
receptor, the urea-based receptor showed no signal response to acetate by 1H-NMR. 
Selectivity of the receptors for different anions can be explained by differences in 
receptor design that affect receptor shape and size, leading to different H-bonding 
interactions.  
 
Figure 1.1 Two anion binding receptors of different cleft sizes from RoyChowdhury et al. 
and their binding of different anions through H-bonding.3 
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Isothermal titration calorimetry (ITC) is another technique for direct observation 
of a binding event, but it does not give information about atom-level interactions. Instead, 
the thermodynamic driving forces for binding can be determined by measurement of heat 
changes, expressed as ΔH enthalpy values, upon titration of binding partners. These data 
are iteratively fit to give a binding stoichiometry and equilibrium association constant, 
Kass, from which the entropy of the interaction, ΔS, can be calculated using the Gibb’s 
free energy equation (Equation 1.1): 
ΔG = ΔH – TΔS    (Equation 1.1) 
When a binding interaction cannot be directly transduced into an observable 
signal, it is necessary to append a molecule to the host that is capable of generating a 
response upon the binding event. The addition of chromophores, fluorophores, and 
electrochemically sensitive groups to hosts give signals that can be modulated upon the 
binding interaction, resulting in transduction of the binding event. Fluorogenic tripodal 
anion receptors based on 1,3,5-triethylbenzene substituted with pyrrole and thiourea 
anion-binding groups have been reported by Anzenbacher et al. (Figure 1.2).4 These 
receptors are modified with fluorophores, including fluorescein (1.2c) and naphthalimide 
(1.2b and 1.3c), and exhibit strong fluorescence in the presence of anions. The 
fluorescence turn-on occurs in response to the binding of anions in the cavity formed by 
the alternately arranged hydrogen-bond donor arms and serves as a reporter of the 
binding event, although the fluorophore is not directly involved in anion recognition. The 
higher affinity for C3-symmetrical anions, such as phosphonate and phosphate, is likely 
due to the bowl-shaped design of the receptor cavity and makes these fluorophore-
appended receptors useful for optical signaling of the hydrolysis products of sarin nerve 
gas.  
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Figure 1.2 Tripodal receptors derived from 1,3,5-triethylbenzene and appended with 
fluorogenic groups for anion detection, prepared by Anzenbacher et al.4 
1.1.1.1 Synthetic Receptors for Anion Sensing 
Anions are important targets for molecular sensing owing to their prominence in 
biological functions that depend on, for example, anion transport;5 they are also found in 
industrial processes and are present in the environment as pollutants.6 While abiotic 
sensors for cationic analytes have been well developed in the past four decades, the 
development of analogous anion sensors was slow after first being introduced in the late 
1960s.7 This disparity is due to the greater difficulty of molecular recognition of anions, 
compared to cations and neutral molecules, due to their lower charge density, diverse 
geometries and charge delocalized structures, and large negative free energies of 
solvation.8,9 Challenged by such difficulty, research in anion sensing has grown, and a 
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wide variety of receptor functionalities, for example pyrrole-,8 urea-,10 and guanidinium-
based11  ligands, have been published. 
Pyrrole contains a single H-bond donor, but incorporation of this motif into a 
macrocycle, such as calix[n]pyrrole or porphyrin, allows for arrangement of multiple H-
bond donors in a three-dimensional structure that is favorable for anion binding.12 
Acyclic receptors using pyrrole have been synthesized that show anion binding 
selectivity. Gale et al. prepared 2,5-bis-amidopyrroles that show selectivity for oxoanions 
and that have higher affinity than the monoamido analogs. All of the hydrogen bond 
donor groups in the diamidopyrroles are involved in oxoanion binding (Figure 1.3).13  
 
 
Figure 1.3 A complex of a 2,5-bis-amidopyrrole with benzoate adapted from the crystal 
structure published by Gale et al.13 This structure illustrates the contribution 
of all three H-bond donors in the receptor in complex formation. 
Urea groups can form strong hydrogen-bond complexes with oxoanions. Amides 
in proteins assist in formation of tertiary structures by interactions between N-H and C=O 
groups. Urea, which contains a second N-H group bonded to an amide carbonyl, acts as a 
H-bond donor when neutral, and the adjacent N-H functionality provides directional and 
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chelating properties for anion coordination.14 Substitution of the carbonyl oxygen with 
sulfur weakens the N-H bond and increases its H-bond donating ability. Martinez-Máñez 
et al. synthesized colorimetric sensors containing H-bond donating groups appended to 
an azodye.14-15 Of the amide, carbamate, urea, and thiourea derivatives, only the latter 
two were able to bind oxoanions significantly, presumably due to the better anion 
coordinating properties of urea. 
1.1.1.2 Receptors for Enantiomeric Discrimination 
The ability to discriminate enantiomers is an important area of research, 
especially in drug development where one enantiomer of a drug can have a positive effect 
while the opposite enantiomer can be detrimental (e.g. Thalidomide). Enantiomers share 
the same properties unless they are subjected to an asymmetric environment; as a result, 
synthetic receptors capable of differentiating chiral molecules are themselves chiral. 
Enantiodifferentiation with chiral receptors occurs when diastereomeric complexes of 
chiral receptor and chiral analyte have different stabilities.16 
Chiral receptors have been developed with structures that span a variety of 
functional groups and target different types of chiral anions. Chromatography and NMR 
spectroscopy have been widely adopted to evaluate the ability of a particular receptor to 
resolve enantiomers. Axially chiral enantiomers (M)-1.5 and (P)-1.5 can be discriminated 
by 1H-NMR spectroscopy in D2O using β- or γ-cyclodextrin.17 (Figure 1.4) The 
enantiomers of 1.5 can be distinguished by the splitting of the proton signals upon the 
addition of cyclodextrin, and the signals that correspond to the (M)-enantiomer are 
shifted farther downfield. The association constants for (M)-1.5 with both β- and γ-
cyclodextrin are higher than those of (P)-1.5 because complexation with (P)-1.5 results in 
an enthalpically unfavorable interaction of one carboxylate with the cavity of the 
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cyclodextrin, while complexation of (M)-1.5 leaves both carboxylates solvent-exposed. 
For β-cyclodextrin, the differences in the free energy changes of the diastereomeric 
complexes (ΔΔG) is 5.2 kJ/mol. 
 
 
Figure 1.4 Helical dicarboxylate enantiomers that can be discriminated with 
cyclodextrins through the use of NMR, from reference 17. 
Colorimetric techniques for differentiation of chiral analytes are gaining 
popularity. For example, Zhu et al. prepared a chiral boronic acid receptor for the 
differentiation of enantiomers of α-hydroxy acids.18 Using absorbance spectroscopy, host 
(R,R)-1.6 displayed a preference for complexation with D-phenyllactic acid via reversible 
covalent boronate ester formation, while the (S,S)-enantiomer had the opposite selectivity 
(Figure 1.5). 
 
Figure 1.5 Boronic acid-based receptors for enantiodifferentiation of α-hydroxy acids, 
prepared by Zhu et al.18 
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1.1.2 Array Sensing for Small Molecules 
1.1.2.1 Differential Arrays 
Although biological systems use highly specific interactions for recognition, 
differential sensing is inspired by another type of sensing motif found in nature: 
biological recognition of analytes by receptors in the nose and tongue. The mammalian 
senses of taste and smell are produced by receptors that are sensitive to classes of 
analytes. Differentials arrays utilize cross-reactive receptors, often biased towards a class 
of analytes, that do not necessarily require specificity or high affinity.19 Instead, analytes 
can be discriminated by their diagnostic patterns of interaction with an array of receptors 
of moderate affinity, where each receptor responds to each analyte to a different degree.20 
Therefore, the fingerprint that results is not necessarily a response of specific recognition 
interactions between host and guest.19, 21 
Array sensing is a powerful tool for analyte discrimination, and as such, a variety 
of chemical noses and tongues have been developed using electrochemical and optical 
responses for vapor- and solution-based analytes.21 
1.1.2.2 Indicator Displacement Assays 
Popularized by Anslyn et al. in 2001,22 indicator displacement assays (IDAs) are 
used for colorimetric and/or fluorometric sensing by binding of a pH or solvatochromatic 
indicator to a receptor through reversible interactions, causing the indicator to change 
color.23 The indicator is displaced upon addition of an analyte, which competes for the 
binding site on the receptor, leading to a UV/Vis absorption or fluorescence signal 
change. Because synthesis is not required to attach the chromophore to the receptor, 
indicators can easily be screened and stoichiometrically adjusted to improve the optical 
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signal, giving IDAs an advantage over sensors that use a non-reversibly attached 
chromophore.  
Through the use of an IDA, Metzger and Anslyn developed a chemosensor 
specific for citrate in highly competitive media.24 A binding constant for the tripodal 
guanidinium-based receptor with citrate was determined to be 3 x 105 M-1 by indicator 
displacement in aqueous methanol using a UV/Visible titration. The absorbance intensity 
from 5-carboxyfluorescein, which was electrostatically bound to the receptor, decreased 
upon addition of citrate, During both titration of host into indicator and displacement of 
indicator with citrate an isosbestic point was observed, which indicates that two 
absorbing species were present. This receptor-indicator pair was used to determine citrate 
concentrations in complex mixtures like sports drinks, sodas, and juices. 
1.1.2.3 Pattern-based enantiodifferentiation 
Mammalian sensory systems for taste and smell are based on proteins composed 
from chiral amino acids, specifically the L-enantiomers. These receptors are thus capable 
of enantiodifferentiation, which is in fact an important aspect of olfaction and gustation. 
For example, enantiomers of carvone exhibit different odor qualities, where (+)-carvone 
smells of caraway, and (-)-carvone smells of spearmint.25 However, human olfaction 
exhibits low chiral specificity.26 Many D-amino acids are reported to taste sweet, and in 
2002 Zuker et al. showed that a mammalian taste-specific receptor, T1R2+3, was 
responsive to D-amino acids but did not respond to the standard L-enantiomers.27 
Differential arrays inspired by mammalian gustation and olfaction have been 
combined with IDAs for pattern-based chiral differentiation28  and enantiomeric excess 
determination.29 Shabbir et al. developed an array of three chiral boronic acids and three 
pH indicators that was able to generate patterns to discriminate identity, enantiomeric 
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excess (ee), and concentration of structurally similar chiral threo diols.30 The use of IDAs 
in enantiodifferentiation is based on the displacement of the indicator being 
enantioselective.18 Because the indicator and analyte compete for a binding site on the 
receptor, differences in affinities of chiral analytes for chiral receptors lead to different 
extents of indicator displacement, which can manifest as distinct optical signals for the 
enantiomers. For threo diol enantiomers, Shabbir et al. used Principal Component 
Analysis (PCA) and an Artificial Neural Network (ANN) as the pattern recognition 
protocols to convert the absorbance values from the array to diagnostic patterns for 
identity, ee, and concentration discrimination.30 
 
1.2 CHIRAL CARBOXYLATE SENSING 
1.2.1 Chiral Carboxylate Sensors 
Many chiral carboxylate sensors can be found in the literature; such hosts utilize 
ureas,31 diamines,32 amino acids.32c, 33 and transition metals,31, 34 incorporated into chiral 
molecules as recognition units for chiral amino acids and chiral aromatic carboxylates. 
However, differentiation of other types of chiral carboxylates is still underdeveloped.35 
Sessler et al. used ITC and 1H-NMR to show differential binding of enantiomers 
of 2-phenylbutyrate to enantiomerically pure calix[4]pyrrole appended with an optically 
active BINOL group. The (S)-receptor exhibited a preference for the (S)-carboxylate 
manifested as a ~10 times higher association constant in MeCN.36  
Joyce et al. reported the formation of enantiomeric complexes with an achiral 
copper(II) host upon chiral carboxylate coordination.37 The induced helicity from 
carboxylate binding generated an exciton signal that was observable by circular 
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dichroism spectroscopy (CD). The resulting enantiospecific CD spectra were used to 
identify and discriminate between six pairs of enantiomeric α-chiral carboxylates. 
1.2.2 Guanidinium Groups for Carboxylate Sensing 
In particular, the guanidinium group has emerged as a successful abiotic sensor 
for oxoanions, inspired by biogenic examples of carboxylate, phosphate, and sulfate 
binding by the amino acid arginine, which contains a guanidinium group in its side chain 
(Figure 1.6).15  
 
Figure 1.6 The amino acid arginine and its possible interactions with oxoanions 
The side chain of arginine is used for oxoanion recognition in proteins, enzymes, and 
antibodies, and contributes to protein tertiary structure by formation of salt bridges with 
carboxylates.35 The guanidinium group binds oxoanions through an ionic hydrogen bond, 
which is facilitated by three planar nitrogens that share a positive charge and remain 
protonated over a large pH range (pKa 12-13). Arginine is able to complement the 
bidentate structure of oxoanions through two possible binding modes involving four 
hydrogen bonds (Figure 1.6). This interaction is strong in hydrophobic pockets where 
recognition commonly occurs in biological systems; however, most synthetic receptors 
are designed to work in polar solvents where complexation competes with solvation. 
Therefore, receptors must be designed to provide favorable interactions that outweigh the 
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free energies of solvation of both binding partners. Such affinity has been achieved 
through structural changes to the receptor that increase non-covalent interactions like 
coulombic attraction and H-bonding. Carsten Schmuck designed a receptor for 
carboxylates in aqueous solvents by adding pyrrole and amide functionality to the 
guanidinium group for additional H-bond donation, improving carboxylate binding over 
100-fold compared to guanidinium chloride.38 
Incorporation of the guanidinium functionality into a bicyclo[4.4.0]decaline 
structure increases its solubility in apolar solvents, where higher association constants are 
observed due to greater H-bonding.35 The bicyclic structure forces the syn conformation, 
allowing a robust donor/donor-acceptor/acceptor (DD-AA) interaction (Figure 1.7). 
Schmidtchen et al. reported the first bicyclic guanidinium receptor in 1988, observing 
Kdiss=7×10-6 M for allyl substituted guanidinium and the tetrabutylammonium (TBA) salt 
of p-nitrobenzoate in CDCl3.39 Modifications to the guanidinium anchor groups that 
introduced charge neutrality40,41 and additional hydrogen bond donors42 were 
hypothesized to improve oxoanion binding through increased enthalpic attraction. 
Surprisingly, ITC studies showed that more favorable association constants for oxoanions 
were due to increased entropies of association, arising from a variety of distinct anion 
binding modes.41-42  
 
Figure 1.7 The DD-AA arrangement in the syn-conformation of bicycloguanidinium 
N
N
NR1 R2
O O
R3
H H
 14 
The introduction of stereogenic centers to the bicyclic structure can impart the 
molecule with C2 symmetry and allows for chiral oxoanion recognition through binding 
of guests in an asymmetric environment.35 Enantiorecognition studies using this structure 
have focused on chiral carboxylate anions; the first of such receptors extracted N-
protected sodium tryptophan salts from water by binding the C-terminus through ionic 
hydrogen bonding at the guanidinium group while naphthoyl side arms engaged in π-
stacking.43 Addition of a crown ether as an anchor group for ammonium binding 
expanded the receptor’s utility to selective extraction of D- or L-enantiomers of 
phenylalanine, tryptophan, and valine using the (S,S)- and (R,R)-receptors respectively44. 
Although Schmidtchen was able to observe diastereoisomeric complexes of racemic 
carboxylates and a bicyclic guanidinium by 1H-NMR,45 ITC studies showed no 
difference in association constants for α-chiral carboxylate enantiomers until the host was 
incorporated into a macrocycle, where restricting the conformational space of the 
receptor leads to geometrically unique binding modes for enantiomers and 
enantiodifferentiation is entropy driven (Figure 1.8).46,47  
Figure 1.8 Adapted from Jadhav and Schmidtchen: enantioselection occurs only for the 
macrocycle.48 
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1.3 BIPYRIDYL-FUNCTIONALIZED BICYCLOGUANIDINIUM COMPOUNDS FOR CHIRAL 
CARBOXYLATE SENSING  
This research aimed to develop a colorimetric assay for the detection of chiral 
carboxylate anions through the use of an IDA. The guanidinium receptor used in this 
research for α-chiral carboxylate sensing has the bicyclic guanidinium core 
functionalized with isoleucine arms capped with bipyridyl (BIPY) units (Figure 1.9).  
 
 
Scheme 1.1 The bicycloguanidinium group containing amino acid arms capped with 
BIPY units (1.1); the receptor complexed with copper (1.1:Cu(II)); 
binding of a chiral α-carboxylate by 1.1:Cu(II) (1.2). 
Collins49 synthesized 1.1 as the chloride salt by first attaching the isoleucine residues to 
the bicyclic core and then adding the BIPY groups. The isoleucine groups introduce 
additional hydrogen-bond donor functionality and act as a chiral spacer, while the BIPY 
groups will chelate copper(II) in a 2:1 BIPY:Cu(II) complex.50 Complexation by copper 
ensures that the amino acid arms are conformationally locked around the binding site, 
creating a sufficiently restricted environment for enantioselection. The IDA used in this 
research thus consists of a bicyclic guanidinium receptor, Cu(II) chloride, and a UV/Vis 
indicator Alizarin Red S or Pyrocatechol Violet.  
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1.3.1 Receptor Assembly with Copper (II) 
In order to investigate the complexation of Cu(II) with 1.1, a titration of 1.1 with 
CuCl2 was undertaken. An increase in the d-to-d copper transitions was observed, with 
λmax shifting from 715 nm to 775 nm over the course of the titration (Figure 1.9).  
 
 
Figure 1.9 Titration of 100mM CuCl2 in 90%DMSO/H2O (v/v) with 10mM HEPES into 
1mM 1.1 in the same buffer. 
A control titration of CuCl2 into buffer showed an increase of the d-to-d copper 
transitions at 800 nm (Figure 1.10).  
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Figure 1.10 Control Titration of 100 mM CuCl2 in 90%DMSO/H2O (v/v) with 10mM 
HEPES into the same buffer 
The control titration data at 775 nm was fit to a polynomial and then the calculated value 
at the corresponding equivalents was subtracted from the host titration data at 775 nm. 
Although the resulting absorbance intensity was very weak, a binding isotherm was 
obtained, and repetition of the experiment gave consistent results (Figure 1.11).   
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Figure 1.11 Titration of 100 mM CuCl2 in 90% DMSO/H2O (v/v) with 10 mM HEPES 
into 1mM 1.1 in the same buffer, subtracted from control data at 775 nm. 
The data indicate that the copper sequentially formed 1:1 and 2:1 complexes with the 
host. Considering the requirement of host design that copper complexation would pre-
organize the host into a macrocycle, one equivalent of CuCl2 was used in further 
experiments with indicator and carboxylate ions. 
1.3.2 Receptor Association with Indicators and Chiral Carboxylates 
1.3.2.1 Studies with Pyrocatechol Violet 
As another control titration, aliquots of CuCl2 were added to a solution of 
pyrocatechol violet (PV) to examine the interaction of indicator alone with Cu(II). 
Initially, the free indicator peak at 435 nm decreased, while an increase at 280 nm was 
observed (Figure 1.12).  
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Figure 1.12 Titration of 1.5 mM CuCl2 in 90%DMSO/H2O (v/v) with 10 mM HEPES 
into 20 μM Pyrocatechol Violet in the same buffer. 
After addition of 0.6 equivalents of CuCl2, a peak at 675 nm appeared, and the 
solution changed colors from yellow to green.  Over the course of the titration, the peak 
at 675 nm began to decrease, and a peak at 610 nm appeared. Repeated measurements 
after addition of 3.75 equivalents of CuCl2 indicated that the system continued changing 
over time. The absorbance values at 675 nm and 440 nm were therefore monitored at 
one-minute intervals over a period of 15 minutes and 30 minutes, respectively, after 
addition of one equivalent of CuCl2 to a solution of PV. After these time intervals, the 
absorbance intensities at both wavelengths continued to decrease and did not stop 
changing over a period of several days. From these studies it was determined that PV is 
not an adequate indicator for the conditions used in this system. 
An indicator uptake assay was initially employed in lieu of an IDA to overcome 
the kinetic instability of PV in the presence of Cu(II). Addition of excess PV to an 
equimolar solution of 1.1:Cu(II) and an achiral oxoanion, phosphate or acetate, resulted 
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in the appearance of two peaks: the free indicator at 435 nm and the indicator-1.1:Cu(II) 
complex at 675 nm (Figure 1.13).  
 
 
Figure 1.13 Addition of Excess PV (20 μM) in 90% DMSO/H2O (v/v) with 10 mM 
HEPES to 75 μM oxoanion (phosphate or acetate) pre-complexed with 75 
μM 1.1:Cu(II) in the same buffer. 
Over 12 hours, both peaks diminished in intensity, with the most dramatic decrease for 
the peak at 675 nm. There was no appreciable difference in the spectral behavior of 
acetate versus phosphate upon addition of PV, indicating the receptor cannot differentiate 
between different oxoanion types with the same charge. 
Following the same approach, an α-chiral carboxylate, (R)-or (S)-2-
phenylbutyrate, was complexed to 1.1:Cu(II) and an excess of PV was then added. 
Again, two peaks at 435 nm and 675 nm appeared, corresponding to the free indicator 
and the indicator-1.1:Cu(II) complex respectively (Figure 1.14).  
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Figure 1.14 Addition of excess PV in 90% DMSO/H2O (v/v) with 10 mM HEPES to 1.5 
mM (R)- or (S)-2-phenylbutyrate pre-complexed with 1.5 μM 1.1:Cu(II) in 
the same buffer. 
Initial results showed that 1.1:Cu(II) gave a larger signal change for the (S)-2-
phenylbutyrate enantiomer. Because the receptor was only synthesized as the (S,S)-
enantiomer, cross reactivity of the receptor was not studied. An IDA was therefore 
undertaken to confirm the selectivity of the receptor for (S)-2-phenylbutyrate. 
1.3.2.2 Studies with Alizarin Red S 
Due to the kinetic instability of PV in this system an indicator screening was 
undertaken; Alizarin Red S (ARS) gave a signal change when bound to the receptor that 
took only one hour to reach equilibrium and was chosen for further studies. Titration of 
1.1:Cu(II) into a constant concentration of ARS showed a decrease of the free indicator 
at 435 nm and an increase in the host-bound indicator at 530 nm, with an isosbestic point 
at 460 nm (Figure 1.15 inset).  
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Figure 1.15 Titration of 1.1:Cu(II) (0-750 μM, blue diamond) in 90% DMSO/H2O (v/v) 
with 10 mM HEPES into 250 μM Alizarin Red S in the same buffer. 
Although a 1:1 binding curve could not be fit to the data, ARS was estimated to be 
ideally bound at 1 equivalent of 1.1:Cu(II) (Figure 1.15, blue diamond). Titration of 
ARS with a solution of CuCl2 without 1.1 showed ideal ARS binding at 0.5 equivalents 
of CuCl2, indicating that the presence of the receptor influenced indicator binding (Figure 
1.15, red square).  
Addition of (R)- or (S)-phenylbutyrate into 1.1:Cu(II) complexed with one 
equivalent of ARS gave a decrease in the indicator-1.1:Cu(II) absorbance at 535 nm 
(Figure 1.16). No increase in the free indicator peak was observed, even after adding 25 
equivalents of anion. No appreciable difference in absorbance at 535 nm for (R)- or (S)-
phenylbutyrate was observed (Figure 1.17).  
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Figure 1.16 Titration of 35.5 mM (R)-2-phenylbutyrate in 90%DMSO/H2O (v/v) with 10 
mM HEPES into ARS-1.1:Cu(II) in the same buffer. 
 
 
Figure 1.17 Titration of 35.5mM (R)- and (S)-2-phenylbutyrate in 90% DMSO/H2O (v/v) 
with 10 mM HEPES into ARS-1.1:Cu(II) in the same buffer at 535 nm. 
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The same titration with (R)- or (S)-bromopropanoate also showed a decrease in 
the 535 nm peak, while a small increase at 435 nm and an isosbestic point at 460 nm 
were also observed (Figure 1.18). Again, no appreciable difference between absorbance 
values at 535 nm for the (R)- and (S)-enantiomers was observed (Figure 1.19).  
 
 
Figure 1.18 Titration of 25.5 mM (R)-2-bromopropionate in 90% DMSO/H2O with 10 
mM HEPES into ARS-1.1:Cu(II) in the same buffer. 
 25 
 
Figure 1.19 Titration of 25.5 mM (R)- and (S)-2-bromopropionate in 90% DMSO/H2O 
with 10 mM HEPES into ARS-1.1:Cu(II) in the same buffer at 535 nm. 
These data show that the receptor does not exhibit enantioselectivity for α-chiral 
carboxylates. However, the receptor did show a difference in absorbance intensity with 
ARS for the two types of α-chiral carboxylates tested, 2-phenylbutyrate and 2-
bromopropionate.  
 
1.4 LUMINESCENT EUROPIUM COMPLEXES FOR CHIRAL ANION SENSING 
1.4.1 Lanthanide Complexes 
Europium is a member of the lanthanide series of period six elements in the 
periodic table. Lanthanide ions can exhibit luminescence that is enhanced upon 
coordination with organic ligands.51 The emission lifetimes for such complexes can range 
from micro- to milliseconds, have characteristically large Stokes shifts, and sharp 
emission peaks of ~10 nm.52 Due to long emission wavelengths and long emission 
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lifetimes, the use of lanthanides in assays helps eliminate background noise from 
fluorescence of an analyte or media through the use of time-resolved spectroscopy. 
All lanthanides form lanthanide(III) ions, which are usually octa- or 
nonacoordinate. They are hard ions and thus form more stable complexes with oxygen 
donors compared to nitrogen.51 Water and hydroxide strongly coordinate with Ln3+, so in 
aqueous solution, only negatively charged donors or multidentate neutral donors bind 
strongly.  
Lanthanides electronic transitions occur in the 4f shell, which is highly shielded, 
resulting in narrow bands for f-f transitions.53 Transitions between f orbitals are Laport-
forbidden, resulting in low absorption coefficients and long radiative lifetimes. 
Population of lanthanide excited states can be achieved by sensitization using antenna 
ligands.54 Excitation of ligands bound to the metal results in energy transfer to the 
lanthanide center. The sensitized responses to ligands occur in the 5D4 à 7F5 and 7F4 
transitions for Tb3+ and 5D0 à 7F2 and 7F4 for Eu3+ due to the electric dipole character of 
the transitions.51 The 5D0 à 7F2 europium transition is hypersensitive to ligand 
environment because of the magnetic dipole change. 
Lanthanide(III) complexes of europium and terbium have been prepared with 
peptides,55 beta-diketones,52 pyridyl bis-amidothioureas,56 and bipyridine ligands.57 H-
bond donating groups have been used for sensing anions with lanthanides, either by 
interaction with the metal ion to directly perturb its emission or at the ligand antennae 
giving rise to modulated sensitization and thus changing the population of the metal 
excited state.56 
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1.4.2 Chiral Lanthanide Complexes 
Chiral luminescent europium complexes have been prepared using chiral 
pyridylamide ligands derived from aminoethylnapthylene58 and tryptophan54 as well as 
with tris(2-pyridylmethyl)amines59. These complexes self-assemble in organic solvents 
such as methanol and acetonitrile.  Gunnlaugsson et al. found that the chirality of the 
pyridylamide ligands was transferred to the lanthanide, resulting in the Δ or Λ isomers 
(Figure 1.20).58 Yamada and coworkers tested a variety of achiral monoanions with 
chiral amine complexes and found that the anion sensitivity and selectivity varied 
depending on the lanthanide and chiral ligand used in the complex.59 Binding of anions 
induced a change in the circular dichroism spectrum indicating that the anion 
coordination influenced the arrangement of the chromophores. When an achiral ligand 
was complexed with Tb3+, binding to Cl- was favored. When the (R)-enantiomer of the 
same ligand was used, binding to NO3- was preferred. 
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Figure 1.20 (R,R)- and (S,S)-complexes of aminoethylnaphthalene derivative 1.7 with 
Europium, adapted from Gunnlaugsson et al.58 (R,R)-1.7 forms the lambda 
Λ enantiomer, while (S,S)-1.7 forms the Δ. 
To date, chiral luminescent complexes have not been employed for sensing of 
chiral anions. Instead, racemic mixtures of lanthanide complexes have been exposed to 
chiral analytes to produce a “Pfeiffer-effect” perturbation in the equilibrium of 
luminescent chiral complexes observable using circularly polarized luminescence 
(CPL).60 It is clear that anion binding, either by coordination to the metal or through 
interaction with the ligand antenna, can modulate lanthanide complex luminescence.  
Differential binding of chiral anions to chiral lanthanide complexes should therefore 
result in differential luminescence, dependent on the chirality of the anion.  
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1.4.3 Development of Chiral Luminescent Complexes with Bicycloguanidinium 
Receptors for Chiral Carboxylate Sensing 
This research aimed to develop a luminescent assay for the detection of chiral 
carboxylate anions using bicycloguanidinium compounds and europium(III). The 
guanidinium receptors used in this research have a bicyclo[4.4.0]guanidinium core 
functionalized with variable peptide sequences (Figure 1.21).49 The peptidic arms 
introduce additional H-bond donor functionality to the guanidinium and act as chelation 
units to Eu3+.  
 
Figure 1.21. The bicycloguanidinium group containing amino acid arms. 
 Complexes of bicycloguanidinium derivatives with Eu(CF3SO3) were prepared 
following the procedures of Gunnlaugsson.58 Although crystal structures could not be 
isolated, the complexes exhibited luminescence that was enhanced over that of 
Eu(CF3SO3) (Figure 1.22). To investigate the binding stoichiometry in solution, a titration 
of Guan-Gln with Eu(CF3SO3)3 was carried out in MeOH. Increasing equivalents of 
europium(III) resulted in increased emission at 617 nm until saturation of the 
luminescence signal was reached (Figure 1.23). Although the stoichiometry of the 
complex in MeOH does not appear to be straightforward, eight equivalents of Eu3+ to 
Guan-Gln were used to ensure the complex signal was saturated.  
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Figure 1.22 Luminescence for the complex obtained after reaction of Eu(CF3SO3)3 with 
Guan-Gln compared to the europium salt alone in MeOH. 
 
 
Figure 1.23 Luminescence change at 617 nm upon the addition of increasing equivalents 
of Eu(CF3SO3)3 to Guan-Gln in MeOH. [Guan-Gln] =100 μM  
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Addition of (R)- or (S)-2-phenylbutyric acid to the europium complex with Guan-
Gln resulted in an initial increase, followed by a decrease of the emission at 617 nm 
(Figure 1.24). The maximum signal intensity occurs at 0.5 equivalents for the (R)-
enantiomer but 1.0 equivalents for the (S)-enantiomer, after which the emission gradually 
decreases. The difference in signal intensity between the enantiomers remains constant 
over 1-6 equivalents of acid and then decreases from 6-12 equivalents. The decrease in 
emission intensity did not saturate, even after the addition of 13 equivalents of acid. 
 
 
Figure 1.24 Luminescence change at 617 nm upon the addition of increasing equivalents 
of (R)- or (S)-2-phenylbutyric acid to Guan-Gln complexed with 
Eu(CF3SO3)3 in MeOH. [Guan-Gln] = 1800 – 500 μM, [Eu(CF3SO3)3] = 220 
– 60 μM, [2-phenylbutyric acid] = 0 – 750 μM 
 A major concern was that the difference between enantiomers was due to solution 
pH differences as the titrations were performed in pure MeOH. For this reason, titrations 
were repeated in water buffered with 2-(N-morpholino)ethanesulfonic acid (MES) at pH 
7.4. These titrations were undertaken with EuCl3 in order to use a complimentary counter 
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ion to that in Guan-Gln. The luminescence at 617 nm increased upon the addition of Eu3+ 
to Guan-Gln, with signal saturation occurring at 0.7 – 0.8 equivalents (Figure 1.25). 
Based on this titration, the stoichiometry was determined to be 2:1 Guan-Gln:EuCl3. 
Titration of (R)- or (S)-2-phenylbutyric acid into a solution of 2:1 Guan-Gln:EuCl3 
resulted in a signal increase at 617 nm. However, saturation was not reached even after 
addition of 44 equivalents of acid. There was no significant difference between the 
luminescence behavior at 617 nm with the addition of (R)- or (S)-enantiomers (Figure 
1.26) 
 
 
Figure 1.25 Luminescence change at 617 nm upon the addition of increasing equivalents 
of EuCl3 to Guan-Gln in 10 mM MES pH = 7.4 [Guan-Gln] = 500 μM, 
[EuCl3] = 0 – 670 μM 
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Figure 1.26 Luminescence change at 617 nm upon the addition of increasing equivalents 
of (R)- or (S)-2-phenylbutyrate to EuCl3 complexed with Guan-Gln in 10 
mM MES pH = 7.4 [Guan-Gln] = 500 μM, [EuCl3] = 2 mM, [acid] = 0 – 22 
mM.  
 
1.5 CONCLUSIONS 
Incorporation of the guanidinium group into a bicyclic structure contained within 
a Cu(II)-complexed macrocycle was hypothesized to give enantioselection for α-chiral 
carboxylates. Although the receptor was preorganized to provide a sufficiently chiral 
environment for enantioselection, there was no significant difference in the receptor’s 
UV/Vis response to the tested α-chiral carboxylates when the receptor was bound to 
Alizarin Red S. Since IDAs have the advantage of reversible interactions between host 
and indicator, indicator screening was undertaken to optimize the system; however, other 
suitable indicators were not found. It is possible that the free energy difference between 
diastereomeric complexes of each enantiomer with the receptor was not significant, or 
that the indicator was not displaced upon addition of analyte. The former could be due to 
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enthalpic compensation for the expected entropic differences for enantiomer binding, or 
perhaps the receptor was not sufficiently rigid.  
Many chiral carboxylate chemosensors have been reported that use colorimetric 
or fluorogenic signaling. The use of sensitized lanthanide luminescence for carboxylate 
sensing would eliminate potential interferences in samples that may be complex mixtures. 
Complexes of Eu3+ with bicycloguanidinium compounds derived with variable peptide 
arms were observed using time-resolved fluorescence titration and the emission increased 
upon addition of carboxylates. Although the tested receptors did not display differential 
luminescence sensitization with the tested chiral carboxylates in buffer, the complexes 
did show differences for the enantiomers in MeOH; however, it is unclear if the 
differences observed in methanol arise from pH effects. Additionally, because water 
coordinates strongly to lanthanide(III) ions, it is possible that the lack of 
enantioselectivity in water is due to the weak coordination of bicycloguanidinium cations 
to Eu3+, which may minimize the free energy differences between expected 
diastereomeric complexes upon carboxylate coordination. 
 
1.6 EXPERIMENTAL 
1.6.1 Chiral Carboxylate Sensing using a Bipyridyl-Functionalized 
Bicycloguanidinium Compound 
Absorbance spectra were measured using a Beckmann Coulter DU 800 UV/Vis 
Spectrophotometer scanning at 1 nm intervals. Absorbance values for well plate 
experiments were measured using a BioTek Synergy 2 Well Plate Reader scanning at 5 
nm intervals. 
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1.6.1.1 Titration of Receptor with CuCl2 
Stock solutions of 1.1 (1 mM) and CuCl2 (100 mM) were made in 90/10 
DMSO/H2O containing 10 mM HEPES buffer. The copper solution was added in aliquots 
to a solution of 1.1, and the UV/Vis absorbance was monitored after each addition. The 
pH after the titration was monitored and stayed between 7.5-8.0. 
1.6.1.2 Titration of Pyrocatechol Violet with CuCl2 
From a 100 mM stock solution, 1.5 mM CuCl2 in 90/10 DMSO/H2O with 10 mM 
HEPES was prepared. Aliquots of this solution were added to 500 uL of 20 μM 
pyrocatechol violet in the same buffer, and the absorbance spectrum monitored. After 
measuring the spectrum from 200-1000 nm, 1 equivalent of CuCl2 was added to fresh 
pyrocatechol violet solutions, and the absorbance values at 675 nm and 430 nm were 
monitored over a period of 15 and 30 minutes respectively. 
1.6.1.3 Indicator Uptake Experiments 
Carboxylate Discrimination 
A stock solution of sodium acetate, 15 mM in 100 mM HEPES, was prepared and 
then diluted to 1.5 mM in 90/10 DMSO/H2O (10 mM HEPES). Equal amounts of this 
solution and a 1.5 mM solution of 1.1:Cu(II) were combined and diluted to make a 75 
μM solution of each in 90/10 DMSO/H2O with 10 mM HEPES. An excess of 
pyrocatechol violet was added to the 1.1:Cu(II) and acetate solution, and the UV/Vis 
absorbance was monitored over time. The above procedure was repeated for monobasic 
sodium phosphate. 
Enantioselective Discrimination of Carboxylates 
A 15 mM stock solution of either (R)- or (S)-phenylbutyric acid in 100 mM 
HEPES was diluted to 1.5 mM in 90/10 DMSO/H2O with 10 mM HEPES. One 
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equivalent of these solutions was added into a solution of 1.1:Cu(II), and the solution 
was pH-adjusted to 8.10. One equivalent of PV was then added to this mixture, and the 
UV/Vis absorbance changes for the (R)- or (S)-complexes were observed five seconds 
later.  
1.6.1.4 Titration of Receptor/CuCl2 with Alizarin Red S 
In a 384-well plate, variable amounts of 1.1:Cu(II) were added to 50 uL of 500 
μM Alizarin Red S. Each well was diluted with 90/10 DMSO/H2O containing 10mM 
HEPES, until the final concentration of Alizarin Red S was 250 μM and the 
concentration of 1.1:Cu(II) was 0-750 μM. After sitting for 1.5 hours, the absorbance 
spectrum for each well was measured. This titration was repeated for CuCl2 without 1.1. 
1.6.1.5 Indicator Displacement Experiment 
Stock solutions of (R)- or (S)-phenylbutyric acid (51 mM) and (R)- or (S)-
bromopropanoic acid (71 mM) were prepared in DMSO. These solutions were diluted by 
half with 100 mM HEPES and DMSO, such that the final solutions contained 10 mM 
HEPES and 90/10 DMSO/H2O along with the (R)- or (S)-acid. Equal concentrations of 
Alizarin Red S and 1.1:Cu(II) were added to a 384-well plate, and then the (R)- or (S)- 
acid was titrated in. Each well was diluted to the same total volume using 90/10 
DMSO/H2O 10 mM HEPES buffer, such that the concentration of ARS and 1.1:Cu(II) 
remained constant.  
1.6.2 Luminescent Europium Complexes for Chiral Anion Sensing 
Luminescence spectra were measured using a PTI QuantaMaster™Fluorimeter 
equipped with a pulsed xenon flash lamp. Scans were taken at 1 nm intervals, 16 nm slit 
widths, a 150 usec delay and integration to 500 usec, 20 shots per scan, 300 Hz, and with 
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two averages. The minimum volume of titrand, 800 uL, was added to a quartz 
fluorescence cuvette for each titration. 
MES buffer was prepared by weighing 488.27 mg MES hydrate into a 250 mL 
volumetric flask. The volumetric flask was filled ~90% with ddH2O and the pH was 
adjusted to 7.4 using saturated NaOH, after which the flask was filled to volume with 
ddH2O to give a final concentration of 10 mM MES. 
1.6.2.1 Synthesis of bicycloguanidinium complexes with Eu(CF3SO3)3 
Following the procedure reported by Gunnlaugsson et al (REF), complexes of 
Guan-Gln and Guan-Met with Eu(CF3SO3)3 were prepared using a microwave reactor. 
6.51 mg Eu(CF3SO3)3 was weighed into a microwave tube, and to this was added 44.32 
mg of Guan-Gln (7.3 equivalents). 12.66 mg Eu(CF3SO3)3 was weighed, and to this 60.43 
mg Guan-Met was added. The microwave tubes were each filled with 7.5 mL HPLC 
grade MeOH and equipped with a stir bar and a cap. The tube was heated at 70°C for 10 
minutes. Ether was added to the solutions cooled on ice, which resulted in formation of a 
white precipitate. The ether was decanted and the solutions air-dried to isolate the solids.  
1.6.2.2 Titration of Guan-Gln with Eu(CF3SO3)3 
Stock Guan-Gln was prepared by weighing 2.50 mg into a 5 mL volumetric and 
filling to volume with MeOH to give a solution of 888 μM. 25 uL of this stock was added 
to a 1 mL volumetric flask and filled to volume with MeOH  to give a 22.2 μM solution 
of Guan-Gln to be used as titrand. 
Stock Eu(CF3SO3)3 was prepared by weighing 2.10 mg into a 5 mL volumetric 
flask and filling to volume with MeOH to give a 701 μM solution. 715 uL of this stock 
was added to 25 uL of stock Guan-Gln in a 1 mL volumetric flask and then diluted to 
volume to give a titrant solution of 500 μM Eu(CF3SO3)3 with 22.2 μM Guan-Gln. 
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1.6.2.3 Titration of Guan-Gln/Eu(CF3SO3)3 complex with (R)- and (S)-2-phenylbutyric 
acid 
Stock solutions of acid were prepared by weighing 2.99 mg of (R)-2-
phenylbutyric acid and diluting with 1 mL MeOH to give a solution of 18.21 mM. 3.00 
mg of (S)-2-phenylbutyric acid was diluted with 1 mL MeOH, giving a solution of 18.27 
mM. These solutions were diluted as follows: 549 uL of 18.21 mM (R)-2-phenylbutyric 
acid was added to a 10 mL volumetric flask and diluted to volume with MeOH; 547 uL 
of 18.27 mM (S)-2-phenylbutyric acid was added to a 10 mL volumetric flask and diluted 
to volume with MeOH. 
Titrand solutions were prepared with 250 μM Eu(CF3SO3)3 with 22.2 μM Guan-
Gln. Over the course of the titration, the titrand was diluted ~4x. 
1.6.2.4 Titration of Guan-Gln with EuCl3 
To prepare the titrand, 2.41 mg of Guan-Gln was weighed into a 1 mL volumetric 
flask and filled to volume with 10 mM MES buffer, resulting in a solution of 4.28 mM 
Guan-Gln. 116.8 mL of the 4.28 mM Guan-Gln solution was transferred into a 1 mL 
volumetric flask and diluted to volume with 10 mM MES to give a 500 μM Guan-Gln 
solution. 
To prepare the titrant, a solution of 8.62 mM EuCl3 was prepared by weighing 
53.5 mg EuCl3 into a 25 mL volumetric flask. The flask was filled to volume with 10 mM 
MES buffer. To a 2 mL volumetric with 233.6 uL 4.28 μM Guan-Gln, 464 uL 8.62 mM 
EuCl3 was added. The flask was filled to volume using 10 mM MES to give a solution 
with 500 μM Guan-Gln and 2 mM EuCl3.  
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1.6.2.5 Titration of Guan-Gln/EuCl3 complex with (R)- and (S)-2-phenylbutyric acid 
 (R)-2-phenylbutyric acid (100 mM) was prepared by weighing 165.26 mg into a 
10 mL volumetric flask. The volumetric flask was filled ~90% with 10 mM MES. The 
pH was adjusted to 7.31 using saturated NaOH and 5 M HCl. Addition of NaOH beyond 
pH = 13 caused MES to precipitate, while at pH < 5 the acid was not completely soluble. 
After pH adjustment, the flask was filled to volume with 10 mM MES. 100 mM (S)-2-
phenylbutyric acid was prepared in a similar manner to the R- enantiomer by weighing 
164.82 mg into a 10 mL volumetric flask. The pH was adjusted to 7.75.  
Guan-Gln (2.61 mM) was prepared by weighing 1.47 mg into a 1 mL volumetric 
flask and diluting to volume with 10 mM MES. This solution was used to prepare a 2:1 
Guan-Gln:EuCl3 1 mM: 500 μM solution by adding 766 uL of 2.61 mM Guan-Gln and 
116 uL of 8.62 mM EuCl3 to a 2 mL volumetric flask and diluting to volume with 10 mM 
MES. This solution was diluted by a factor of two to give the titrand solution of 500 
μM:250 μM Guan-Gln:EuCl3. 
Titrant solutions were prepared by adding 398 uL of 100.38 mM (S)-2-
phenylbutyrate or 397 uL of 100.65 mM (R)-2-phenylbutyrate to a 1 mL volumetric flask 
with 500 uL of 1 mM:500 μM Guan-Gln:EuCl3 and filling to volume with 10 mM MES. 
This gave a solution of 500 μM:250 μM Guan-Gln:EuCl3 with 40 mM either (R)- or (S)-
2-phenylbutyrate. 
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Chapter 2: Introduction to Multivalent Biological Analyte Sensing 
Biological targets, such as proteins and cells, are challenging analytes owing to 
their complex structures. Protein macromolecules exhibit secondary and tertiary 
structures as well as post-translational modifications, such a glycosylation, that influence 
their function and shape. Cell surfaces contain of a variety of proteins, lipids, and 
carbohydrates, which differ in composition according to cell type.1 Cancer cells exhibit 
changes in the number and distribution of these macromolecules on their surface 
membranes compared to normal cells.2 Cell surface macromolecules use multivalent 
interactions for signaling, conformational contact between surfaces, and strong binding.3 
Analytes such as proteins and cells are currently detected by bioimaging,4 sequencing,5 
or highly selective receptors, such as antibody arrays.6 Differential arrays for multivalent 
biological analytes have emerged more recently, and such receptor arrays are also useful 
for detection and differentiation of multivalent analytes such as proteins and cells. 
 
2.1 MULTIVALENCY 
Multivalency, or polyvalency, is the simultaneous interaction of multiple binding 
units on one entity with multiple binding units on a complementary entity, where binding 
units are typically molecules.3 The number of shared, complementary interactions 
between a host and guest defines the valency of a complex,7 and a multivalent complex is 
defined when the separation of the complex requires the dissociation of at least two 
interactions between partners with multiple binding units (Figure 2.1).7  Compared to 
monovalent interactions, multivalent associations have unique thermodynamic and 
kinetic properties, resulting in advantages in molecular association compared to an 
equivalent number of monovalent interactions or a single strong monovalent interaction.  
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Figure 2.1 Illustration of the valency of complexes. A monovalent complex formed from 
a monovalent host and a monovalent guest (A) and a multivalent complex 
(trivalent) formed from a trivalent host and a trivalent guest (B). 
Multivalent receptors can also form complexes with multiple multivalent ligands 
in an intermolecular fashion, which leads to the formation of aggregates (Figure 2.2). 
After the first association between complementary units on a multivalent host and a 
multivalent guest, the probability of subsequent inter- or intramolecular binding to a 
neighboring host site depends on the effective concentration of the now tethered guest 
compared to the concentration of a second guest free in solution.7 Intermolecular binding 
is favored at high concentrations and with small, rigid entities with low directionality, 
while formation of a multivalent complex is favored at low concentrations. Receptors can 
be designed with high directionality and some flexibility in order to favor formation of 
multivalent complexes. 
A
B
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Figure 2.2 After the first association of multivalent hosts and guests, subsequent binding 
results in either intermolecular binding to form aggregates (A) or 
intramolecular binding to form a multivalent complex (B), depending on the 
effective concentration of a second ligand. 
Statistically, multivalent complex formation is more favorable than monovalent 
complex formation because there are multiple, simultaneous interactions, and as such 
multivalent interactions can be much stronger than a single monovalent one. The energy 
of association of a multivalent complex is described by its Gibbs free energy (equation 
2.1). Association of ligands and receptors to form multivalent complexes can occur with 
favorable or unfavorable enthalpic and entropic components.  The entropy and enthalpy 
can be enhanced compared to the monovalent interaction if the average multivalent 
interaction has a more negative enthalpy and more positive entropy. Rigid linkers can 
lead to spacial mismatches between multivalent receptors and ligands, which results in 
enthalpically diminished binding. Flexible linkers may lead to entropically diminished 
associations due to loss of conformational entropy upon binding; however, the 
dependence of the free energy of multivalent interactions on linker length is weak, and 
strong associations with flexible linkers have been observed, likely due to their higher 
effective concentrations.8,9 
A
B
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!∆!!"#!"#$ = ∆!!!"#$ = ∆!!!"#$ − !∆!!!"#$   (equation 2.1) 
The association for two interacting units can be represented as an affinity constant, !!""!"#", determined from the Gibbs free energy. This constant differs from the association 
constant of a multivalent interaction, referred to as avidity, which is defined by the 
average of the association constants multiplied over N interactions between N ligands and 
N receptors on two entities (equation 2.2). When !!!"#$ > !!""!"#" the multivalent 
interaction exhibits enhanced affinity over the monovalent interaction. This can be 
associated with positive, negative, or non-cooperativity.  
    (equation 2.2) 
Cooperativity (α) of multivalent ligand association can be evaluated by 
comparing the average free energy of the multivalent interactions to that of the 
monovalent interaction. If α = 1, there is no enhancement to subsequent association of a 
ligand in the multivalent complex. If α > 1, there is an enhancement. If α < 1, subsequent 
binding is thermodynamically unfavorable compared to the first association (equation 
2.3). Often the valency, N, of a complex is not known, which makes it impossible to 
determine cooperativity.3 Additionally, a multivalent interaction can be much stronger 
than a single monomeric interaction that contributes to the complex, even if the 
monomeric interactions interfere with one another (α < 1). The parameter β describes the 
enhanced affinity of a multivalent interaction compared to a monovalent one (equation 
2.4). A multivalent association will be useful if β > 1 regardless of the cooperativity. For 
such a case, !!!"#$ > !!"#" even if !!!"#$ ≤ !!!"! !. ∆!!"#!"#$ = !∆!!"#"    (equation 2.3) ! = !!!"#$!!"#"     (equation 2.4) 
Compared to monovalent interactions, the kinetics of multivalent interactions is 
advantageous for maintaining complex association. The kinetics of association, kon, for 
KNpoly = (Kavgpoly )N
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multivalent interactions is the same as that of the monovalent case. In contrast, the rate of 
dissociation, koff, depends on the stepwise dissociation of all of the interactions in the 
multivalent complex, and the complex is fully dissociated when dissociation of the 
monovalent interaction between two entities has occurred.7 If the local concentration is 
high, then partially dissociated complexes will further bind, leading to low koff. 
Heteromeric multivalency can result in greater strength and specificity than the 
equivalent monovalent interactions. This type of interaction involves a mixture of ligand-
receptor pairs of different types. Additional ligand types may increase the number of 
interactions between two multivalent entities and therefore increase the avidity of the 
interaction.3 Heteromeric multivalency is more broadly applicable than the homomeric 
analog because it gives the ability to target multivalent ligands that do not have multiple, 
closely associated identical binding sites. Monomeric proteins, for example, are 
multivalent ligands that often display a main binding site with secondary binding sites, 
such as adjacent hydrophobic pockets, which are best targeted with heteromeric 
multivalent receptors.9  
 
2.2 DESIGNED AND EVOLVED RECEPTORS FOR MULTIVALENT BIOLOGICAL ANALYTES 
Multivalent interactions are common in biological systems and come with a 
variety of functional advantages. The capability of multiple interactions allows for a 
range of signal strengths, which is more useful than a binary on/off response from a 
single interaction.3 Multiple interacting ligands on two entities allows for conformal 
contact not achievable by a single, strong interaction. This contact can also lead to 
conformational changes that act as signaling mechanisms. Cell adhesion represents a 
multivalent interaction that is regulated by dynamic adhesive contacts from adherent 
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molecules diffusely distributed over the cell surface, such as cadhedrin, immunoglobulin, 
selectin, proteoglycan, and integrin.10 Interaction of cell surfaces with multivalent 
molecules can lead to reorganization and redistribution of molecules on the cell surface.3 
Biological receptors exhibit high specificity, high affinity, and reversibility for 
their ligands as a result of evolution, lending recognition and differentiation that allow for 
the complexity of life.11 Hence, it makes good sense that biopolymers can be used to bind 
particular biological targets in lieu of small molecules, taking advantage of the properties 
afforded from multivalent interactions. Nucleic acids, proteins, peptides, and antibodies 
are some of the multivalent receptors that have been developed for biological analyte 
recognition, through the use of highly specific interactions. 
2.2.1 Highly Specific Arrays 
Nucleic acids have recently gained popularity as sensing platforms, particularly in 
biosensing. For example, DNA microarrays contain an assortment of specific DNA 
sequences that hybridize with cyanine dye-labeled complementary sequences in a sample, 
and can be used for genotyping, detection of single nucleotide polymorphisms (SNPs), 
and measuring gene expression.12 DNA hybridization is a highly specific, multivalent 
interaction governed by Watson and Crick base pair complementarity.13 The specificity 
of the interaction does, however, depend on effects like matching between probe and 
target, probe length, and probe GC content. At the microarray level, specificity can be 
affected by sample purity and probe quantity. Nevertheless, such gene analysis is useful 
for comparison and monitoring of normal and disease states. 
Gene activity and regulation is a complex, dynamic process and not necessarily 
linearly related to protein expression.14 Therefore, array technologies to profile, detect, 
and quantitate proteins have been developed that consist of proteins, antibodies, tissues, 
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or small molecules that are designed for highly specific interactions with analytes. 
Identification of protein sequence, structure, post-translational and structural 
modifications, and interaction partners is useful for characterization of biological states. 
To generate protein-profiling arrays, biological or biologically relevant molecules 
are attached to support surfaces, referred to as chips, in high density and then tested in 
order to determine a sample’s composition. Such arrays have been used for antibody 
specificity, cross-reactivity, and immune marker identification; protein-protein, protein-
drug, and protein-ligand interactions; and sera analysis and epitope mapping. These 
arrays utilize specific receptors that are not necessarily cross-reactive, but are useful for 
their high information-density and fast readouts. The ultimate goal of specific array 
sensing is systemic analysis of biomolecules and their roles in disease. 
2.2.2 Phage Display and SELEX 
Instead of using proteins, antibodies, or small molecules designed for specificity, 
receptors for biomolecules can be discovered in an analogous manner to natural selection 
by screening large libraries of diverse chemical structures. These libraries can be 
generated through combinatorial chemical synthesis or by utilizing biological machinery. 
Biopolymers are particularly suited for generating diverse libraries to discover receptors 
for biological analytes as they can be easily replicated and therefore artificially evolved.  
The use of building blocks to generate diverse structures parallels what arose 
through nature and billions of years of evolution.15 Using nucleotide, amino acid, and 
sugar building blocks, complex structures like oligonucleotides, peptides and proteins, 
and carbohydrates can be generated.16 Diverse biopolymer libraries can be created using 
chemical synthesis,17 by harnessing biology,18 or using a biosynthetic combination of 
both.19  
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Both the generation of molecular diversity and the selection of molecules that 
have high affinity for a biological target can be achieved using biological machinery. 
Exposure of biopolymers to a target analyte or analyte mixture in combination with a 
selection pressure, such as an affinity assay, winnows libraries of random biopolymer 
sequences to those sequences that are best suited to the target. Such “artificial evolution” 
mimics the diversity created through evolution but occurs at an accelerated rate due to the 
increased rate of diversity generation compared to that of nature.  
Two major methods of artificial evolution are phage display and SELEX  
(Systematic Evolution of Ligands by EXponential enrichment). Phage display is an in 
vivo way of generating diverse libraries where a viral DNA programs the expression of a 
peptide of a particular sequence on a bacteriophage coat protein.18 Combinatorial 
libraries can be made from a heterogeneous mixture of phages, each with a unique DNA 
plasmid and therefore expressing a particular peptide. Exposure of the phage library to a 
target or mixture of targets and subsequent affinity purification leads to capture of the 
bound phages. The bound members of the library are copied, passing along any mutations 
in the encoding DNA, and amplified when the bacteriophage infects a bacterial host and 
replicates. The replicated library is used for further affinity purification and the library’s 
peptide sequences are identified using the DNA sequences of the plasmids in the selected 
phages.  Such libraries have been used to generate human antibody fragments in vitro,20 
and to generate peptide ligands for drug discovery.21 Weiss et al. developed a biosensor 
for prostate specific membrane antigen (PSMA) by screening a library of phage-
displayed peptides in order to isolate an unnatural polypeptide that selectively binds 
PSMA.22 The chosen peptide was displayed on a virus and used for the fabrication of 
nanowires as part of a PSMA detecting device. 
 52 
Another popular example of artificial evolution is SELEX, an in vitro method 
where large libraries of oligonucleotides are synthesized chemically, amplified using 
polymerase enzymes, and exposed to a biological target in an iterative process (Figure 
2.3).23 A library of single-stranded DNA or RNA sequences is screened against a 
biological target for affinity and the binding sequences retained are replicated using PCR. 
The double strands resulting from PCR are separated to give single strands. For RNA 
libraries, the resulting dsDNA is reverse transcribed, and RNA single strands are isolated. 
The new library of binding sequences is used for further affinity purification, until 
multiple cycles with increasing selection pressure and subsequent amplification lead to 
purification of a small number of sequences specific to the biological target. These 
oligonucleotides can be sequenced to determine sequence homologies of the winnowed 
pool to identify binding structures. Single stranded nucleic acids that show high affinity 
and specificity for a target are known as aptamers. Using SELEX, aptamers have been 
generated for a variety of applications requiring high sensitivity and selectivity, such as 
affinity purification, biosensors, and therapeutics.24 
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Figure 2.3 The process of SELEX. 
Aptamers have been generated for both bacterial and eukaryotic cells.25 Some 
aptamers are generated against specific epitopes on cell surfaces, while others have been 
selected against whole cells using a process known as cell-SELEX.26 Cell-SELEX can 
generate aptamers specific to particular cell types by using negative selections against 
control cells to remove sequences that do not specifically bind the target cell. This allows 
for the generation of receptors that preferentially bind one type of cell over another 
without characterizing the cell surface features that differ between analytes. 
 
2.3 DIFFERENTIAL SENSING OF MULTIVALENT BIOLOGICAL ANALYTES 
Molecular sensors, such as DNA microarrays and aptamers, have traditionally 
been designed for high affinity and specificity to a particular analyte.27 In contrast, 
differential sensing is inspired by biological recognition of analytes by receptors in the 
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nose and tongue and utilizes an array of cross-reactive receptors that do not necessarily 
require specificity or high affinity.28 Instead, analytes can be discriminated by their 
diagnostic patterns of interaction with an array of receptors, where each receptor 
responds to each analyte to a different degree.29 
Differential arrays have been developed for multivalent biological analytes, such 
as proteins and cells, using multivalent receptors. These arrays are capable of analyte 
detection at nanomolar concentrations due to multivalent interactions. 
2.3.1 Differential Sensors for Peptides and Proteins 
Proteins are highly complex molecules; therefore, the design of synthetic 
receptors that target proteins with high affinity and specificity is challenging. As a result, 
differential sensing methods have been developed using receptors of good affinity that 
are capable of responding to many analytes. Using a resin-bound array based on a 
combinatorial library consisting of 193 members of 1,3,5-triethylbenzene substituted with 
binding arms composed of amino acids and boronic acids, Wright et al. were able to 
distinguish classes of proteins through the ion pairing, hydrogen bonding, reversible 
boronate ester formation, and hydrophobic interactions built into the receptor hosts 
(Figure 2.4).30  The proteins tested varied in molecular weight (MW), glycosylation, and 
isoelectric point (pI).  Using chemometric techniques to reduce the high dimensionality 
of the measured indicator uptake rates across the array, the tested proteins were 
effectively grouped into classes based on their pI and were well separated according to 
their glycosylation state. 
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Figure 2.4 The receptors and indicator used by Wright et al. (top) and the resulting PCA 
score plot of proteins using optical data from the resin-bound array 
(bottom). 
You et al. employed a “chemical nose” sensory composed of nanoparticles and 
fluorescent polymers.31 The researchers chose nanoparticles as receptor scaffolds because 
their size and surface areas, especially compared to small molecules, are appropriate for 
conforming contact with protein surfaces and their surface structure can be manipulated. 
Cationic gold nanoparticles functionalized with six end groups, four of which were 
hydrophobic, one aromatic, and one alcoholic, quenched the fluorescence of bound 
polymer. When the polymer-bound particles were exposed to solutions of protein, the 
polymer was displaced from the nanoparticle and its fluorescence restored. The 
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fluorescence signal differed for the seven proteins tested, and the values were input into 
chemometric analysis routines for classification (Figure 2.5). 
 
 
Figure 2.5 Fluorescence patterns generated from displacement by proteins of a quenched 
polymer bound to functionalized nanoparticles (top). LDA classification of 
proteins based on the fluorescence response (bottom). 
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The linear discriminant analysis (LDA) score plot shows separation and 
classification of the different proteins and proteins tested, and most of the samples fall 
within the 95% confidence ellipses. However, 96.4% of the classification is captured on 
the first axis, while a paltry 1.9% is captured on the second axis. This indicates that the 
nanoparticles used in the array all behaved in a similar manner, and the end group 
functionalization had minimal impact on the interaction of the nanoparticle with the 
tested proteins. The plot of fluorescence response of each nanoparticle to each protein 
indeed shows that, for the majority of the responses, each nanoparticle gives a 
fluorescence response of similar direction and magnitude. Such responses suggest that a 
single nanoparticle could have been employed to achieve protein differentiation and that 
an array of nanoparticles is superfluous.32 
Despite this, the group continued employing the array for detection of proteins in 
complex media such as human serum with good differentiation but poor cross-
reactivity.33 Introduction of additional aromatic functionalities to the nanoparticle array 
and signal generation by the activity of β-galactosidase on a sugar-quenched fluorophore 
lead to a fluorescence response that exhibited greater cross-reactivity and still allowed for 
protein classification using LDA classification.34  
2.3.2 Differential Sensors for Cells 
Differential sensing arrays are capable of discriminating complex mixtures, as a 
unique pattern is produced in the array that is diagnostic for the mixture.35 Cell surfaces 
are complex mixtures of which all of the component structures, various lipids, 
carbohydrates, and proteins, are not thoroughly defined. The number and type of these 
structures can differ between cells of different tissue origins, different cancer states, and 
in response to non-native effectors such as transfection.  
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Rotello and Bunz expanded the use of arrays of functionalized gold nanoparticles 
to patterning cancer cells. Their first array consisted of three nanoparticles functionalized 
with an aryl, alkyl, or alcohol residue and was used to discriminate cancer cells of 
different tissue origin, breast cancer cells of different metastatic states, and isogenic 
murine cells of different metastatic states.36 Except in the latter case, greater than 96% of 
the classification was captured on the first factor. Discrimination of isogenic murine 
cancer cells that had been transfected to become cancerous (TD) and metastatic (V14) 
was achieved using the nanoparticle array, resulting in significant classification on the 
first two factor axes (Figure 2.6). 
 
Figure 2.6 Fluorescence patterns generated from displacement by cells of a quenched 
polymer bound to functionalized nanoparticles (top). LDA classification of 
cells based on the fluorescence response (bottom) 
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Modifications of this concept using only the fluorescent polymers themselves,37 
or using the nanoparticles with green fluorescent protein (GFP)38 for signaling led to 
classification of cancer cell states using LDA, again with >93% of classification achieved 
by the first factor. This method was, however, proven effective for measurement on 
samples of approximately 5000 cells, which was a four-fold increase in sensitivity 
compared to previous reports. Application of this method to lysates of tissues that were 
metastatic growths from one tumor type was also pursued. The metastatic sites could be 
discriminated from each other and from normal tissues (Figure 2.7). 
 
 
Figure 2.7 LDA classification of tissues from metastatic sites using nanoparticle arrays 
with GFP. 
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Zhou et al.39 found that nanoparticles displaying dual-ligands gave better 
discrimination for different cancer cell types compared to nanoparticles expressing only 
one ligand, presumably due to heteromeric multivalent interactions. Gold nanoparticles 
functionalized with folic acid ligands, dual-functionalized secondary ligands, or both 
were exposed to cancer cells and the gold content measured. More nanoparticles bound 
when both FA and ligands were present, compared to FA or ligands alone, and this effect 
was more than additive (Figure 2.8). This illustrates the power of multivalent interactions 
for discrimination of cells. 
 
Figure 2.8 Binding of gold nanoparticles to different cell types. Dual functionalized 
ligands (D) give higher response than folic acid (FA) or secondary ligands 
(M) alone. 
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Rotello and Bunz have recently developed differential arrays composed of 
nanoparticles functionalized with variable sensing groups electrostatically bound to a 
signaling molecule for patterning proteins31, 33-34, 40 and cells36, 38, 41. These arrays work 
by displacement of a fluorescent molecule38 or activation of an enzyme34 upon 
nanoparticle binding to the protein or cell and are capable of detection at nanomolar 
concentrations due to multivalent interactions with the analyte. However, chemometric 
results show that discrimination is primarily along only one factor axis, suggesting that 
all the receptors act similarly, possibly eliminating the need for an array.37 Zhou et al.39 
found that nanoparticles displaying dual-ligands gave better discrimination for different 
cancer cell types compared to nanoparticles expressing only one ligand, presumably due 
to heteromeric multivalent interactions.  
 
2.4 CHEMOMETRIC ANALYSIS OF MULTIVARIATE DATA 
 Part of the power of array sensing arises from the use of multiple receptors; the 
response of each of these represents a new variable. Although the addition of variables 
improves analyte classification and discrimination, the data sets generated can often be 
very large and hard to interpret because each additional variable increases the 
dimensionality of a data set. In differential arrays, multiple receptors respond to a single 
analyte and a single receptor is capable of responding to multiple analytes, which leads to 
multiple variables correlated to a single response and to other variables. In order to 
reduce the dimensionality of large data sets and improve their interpretability, 
multivariate data analysis techniques have been developed. When such analysis 
techniques are applied to chemical data sets, they are considered chemometrics, which is 
a term that encompasses data- and computer-driven chemical analysis.42 
 62 
2.4.1 Principal Component Analysis 
Principal component analysis (PCA) and discriminant analysis (DA) are statistical 
analysis techniques often employed for interpreting multivariate chemical data. PCA is an 
exploratory technique that takes p variables and transforms them to q new variables using 
a variance maximizing rotation; often the goal is to reduce the variables such that p >> q 
while retaining the essential information of p and removing redundant information.43 
PCA reduces data set dimensionality and reduces variable redundancy by first finding a 
vector, named a principal component, in the multidimensional variable space that 
describes the most variance in the data set.32 Subsequent principal components are 
defined by vectors that maximize the remaining variability that is uncorrelated, or 
orthogonal, to that described by previous components.  These orthogonal axes are the 
latent variables and describe decreasing amounts of the variance in the data set. PCA thus 
represents a basis set transformation where the principal components extracted from the 
data set are a linear combination of the original variables that describe the maximum 
variance. This can be represented by: !!! = !!!!! + !!!!! +⋯+ !!"!!  (equation 2.5) 
where PCi is the ith principal component extracted from the data and is formed from the 
sum of each original variable, x, multiplied by the contribution of that variable, b, to the 
principal component.  
For PCA, either the correlation or covariance matrix is used to describe the 
variance for the p values of m variables measured across n cases. The variance of a 
variable X across n cases is given by the square of the standard deviation: !"# ! = !!!! !! − !! !!!!!   (equation 2.6) 
where !! is an instance of n on variable X and !! is the mean of n measurements of 
variable X. The covariance of two variables Xa and Xb is given by: 
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!"#$% !! ,!! = !!!! !! − !!! !! − !!!!!!!!!!!  (equation 2.7) 
where xi and yj are instances of n on the two variables, Xa and Xb, respectively. This 
equation shows that variance is actually a special case of covariance where the two 
variables tested are identical. The covariance matrix is square and consists of the 
covariance values of pairs of variables X1,X1 through Xm,Xm for m total variables: !"#$%(!!,!!) ⋯ !"#$%(!!,!!)⋮ ⋱ ⋮!"#$%(!!,!!) … !"#$%(!!,!!)  
It is therefore expected that the covariance value of [X1,Xm] will be identical to [Xm,X1], 
resulting in a symmetric matrix across the diagonal. Additionally, the diagonal of the 
matrix is simply the variance of each variable. 
The correlation matrix is created in a similar manner to the covariance matrix; 
however, the correlations are normalized by the product of the standard deviations, 
according to Pearson’s method, resulting in values between -1 and 1.  !"## !! ,!! = !"#$% !!,!!!!"!!"    (equation 2.8) 
The diagonal of this matrix represents the correlation of each variable to itself, which 
should be perfectly positive, resulting in a value of 1.  
The variances described by each principal component and the contribution of each 
variable to that principal component are calculated using singular value decomposition 
(SVD), which is an eigenvalue problem.32 Any symmetric matrix can be decomposed 
into the product of three matrices: ! = !"!!    (equation 2.9) 
where A is the symmetric matrix, U is a matrix of eigenvectors, S is a diagonal matrix of 
eigenvalues, and UT is the transposed matrix of U. The symmetric matrix A is either the 
correlation or the covariance matrix calculated from a data set consisting of 
measurements across multiple variables. The eigenvectors in matrix U are the weights, b, 
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that create new, uncorrelated variables from the original variables, x. These new variables 
are the principal components. The eigenvectors define a new coordinate system and 
transform the data in A to reference positions on the new axes.  
Scores for each case along each component are calculated by inputting the values 
across each of the original variables x into equation 2.5. The scores for all of the cases in 
the new coordinate system can be represented by a score plot of chosen PCs (Figure 2.9). 
Score plots are useful when PCA is used as a classification tool, as similar cases will be 
grouped together. The contributions of the original variables to the new, latent variables 
in the extracted coordinate system are the variable loadings. The loadings for all of the 
variables across chosen PCs can be represented in a loading plot (Figure 2.9). 
 
Figure 2.9 Left: PCA score plot for measurements on five analytes (G1-G5). Right: PCA 
loading plot of the contribution of receptors (H) to the first two PCs. 
Each eigenvector, b, is associated with an eigenvalue, λb. The sum of the diagonal 
eigenvalue matrix S is equivalent to the sum of the diagonal of A because the eigenvalues 
capture the variance of the new variables, which describe the variance in the original 
data. The variable space has, however, been transformed such that each eigenvalue 
corresponds to the variance along a principal component. The importance of that 
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principal component can be evaluated by calculating the amount of variance it describes 
by dividing its eigenvalue by the sum of the eigenvalue matrix. Through the use of 
eigenvectors and eigenvalues, SVD can retain the essential information from a data set 
while transforming and simplifying it. 
2.4.2 Discriminant Analysis 
In PCA, each data point is treated in the same manner as other data points. In 
contrast, for discriminant analyses a dataset is transformed in order to maximize 
classification of pre-defined groups identified in the data.32 This is achieved by a 
combination of variables that define axes that maximize the distances between groups 
and minimize the distances within groups. Variables are added to the classification model 
in a stepwise manner if they contribute to the prediction of group membership, using the 
group means and variances.44 The mean values of the pre-defined groups across each of 
the measured variables are calculated, the statistical significances between the means are 
tested, and if these are significantly different according to a variable then that variable 
discriminates the groups and is added to the model. 
Linear discriminant functions can be determined using Bayes or Fisher 
discriminant analysis.45 Bayesian discrimination calculates a posterior probability, P(l|x), 
for a data distribution fj  of k groups that depends on the mean, μj, and covariance, Σj. The 
probability that a measurement x belongs to a particular group l is based on a prior 
probability, pj, shown in equation 2.6. ! ! ! = !! ! !!!! ! !!!!!!     (equation 2.10) 
For linear discriminant functions, an assumption is made that the covariances of different 
groups are equal. This assumption can be tested using Box’s test with the F distribution 
for more than five classes and/or variables. If this assumption is not valid, quadratic 
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functions could be determined instead to give an optimal classification rule. (Figure 2.10) 
Prior probabilities are estimated from the group size divided by n total samples, means 
are calculated by the arithmetic means of the groups, and the covariances are estimated 
from the pooled sample covariance matrix, SP, which is a weighted sum of the group 
covariance matrices, Sk.  !! = !!!! !!!⋯! !!!! !!!!!⋯!!!!!    (equation 2.11) 
 
 
Figure 2.10 Left: Covariances of different groups are equal. Different prior probabilities 
affect the decision boundary. Right: Covariances of different groups are not 
equal; quadratic functions should be defined. 
Linear discriminant scores are calculated from classification rules derived by 
plugging the data into the posterior probability equation 2.10. The linear functions 
depend on multiplication of a loading vector, bBAYES, with a measurement x, and adjusting 
this term for the mean and the prior probabilities (second and third terms, respectively).  !! ! = !!"#$%!− !!"#$%!!! + log  (!!)  (equation 2.12) 
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The loading vector depends on the population means and the pooled covariance. Objects 
are assigned to a group that gives the largest value of P(l|x), which is the largest 
discriminant score dj(x). 
Fisher discriminant analysis does not use the prior probabilities to determine 
linear functions for classification, and linear functions can be derived for groups without 
equal covariance matrices, although in such a case the functions will not give optimal 
minimization of misclassification. Fisher rules are determined when multivariate data is 
transformed into univariate discriminant variables using linear combinations of the 
original variables that give maximum separation between groups, similar to PCA (see 
equation 2.5). ! = !!!! + !!!! +⋯+ !!!!   (equation 2.13) 
Here x-values are the values of a measurement on a variable x of m total variables, and b-
coefficients are loadings; b1…bm determine a loading vector b that defines a direction in 
m-dimensional variable space. This is very similar to PCA, however the Fisher rule uses 
the variation between the groups, B, and the covariance within a group, W, to determine 
the loadings. !"#$%$&'() = !!!"!!!"   (equation 2.14) 
This leads to an eigenvalue problem, where b is an eigenvector of W-1B that gives a 
corresponding eigenvalue of separation. Fisher discriminant analysis therefore allows for 
dimension reduction by plotting the data along the eigenvectors that give the highest 
eigenvalues, or the dimensions that result in the best separation of groups. 
Assignment of a measurement to a group is based on its Fisher discriminant score. 
Typically, the Fisher discriminant scores are calculated using Mahalanobis distances to 
the group means. Mahalanobis distances calculated from each observation to a data 
center are independent from variable scaling and account for the covariance structure, C.  
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! !! = !! − ! !!!!(!! − !) !.!  (equation 2.15) 
For LDA, the matrix of eigenvectors b that maximize the separation between groups is 
used as the covariance structure.42, 46 Other distance methods can be used with the matrix 
of eigenvectors, such as Euclidean distance, to calculate discriminant scores.46 A 
measurement is assigned to the group that gives a minimum Fisher score. 
2.4.3 Summary 
PCA is useful for dimensionality reduction of a data matrix in a manner that 
uncovers the latent variables, which describe the variance in the data structure. The score 
plots and loading plots can be evaluated visually to give an understanding of the data. For 
pattern recognition, DA can be utilized to separate objects by a decision surface that is 
defined by a discriminant variable. For LDA, this surface is a plane that defines a linear 
latent variable that seeks to maximize the variance between pre-defined groups and 
minimize the variance within groups. LDA can be used for data sets that have highly 
correlated variables, and Fisher LDA can be used for data sets where there are more 
variables than objects per group, as it results in data reduction. These chemometric 
methods are useful tools for analysis of multivariate data sets, which are produced when 
collecting data from differential arrays. 
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Chapter 3: Spectroscopic Discrimination of Multivalent Analytes 
The utility of multivalent interactions is illustrated by the evolution of such 
interations in biological systems. Synthetic multivalent receptors for biological analytes 
have been developed and have also proven particularly useful for analyte discrimination. 
Fluorescence signals generated as the response of an array of receptors to a multivalent 
analyte can be analyzed using chemometrics in order achieve classification based on the 
pattern of response of the receptor array. We have chosen to develop a dynamic 
templating process for our receptor array in order to discriminate cell surfaces, a 
representative multivalent biological analyte. Differential array sensing has been shown 
to be a powerful tool for discrimination of complex mixtures. The cross-reactive array 
developed herein was applied to the discrimination of cell surfaces because they are 
complex mixtures for which the exact composition is not well defined and is variable 
across cell types. Development of an array of multivalent receptors capable of 
dynamically arranging on a scaffold was hypothesized to provide better analyte 
complementarity, which would lead to better discrimination. 
 
3.1 BACKGROUND 
The Rotello and Bunz collaboration resulted in the development of arrays of 
multivalent receptors for the discrimination of biological analytes such as proteins and 
cells.1 These receptors, which consist of functionalized gold nanoparticles or polymers, 
are static; the recognition groups are not capable of rearrangement in response to a 
particular analyte. Additionally, the receptors consist of simple recognition units that 
span basic molecular properties, such as variable hydrophobicity, but do not target known 
motifs on the chosen analytes. Although the Rotello group has incorporated more 
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complex recognition units by using peptide-functionalized nanoparticles for protein 
discrimination, these peptides were simply used to increase the hydrophobicity of their 
nanoparticles and to allow for chiral surface interactions (Figure 3.1).2 Nevertheless, such 
peptides were able to differentiate α-chymotrypsin and cytochrome c, two proteins with 
variable hydrophobicity, without developing peptides to target specific motifs on those 
proteins. 
 
Figure 3.1 Proteins differentiated by peptide-functionalized gold nanoparticles, based on 
hydrophobic and chiral surface interactions. 
3.1.1 Cancer Cells as Multivalent Analytes 
Cancer cells exhibit differences in expression of surface proteins, sugars, and 
lipids between different tissue types and different metastatic states within the same tissue 
type.3 Much work has been done to identify specific receptors and expression changes at 
both the protein- and gene-level that occur to give rise to the altered growth and adhesion 
properties associated with cancer tissues. Targeting with highly specific receptors, such 
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as antibodies, has led to the identification of malignant and tumor-associated receptors or 
changes to receptor expression. However, characterization of the entire cell surface 
composition and cancer associated surface changes has not yet been achieved. Cell 
surfaces, therefore, represent complex mixtures that can be differentiated using cross-
reactive differential arrays.  
Cancer cells of different tissue origin available from the NCI-60 panel were 
chosen for this study. The NCI-60 is a panel of cancer cells that is typically used for in 
vitro screening of anti-cancer drugs.4 The 60 different cancer cell lines comprise 
leukemia, melanoma, and cancers of lung, colon, brain, ovary, breast, prostate, and 
kidney tissues. By comparing the response pattern of a tested compound across the panel 
to those of standard prototype compounds, it is possible to identify a compound’s 
mechanism of action. As molecular targets displayed on each of the cell lines in the panel 
become better characterized, identification of compounds that interact with these targets 
can be achieved. 
Nine cell lines of different tissue origin were chosen for study, eight of which are 
available in the NCI-60. These cell lines are: MOLT-4 (blood), SK-MEL-28 (skin), A-
549 (lung), HCT-15 (colon), U87-MG-VIII (brain), SK-OV-3 (ovary), MDA-MB-231 
(breast), DU-145 (prostate), 786-O (kidney) (Table 3.1). MOLT-4 is a leukemia line 
isolated from peripheral blood of a 19-year-old male in relapse for acute lymphoblastic 
leukemia; it is a suspension cell line of T lymphoblasts. SK-MEL-28 is a malignant 
melanoma isolated from a 51-year-old male. A-549 is a non-small cell lung carcinoma 
consisting of alveolar basal epithelial cells isolated from a 58-year-old male. These cells 
are type II pneumocytes that secrete pulmonary surfactant via exocytosis,5 and are 
capable of synthesizing lecithin with a high percentage of desaturated fatty acids. They 
test positive for keratin by immunoperoxidase staining and express glycosaminoglycans 
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(GAGs) on the cell surface, which are capable of inhibiting coagulation. HCT-15 is a 
colorectal adenocarcinoma isolated from colon tissue; it is Dukes’ type C, meaning the 
tumor had spread to a lymph node close to the bowel. The cells produce keratin. U-87 
MG is a glioblastoma isolated from the brain of a 44-year-old male; U-87 MGΔVIII has 
been transfected with EGFRvIII to emulate endogenous epidermal growth factor receptor 
1 (EGFR) expression in vitro.6 SK-OV-3 is an adenocarcinoma isolated from ovarian 
ascites of a 64-year-old female. It is considered a “typical ovarian cancer line”. The cells 
are tumorigenic, and although they express estrogen receptors, they are growth resistant 
to estrogen.7 They overexpress human epidermal growth factor receptor 2 (erbB-2).8 
MDA-MB-231 is an adenocarcinoma of mammary gland tissue derived from a metastatic 
site from a 51-year-old female; it expresses EGFR and transforming growth factor alpha 
receptors (TGFαR). DU-145 is a carcinoma of prostate tissue derived from a metastatic 
site from a 69-year-old male. 786-O is a renal cell adenocarcinoma derived from the 
kidney of a 58-year-old male. 
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Cell Name Cancer Cell Type Invasiveness 
MOLT-4 Leukemia T Lymphoblast tumorigenic 
SK-MEL-28 Melanoma melanocyte tumorigenic 
A-549 NSCLC epithelial tumorigenic 
HCT-15 Colorectal epithelial metastatic 
U87MGVIII Glioblastoma glial malignant 
SK-OV-3 Ovarian epithelial metastatic 
MDA-MB-231 Breast epithelial metastatic and malignant 
DU-145 Prostate epithelial metastatic 
786-O Renal epithelial tumorigenic 
Table 3.1 Cancer cell lines of various tissue origin, cell type, metastatic potential, and 
tumorigenicity used in the following studies. 
3.1.2 Multicomponent Receptor Design 
The goal of this project is to create a dynamic, multicomponent sensing ensemble 
for the detection of multivalent analytes. The self-assembling multivalent receptor in this 
system consists of a DNA strand and a peptide-conjugated DNA intercalator, thiazole 
orange. DNA has been traditionally used as a highly specific sensor, such as the 
development of aptamers9 or use of complementary sequences in DNA microarrays,10 but 
in this project its utility as a scaffold for creating a differential array of cross-reactive 
receptors was explored. Several DNA intercalators can dynamically insert along the DNA 
backbone to provide the most favorable arrangement of the peptides for binding the target 
analyte. (Figure 3.2) Penta-peptides of variable sequence are attached to thiazole orange 
through standard coupling reactions to serve as cross-reactive receptors. In addition to the 
dynamic nature of the sensing ensemble, the peptide motifs were chosen to bind known 
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structures on the chosen biological multivalent analytes and were also expected to 
interact in a cross-reactive manner. 
 
Figure 3.2 A dynamic, self-assembled multivalent receptor consisting of a DNA strand 
and peptide recognition units, employed for the discrimination of 
multivalent analytes. 
3.1.2.1 Thiazole Orange 
Thiazole orange (TO) is a cyclic cyanine dye with a monomethine bridge that acts 
as a DNA intercalator (Figure 3.3). Its mode of intercalation has been characterized as 
insertion between base pairs, leading to stacking of the benzothiazolium portion with the 
pyrimidine bases thymine and cytidine and the quinolinium portion with the purine bases 
adenine and guanine.11 Substituents on the quinolinium nitrogen protrude from the minor 
groove of the DNA double strand. Recognition units attached to this position should 
therefore exhibit directionality, which has been shown to improve multivalent 
interactions.12 Thiazole orange has an association constant with double-stranded DNA 
(dsDNA) in aqueous buffer at physiological pH of 106 M-1.13 The dye has low background 
fluorescence due to non-radiative relaxation through torsional modes about the methine 
bridge, but fluorescence emission is enhanced upon intercalation in dsDNA where 
rotation is restricted, preventing non-radiative relaxation.14 Fluorescence enhancements of 
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up to 18,900x upon DNA intercalation have been observed with TO,15 making it an 
excellent probe for fluorometric studies.  
 
 
Figure 3.3 The cyanine dye thiazole orange (TO). 
Conjugates of DNA and cyanine dye intercalators, such as TO, have been used to 
probe DNA hybridization16 and sequence,17 elucidate nucleosome formation,18 and detect 
aptamer binding to small molecules.19 Peptide conjugates of TO have been synthesized 
previously and have also been used for nucleic acid studies.16-17, 20 The properties of 
thiazole orange intercalation into linear DNA have been well characterized.13, 21 However, 
no studies on the interaction of TO with supercoiled DNA have been reported, although 
binding of dyes with similar structures to supercoiled DNA has been studied.22 
The first goal in the larger scheme of cellular differentiation using dynamic DNA-
intercalator complexes was to synthesize and characterize the binding stoichiometry of a 
carboxylic acid thiazole orange derivative, TO1 (Figure 3.4), and its peptide conjugates 
with dsDNA. The carboxylic acid unit of TO1 serves to create a spacer between the site 
of intercalation and site of recognition that can serve as a flexible linker while providing 
a functional handle for peptide coupling. DNA strands of different length and shape were 
explored and these effects on intercalator stoichiometry were characterized.  
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Figure 3.4 The carboxylic acid derivative of thiazole orange (TO1). 
3.1.2.2 Sequences of Peptide Conjugates 
Rather than synthesizing peptide conjugates to possess variability in 
hydrophobicity, charge, and acidity by incorporating amino acids of specific 
functionality, peptide sequences were chosen from motifs that had been previously 
identified in the literature as targeting the test-bed multivalent analytes chosen for this 
study, cancer cell surfaces.  
The Kolonin group developed phage display peptides of random sequence and 
tested them against the NCI-60 panel of cancer cells.23 The sequences of peptides after 
exposure to the cancer cells were determined, and tripeptide motifs were identified. Using 
the heat map in Figure 3.5, motifs were chosen that showed high binding to one of the 
chosen cell and displayed cross-reactivity for the others. (Table 3.2) 
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Figure 3.5 Tripeptide motifs identified as highly associated or not associated with 
particular cancer cell lines from the NCI-60 panel. Figure from Kolonin et 
al.23 
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Table 3.2 Peptide sequences developed for the differential array based on motifs 
previously identified to bind different cellular targets. 
With the discovery of the arginine-glycine-aspartic acid (RGD) sequence 
involved in cell adhesion, it was established that three amino acids could form an 
essential recognition site for cells within the context of a large protein.30 Many adhesive 
proteins found in the extracellular matrix (ECM), such as fibronectin and vitronectin, use 
the RGD tripeptide motif to bind to integrins. Integrins are heterodimeric transmembrane 
proteins that are responsible for cell-cell and cell-ECM interactions, and that provide 
signals for cell motility, adhesion, proliferation, and apoptosis (Figure 3.6).  Integrins are 
composed of α and β subunits; there are eighteen types of α and eight types of β subunits 
found in mammals, and these can be combined to form a variety of heterodimers. For 
Peptide (dye-NàC) Cell Target Binding Motif 
VVKLK hyaluronic acid VVKLK24 
KGGRA A-549, SK-MEL-28 GGR23 
KRGSA SKO-V-3, HCT-15 RGS23 
PRGDK integrin PRGD25/RGDK26 
KDGRC integrin DGR27 
GYPYG mannose mimic GYPYG28 
KRSSA MOLT-4, 786-O RSS23 
KAGLA MDA-MB-231, DU-145 AGL23 
KGARC erbB GXRC29 
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example, the αvβ3 integrin is a vitronectin receptor that is capable of binding to a large 
variety of proteins that express RGD. Its expression is increased in epithelial cells 
undergoing angiogenesis, making it a target for tumor inhibition. The α5β1 integrin is a 
more selective receptor that binds fibronectin and is also associated with angiogenesis. 
 
Figure 3.6 The transmembrane heterodimeric proteins known as integrins are composed 
of α (blue) and β (green) subunits (left). The protein unfolds upon 
activation, which leads to downstream signaling (right). 
Peptide mimics of adhesion proteins can easily be synthesized by incorporation of 
RGD into short peptides. The smallest active unit is the RGD motif itself, and only a 
methyl group on the C-terminus of the aspartic acid is required to retain activity. The 
amino acids that flank the RGD motif can influence the specificity of integrin 
recognition, resulting in differential binding to different integrin subtypes. For example, 
PRGD was a conserved motif found in several RGD-containing 15-mers isolated from 
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phage display against αvβ3, and a 15-mer peptide containing this sequence showed 
differential binding to α5β1 and αvβ3 type integrins with preference for the latter.25a  
Additionally, PRGD is found in the integrin-binding site of the disintegrins kistrin and 
dendroaspin, both derived from snake venom, which bind to the fibrinogen receptor 
αIIbβ3 and inhibit platelet aggregation and blood clotting.25b The tetrapeptide motif 
RGDK was found to provide specificity for α5β1 integrin when appended to a cationic 
lipophilic headgroup.26 The specificity was altered by both disruption of the RGD motif 
and elimination of the lysine.  
Non-RGD containing peptides have been found to bind integrins.30 One of these is 
the inverted sequence, DGR, which inhibits fibronectin binding to α5β1 to a lesser extent 
than RGD.31 However, DGR has been shown to be more effective than RGD at inhibiting 
the binding of laminin and collagen to fibroblasts.27 Additionally, DGR is conserved in 
the collagen domain of surfactant collectin proteins.32 
Small peptide sequences are capable of acting as recognition sites for proteins, as 
evidenced in integrin-binding by the tripeptide RGD. Phage display has been used as a 
tool for identification of short, conserved sequences for other cellular targets. Short 
peptides have been shown to target common cell surface features that are expressed 
differently or associated with malignancy, and some of these were chosen from the 
literature for our differential array. The YPY sequence was identified from phage display 
studies as a consensus sequence for mimicking the sugar mannose. The authors 
hypothesize that the tyrosine hydroxyls combined with the hydrophobicity of the 
sequence provide analogs to the hydroxyls and carbons of the sugar ring.28 Mannose is a 
C2 epimer of glucose that is found in post-translational glycosylated proteins. 33 
The sequence VVKLK was identified as a common binding motif in hyaluronan-
binding proteins.24 Hyaluronan, or hyaluronic acid, is an unbranched polysaccharide 
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classified as a glycosaminoglycan and is composed of repeating disaccharide units of 
glucuronic acid and N-acetylglucosamine (Figure 3.7). Hyaluronic acid is a major 
component of the ECM and can be found on cell surfaces where it contributes to cell 
adhesion, motility, and growth. Such characteristics are modified in the development of 
tumors and metastasis; increased levels of hyaluronic acid are associated with 
malignancy and poor prognosis of tumors such as breast and prostate cancers, while 
decreased levels are found in malignant melanomas.34  
 
 
Figure 3.7 The structure of hyaluronic acid, which is composed of repeating units of a 
disaccharide of glucuronic acid and N-acetylglucosamine. Alkyl hydrogens 
have been omitted for clarity. 
GXRC is part of a conserved motif identified in ligands for the tyrosine kinase 
receptors erbB, of which epidermal growth factor receptor (EGFR or erbB-1) is a 
member.29 ErbB-family receptors consist of an extracelluar domain, a transmembrane 
domain, and a cytoplasmic tyrosine kinase domain (Figure 3.8).35 Activation of erbB by 
extracelluar ligand binding leads to receptor dimerization and autophosphorylation, 
which allows for phosphotyrosine-binding proteins to associate with erbB leading to 
signal transduction cascades that ultimately modulate cell proliferation, migration, and 
adhesion. EGFR is amplified, overexpressed, and/or mutated in many cancers, which 
exhibit altered proliferation, migration, and adhesion. Mutations that activate or amplify 
EGFR are found with a high frequency in glioblastomas. Deletions in the EGFR genes 
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are also observed, and a common mutant is EGFRvIII, which is a deletion variant that is 
constantly active, capable of downstream phosphorylation, and less susceptible to 
degradation. Effective chemotherapies, such as afatenib, have been developed that inhibit 
EGFR activity.  
 
Figure 3.8 ErbB monomer (left) and active heterodimer (right). 
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3.2 RESULTS AND DISCUSSION 
3.2.1 Synthesis of a Carboxylic Acid Thiazole Orange Derivative 
Benzothiazolium salt 3.3 was synthesized in good yield from commercially 
available starting materials according to the procedures of Bethge et al.17 (Scheme 3.1).  
 
Scheme 3.1 The reaction of 3.1 and 3.2 to form thiazolium salt 3.3. 
The synthesis of quinolinium salt 3.6 proved to be more challenging (Scheme 
3.2). Following the procedures of Thompson,20d Carreon and Kelley,20b and Bethge et al.17 
using 5-bromovaleric acid (3.5d) and lepidine (3.4) resulted respectively in a black tar, 
the protonated lepidine salt, and no reaction. Modification to the procedure of Carreon 
and Kelley using dry 1,4-dioxane as a solvent yielded a small amount of desired product 
3.6d, though the isolated solid was mostly protonated lepidine.  
 
 
 
Scheme 3.2 The attempted synthesis of quinolinium salts 3.6a-d. 
To expedite the reaction, the modified procedure of Carreon and Kelley was 
adapted for microwave use, but the isolated solid still showed low formation of 3.6d. 
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Repeating this reaction using bromoacetic acid as the electrophile also resulted in low 
formation of product 3.6a; the major product was the protonated lepidine salt, excluding 
β-elimination as the sole mechanism for the proton exchange. The crude product from the 
microwave reaction using bromoacetic acid showed a singlet at 5.52 ppm by 1H-NMR 
not found in either the starting material or the product 3.6a. This signal corresponds to a 
lactone dimer, 1,4-dioxane-2,5-one, formed by intermolecular cyclization of two 
carboxylates. Both lepidine and bromoacetic acid have similar pKa values (pKa 4-5) and 
undergo proton exchange in solution. Once the carboxylate is formed, cyclization to form 
a 6-membered ring by displacement of bromide is possible. Byproduct formation is 
driven by the stability of the lactone dimer and ion pairing of protonated lepidine with the 
bromide leaving group, which prevents substitution by 3.4 to form 3.6a. Five and six-
membered lactone products can also be observed by 1H-NMR when 4-bromobutyric acid 
and 5-bromovaleric acid are used, respectively. When 3-bromopropionic acid is used, β-
elimination occurs to produce acrylic acid; β-elimination is driven in this case by the 
stable α,β-unsaturated configuration. 
In order to prevent protonation of lepidine, the reaction was run with Hünig’s 
base, but the resulting solid was identified as the protonated salt of Hünig’s base. 
Therefore, ethyl 4-bromobutyrate (3.7) was used as the electrophile in order to prevent 
lactone formation (Scheme 3.3). The ethyl ester of 3.8a was obtained and hydrolyzed to 
the acid, but the resulting salt 3.8a was soluble in water, so the product 3.8b was obtained 
by precipitation with KPF6. This salt was reacted with 3.3 according to the procedures of 
Thompson and resulted in both the PF6- salt of TO1 and its methyl ester. Due to 
esterification and the sparing solubility of 3.8b in methanol, the reaction was repeated in 
acetonitrile and resulted in the desired product; however, TO1-PF6 had limited solubility 
in acetonitrile. TO1 was prepared instead by ion exchanging the quinolinium-PF6 salt 
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3.8b for chloride, and then reacting the chloride salt 3.8c with 3.3 in acetonitrile (Scheme 
3.4).  Finally, TO1 was purified by recrystallization from methanol/water. 
 
Scheme 3.3 The synthesis of quinolinium salts 3.8a-c by reaction of 4-methylquinoline 
and ethyl 4-bromobutyrate. 
 
 
Scheme 3.4 Reaction of thiazolium salt 3.3 with quinolinium salt 3.8c to form a 
carboxylic acid thiazole orange derivative TO1. 
3.2.2 Titrations of TO1 and DNA 
Characterization of the intercalation properties of the new thiazole orange 
derivative, TO1, with a variety of DNA strands was undertaken. For our purposes, 
ascertaining the average number of intercalators bound to each strand of dsDNA was 
important for preparing the dynamic arrays. Therefore, initial fluorescence titrations of 
TO1 were undertaken with different lengths of DNA, and the intercalation of TO1 into 
supercoiled DNA was characterized.  We hypothesized that intercalation of TO1 into 
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supercoiled DNA would relax the strand,36 and thus the supercoiled strand would be able 
to incorporate more dyes per base pair relative to linear strands. 
3.2.2.1 Titration with 53 bp dsDNA 
When a 53 bp strand was titrated into a solution of TO1, saturation was observed 
at 0.2 base pair equivalents (bp equivs), corresponding to 1 dye for every 5 base pairs 
(Figure 3.9).  The theoretical maximum of intercalators per strand occurs at 1 dye per 2 
base pairs, or intercalation every other base pair. The measured value is lower than the 
theoretical limit, indicating that the zwitterionic TO1 may have a repulsive interaction 
between the carboxylate and the phosphate backbone, resulting in decreased intercalation. 
Performing the inverse titration, where the concentration of 53 bp dsDNA was held 
constant, resulted in higher fluorescence values and saturation at 0.35 bp equivs, or 1 dye 
every 3 base pairs (Figure 3.9). This titration was performed at a higher concentration 
than the previous titration, indicating that the emission intensity and equivalents are 
concentration dependent. Alternatively, the increase in fluorescence may be due to 
contribution from a fluorescent DNA-templated aggregate of TO1, as the DNA 
concentration in the titrant was lower than that of TO1 for this experiment. DNA-
templated aggregates have been reported for cyanine dyes of similar structure.37 
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Figure 3.9 Titration of TO1 into 53 bp dsDNA in DPBS, pH =7.4. [TO1]=0-3.4 uM, 
[DNA]=5.3 uM (red); [TO1]=0-2.3 uM, [DNAbp]=5.3-2.6 uM (blue). 
λex=498 nm, λem=528 nm. 
3.2.2.2 Titration with 202 bp dsDNA 
Using a longer dsDNA consisting of 202 bps, saturation of emission at 528 nm 
was observed at 0.2 bp equivs, corresponding to 1 dye every 5 base pairs (Figure 3.10).  
Since this strand is a double stranded aptamer template, it is possible that intercalation 
was not as favorable due to the potential non-linear structure of the duplex. 
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Figure 3.10 Titration of TO1 into 202 bp dsDNA in DPBS, pH = 4.4. [TO1]=0-1.9 uM, 
[DNAbp]=11.3-6.0 uM, pH=7.0, λex=498 nm, λem=528 nm. 
3.2.2.3 Titration with 1000 bp dsDNA 
Addition of TO1 to a solution of 1 kb dsDNA led to an emission increase at 528 
nm (Figure 3.11). Saturation behavior was observed at 0.28 bp equivs, corresponding to 1 
dye every 3.5 base pairs (Figure 3.12). A continuous variation analysis was performed 
where the total concentration of TO1 and base pairs of the 1 kb dsDNA were held 
constant (4 uM) and the mole fraction of each component was varied. The highest 
fluorescence was observed when χTO1 = 0.50, which corresponds to 1 dye per every base 
pair (Figure 3.13); this is an unexpected result since the theoretical limit of intercalation 
for a mono-intercalator is one dye every two base pairs.15 Once again, this increase over 
the theoretical limit may be due to DNA-templated aggregation, as the total concentration 
of dsDNA was 4 mM, much higher than that used in the titration experiments. 
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Figure 3.11 Titration of TO1 into 1 kb dsDNA in DPBS, pH = 7.4. [TO1]=0-1.8 uM, 
[DNAbp]=3.2-2.0 uM, λex=498 nm. 
 
Figure 3.12 Titration of TO1 into 1 kb dsDNA in DPBS, pH = 7.4. [TO1]=0-1.8 uM, 
[DNAbp]=3.2-2.0 uM, λex=498 nm, λem=528 nm. 
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Figure 3.13 Job Plot of TO1 and 1 kb dsDNA in DPBS, pH = 7.4, [DNAbp] + [TO1] is 
4.5 uM, λex=498 nm, λem=528 nm. 
3.2.2.4 Titration with Supercoiled dsDNA 
The intercalation of TO1 into supercoiled plasmid DNA was investigated. 
Saturation of the fluorescence signal was observed at 0.25 equivalents, or 1 dye every 4 
base pairs (Figure 3.14). The amount of TO1 required for maximum fluorescence was 
lower with the supercoiled DNA compared to other strands. This indicates that the 
supercoiled DNA did not incorporate more TO1 compared to linear strands. 
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Figure 3.14 Titration of TO1 into 2686 bp Supercoiled dsDNA. [TO1] = 0-1.1 uM, 
[DNAbp] = 5.0 – 2.6 uM, DPBS, pH = 7.4. 
3.2.2.5 Mass Spectrometric Characterization of TO1 Interalation with 14 bp dsDNA 
The intercalation of TO1 into 14 bp dsDNA was analyzed using ESI-MS. These 
titrations showed that at a 1:1 ratio of dye and DNA, one intercalator is loaded for every 
DNA strand, which corresponds to 1 intercalator for every 14 base pairs (Figure 3.15). 
Increasing the ratio of TO1:DNA from 1:1 to 5:1 led to an increase in the signal 
corresponding to the 1:1 dye:DNA complex. At a ratio of 3:1, a peak corresponding to 
two dyes per DNA strand is evident, or 1 dye for every 7 base pairs, and this peak also 
increases with increasing dye concentration. At a ratio of 5:1, a peak can be observed for 
three dyes bound per DNA strand, or 1 dye every 5 base pairs. These results are in good 
agreement with the solution phase studies, especially considering that anion repulsion 
between TO1 and the polyanionic DNA backbone would be stronger in the gas phase. 
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Figure 3.15 ESI-MS of 5 uM dsDNA intercalated with concentrations of TO1 ranging 
from 5 – 25 uM in 30 mM NaOAc buffer, pH = 7.0. Duplex DNA is 
represented by ds and the two single strands are represented by ss a and ss b. 
The inset provided in the spectrum for 1:5 duplex-to-dye shows an enlarged 
view of the triply intercalated duplex in the 7- charge state.   
3.2.3 Peptide Conjugates of Thiazole Orange 
3.2.3.1 Synthesis of TO1-peptides 
Solid-phase Fmoc synthesis was used to prepare the nine peptides with sequences 
shown in Table 3.2. After the peptides were synthesized, the C-terminus was deprotected 
and the amine terminus was capped with TO1 via an amide linkage. The peptides were 
cleaved from the Wang resin and side chains were simultaneously deprotected. HPLC 
purification was performed on the TO1-peptides and the fraction containing the desired 
sequence was verified using LC/MS (Figure 3.16). 
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peptide R1 R2 R3 R4 R5 
TO1-1 Val Val Lys Leu Lys 
TO1-2 Lys Gly Gly Arg Ala 
TO1-3 Lys Arg Gly Ser Ala 
TO1-4 Pro Arg Gly Asp Lys 
TO1-5 Lys Asp Gly Arg Cys 
TO1-6 Gly Tyr Pro Tyr Gly 
TO1-7 Lys Arg Ser Ser Ala 
TO1-8 Lys Ala Gly Leu Ala 
TO1-9 Lys Gly Ala Arg Cys 
Figure 3.16 Structure of TO1-peptides with sequences as shown in Table 3.2. 
3.2.3.2 Titrations of DNA and TO1-peptides 
Titration of each peptide derivative of TO1 was undertaken with 1 kb dsDNA in 
DPBS. Differences in equivalences of peptide required to saturate the fluorescence 
signal, as well as differences in the saturated emission intensity, were observed for the 
variable peptide sequences. For example, titrations of TO1-4 and TO1-7 with 4 nM 
1000mer dsDNA lead to different emission intensities and saturation behaviors. The 
emission of TO1-4 reached saturation at 2000-2500 equivalents (2 – 2.5 bp equivs) with 
a maximum relative emission at 250,000 (Figure 3.17). In contrast, the titration with 
TO1-7 reached saturation at approximately 1000 equivalents (1 bp equivalent) with a 
maximum relative emission of 350,000, which is 1.4x higher than TO1-4 (Figure 3.18). 
Although both peptides contain a single lysine, which allows for greater association with 
the negatively charged DNA, the placement of lysine in TO1-7 is closer to the site of 
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intercalation than that of TO1-4. The additional positive charge closer to the intercalator 
may allow for greater intercalation of TO1-7 compared to TO1-4, resulting in greater 
fluorescence emission and saturation at a lower concentration. 
 
 
Figure 3.17 Titration of 4 nM 1000 bp dsDNA with TO1-4. 
 
Figure 3.18 Titration of 4 nM 1000 bp dsDNA with TO1-7. 
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3.2.4 Patterning of Three Cancer Cell Lines with a 9-Peptide Array 
The next goal of this study was to determine the ability of an array of receptor 
assemblies to discriminate multivalent analytes using a small subset of analytes. To 
achieve this, the multivalent analytes used for these studies were three cancer cell lines 
from the NCI-60 panel of different tissue origin and, therefore, different surface 
characteristics. SK-OV-3, A-549, and MDA-MB-231 cells were chosen for initial 
discrimination studies using a differential array consisting of a 1000-mer strand of 
dsDNA and nine TO1-peptide conjugates. The fluorescence response of peptide 
conjugates TO1-1 through TO1-9, both intercalated into DNA and free in solution, upon 
incubation with cells was measured, and the values were analyzed using chemometric 
statistical techniques. 
3.2.4.1 Fluorescence Response of the Array 
The fluorescence response of the array of peptides to cells was measured after 
incubation at 37 °C for 40 minutes and subsequent washing with DPBS. These values 
were compared to the fluorescence values of the solutions that had not been exposed to 
cells. The DNA intercalated peptides (DNA-peptide) solutions were prepared at 
concentrations where saturation of the fluorescence signal was observed, resulting in a 
maximal fluorescence value for each peptide. The absolute fluorescence values were 
variable, as each peptide sequence has sequence-dependent emission intensity. After 
incubation with cells and subsequent washing, the emission intensities for all sequences 
decreased compared to the solutions not incubated with cells. In order to compare the 
response of the peptides in the array and to eliminate emission intensity bias, the 
fluorescence values of each peptide were expressed as percentage contributions to the 
cumulative emission of the array (Figure 3.19). As shown in Figure 3.19, the unexposed 
peptides have different percent contributions due to their varying emissions, resulting in 
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variable percent contributions of the cell-exposed peptides. In general, those peptides that 
had a large percent contribution before exposure to cells continue to have a large 
contribution after exposure. However, it is clear that the percentage contributions have 
changed upon exposure to cells and that there are subtle differences between the 
percentages that vary according to cell type. In order to elucidate these subtle differences, 
the percentage values were compared between solutions not exposed to cells and those 
exposed to cells by calculating the difference, resulting in a delta percent (Figure 3.20). 
 
 
Figure 3.19 Average percent contribution of each DNA-peptide for each cell line, as 
compared to the contribution of the DNA-peptides not exposed to cells.  
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Figure 3.20 Average delta percent response of the three cell lines to the DNA-peptide 
array. 
The free peptide solutions were prepared at the same concentrations as the DNA-
intercalated solutions, only omitting DNA. The fluorescence values of these solutions 
varied slightly based on the concentration used but were much lower than those of the 
DNA containing solutions. Upon exposure to cells and subsequent washing, the emission 
intensity of the peptides increased greatly. This is due to the ability of the cationic 
peptides to associate with the anionic cell surface, resulting in restriction of rotation of 
the thiazole orange and thus fluorescence emission. The free peptide emissions were also 
expressed as percent contributions (Figure 3.21), and delta percent values were calculated 
from the percentages of the non-exposed and cell-exposed peptides (Figure 3.22). The 
free peptide percentages shown in Figure 3.22 show that emissions of peptides that have 
not been exposed to cells are more similar to each other than those of unexposed peptides 
intercalated into DNA. The emission intensities after exposure to cells are not dependent 
on the original emission intensities of the free peptides, which are representative of the 
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concentrations. The delta percent values show that there are slight differences in the 
response of each peptide to the different cells; however, the response across the peptide 
array is similar for each cell line. 
 
 
Figure 3.21 Average percent contribution of each peptide for each cell line, as compared 
to the contribution of the peptides exposed to cells. 
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Figure 3.22 Average delta percent response of the three cell lines to the peptide array. 
3.2.4.2 Chemometric Analysis 
Classification of three cell types MDA-MB-231, SK-OV-3, and A-549 was 
undertaken in order to validate the discriminatory ability of the array. The response of 
each peptide in the array, represented as a delta percent value, was used as a variable in 
Principal Component Analysis (PCA). One of the major goals of PCA is to reduce the 
dimensionality of multivariate data in order to eliminate redundancy and make the data 
more interpretable. PCA can also be used as a classification tool, although it is not biased 
towards grouping cases of similar class and any clusters that appear in the score plot arise 
naturally from the data.  
First, the 18 total variables were separated into two sets in order to investigate the 
cell-classification ability of the DNA-peptides and the peptides alone. The delta 
fluorescence values across each variable for nine repeats of measurements on different 
cell lines were used as the cases. Using the correlation between the variables, the 
dimensionality of the experimental data sets could consistently be reduced such that 
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>70% of the original variance was described by two principal components (PCs), with 
>40% of the variance on the first PC and >30% on the second PC. Figure 3.23 shows the 
contribution of the variables to the PCs and the classification of the three cell lines using 
the responses of DNA-peptides in a combined loading plot and score plot, referred to as a 
biplot. Many variables contribute to each PC but to varying extents, indicating the 
receptors are behaving in a cross-reactive manner. However, DNATO1-1, DNATO1-3, 
and DNATO1-7 all have similar contributions to the PCs indicating they respond in a 
similar manner. Importantly, the three cell lines are well separated along the two PCs and 
repeats of each cell type are clustered, although there is some scatter. 
 
 
Figure 3.23 Biplot of delta percent response of DNA-peptide array to the three cell lines 
tested, SK-OV-3, A-549, and MDA-MB-231. 
The biplot in Figure 3.24 shows the contribution of the variables to the PCs and 
the classification of the three cell lines using the responses of free peptides. Again, the 
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variables have different yet significant contributions to each PC, although TO1-7 and 
TO1-9, and to a lesser extent TO1-2, respond in a similar manner. The three cell lines are 
also well classified and repeats of measurements are clustered, although again with some 
scatter. 
 
 
Figure 3.24 Biplot of delta percent responses of peptide array without DNA to the three 
cell lines tested, SK-OV-3, A-549, and MDA-MB-231. 
The responses of the peptides with and without DNA were combined, resulting in 
18 variables. For this combination 77% of the variance in the original data was described 
by two PCs. It is evident from the loading plot that many variables contribute to each of 
the two PCs to varying extents, indicating the receptors behave in a cross-reactive manner 
(Figure 3.25). Additionally, combination of the two variable sets did not result in perfect 
correlation of the response of the free peptides to that of the DNA-peptides, although the 
responses of TO1-4, TO1-5, TO1-6, and TO1-8 are similar for both variable sets. 
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Figure 3.25 Loading plot for discrimination of three cell lines, MDA-MB-231, SK-OV-3, 
A-549, using the array of nine peptides, with and without 1000mer dsDNA. 
Using the 18-variable array, the cell lines were again successfully classified 
according to cell type on the PCA score plot (Figure 3.26). The three cell lines are well 
separated on both the first and second PCs. The score of a replicate of a cell line 
measurement on a PC is a sum of its scores on each variable, which is dependent on each 
variable’s contribution to that PC. A positive correlation of a peptide with a PC indicates 
that the response of a case to that peptide variable will result in a positive contribution to 
that case’s score on that PC. Similarly, a negative correlation will result in a case having 
a negative contribution to its score. If a case does not have a strong response to a 
variable, that variable will not have a significant contribution to its score. TO1-4, TO1-6, 
DNATO1-4, and DNATO1-2 are all highly positively correlated with the first principal 
component, F1 (Table 3.2). TO1-4 contains the RGD motif and was designed to bind to 
integrin with potential specificity for α5β1 and αvβ3. TO1-6 contains a conserved 
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sequence found in peptide mimics of the sugar mannose. TO1-2 contains the GGR motif 
that was selected in phage display to bind the cell lines differentially, with preference for 
A-549 and SK-MEL-28. The positive end of this PC appears to be associated with 
adhesion properties of the cells. Of the three cell lines, SK-O-V3 scores the highest on 
this PC, with MDA-MB-231 scoring the second highest. In contrast, A-549 has a 
negative score on the first PC; DNATO1-1, DNATO1-3, DNATO1-7, TO1-2, and TO1-
9 are all highly negatively correlated with this PC (Table 3.3). TO1-1 was selected to 
bind to hyaluronan. TO1-3, TO1-7, and TO1-2 were all selected to bind cells 
differentially with preferences for SK-OV-3/ HCT-15, MOLT-4/786-O, and A-549/SK-
MEL-28, respectively. TO1-9 contains the GXRC motif for binding the erbB family of 
receptors.  The negative end of this PC may be associated with cell surface characteristics 
associated with cell proliferation and survival, as well as specific cell interactions. 
 
 
Figure 3.26 The PCA score plot showing classification of three chosen cell lines using 
the 18-variable peptide array. 
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  F1   F2 
pep4 0.937 pep5 0.894 
pep6 0.891 DNApep5 0.892 
DNApep4 0.876 DNApep9 0.813 
DNApep2 0.816 DNApep6 0.598 
DNApep6 0.663 pep7 0.463 
DNApep8 0.529 pep9 0.440 
pep8 0.366 pep6 0.284 
DNApep5 0.291 pep2 0.261 
pep5 0.181 pep4 -0.130 
pep1 -0.203 DNApep4 -0.156 
pep7 -0.394 DNApep7 -0.250 
pep3 -0.406 DNApep3 -0.282 
DNApep9 -0.429 DNApep2 -0.371 
pep2 -0.735 DNApep1 -0.411 
pep9 -0.741 DNApep8 -0.765 
DNApep7 -0.746 pep3 -0.772 
DNApep3 -0.796 pep8 -0.821 
DNApep1 -0.834 pep1 -0.873 
Table 3.3 Correlations of the peptides with the first two PCs. Variables with a high, 
positive correlation (>0.7) are colored green, while variables with a high, 
negative correlation (<-0.7) are colored red. 
TO1-5, DNATO1-5, and DNATO1-9 are highly positively correlated with the 
second PC, while TO1-1, TO1-8, TO1-3, and DNATO1-8 are highly negatively 
correlated (Table 3.3). TO1-5 contains the inverse integrin binding sequence, DGR, 
which was hypothesized to bind to integrin receptors that recognize laminin and collagen. 
DNATO1-9 contains the GXRC motif for binding erbB-family receptors. TO1-1 was 
designed to bind to hyaluronan. These peptides all target cell surface features that have 
been associated with malignant transformations and are associated with a variety of cell 
types. The positive end of this PC is therefore likely associated with general malignant 
transformation.  TO1-8 and TO1-3 contain motifs for differential cell binding, with 
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respective preferences for MDA-MB-231/DU-145 and SK-OV-3/HCT-15. The negative 
end of this PC appears to be associated with specific cell responses. On this axis, SK-OV-
3 has the highest score, while MDA-MB-231 has the lowest score.  
TO1-4, TO1-5, and TO1-6 contribute to the position of SK-OV-3 on the score 
plot, indicating that this cell line may express receptors for laminin and/or collagen, such 
as β1 integrins and the mannose receptor. Studies have shown that SK-OV-3 significantly 
expresses β1 integrins (96%) and expresses α1-3 (85-92%), α5-6 (94, 79%) and αv 
(93%) integrins to a greater extent than other ovarian cancers.38 The cell line has been 
shown to bind significantly to collagen types I and IV, laminin, and fibronectin, 
Migration of this cell line towards these ECM adhesion molecules was determined to be 
mediated by α2β1, α6β1, and α5β1 integrins, respectively.39 SK-OV-3 also shows a 
positive response for TO1-2 containing the GGR motif in the context of DNA, although 
the response is less positive than for A-549. This motif was selected to bind A-549 and 
SK-MEL-28, which indicates that this peptide is cross-reactive. Without DNA, TO1-3 
and TO1-7 both result in positive fluorescence responses to SK-OV-3, though the 
responses are negative in the multivalent receptor. TO1-3 contains the RGS motif that 
was selected for binding SK-OV-3. Although its response is positive, it is the weakest for 
SK-OV-3 compared to the other cell lines tested and it does not bind well in the context 
of the multivalent DNA assembly. This indicates that the peptide is not behaving as 
hypothesized, but is behaving in a cross-reactive manner. TO1-9 which contains the 
GXRC motif for binding erbB receptors also contributes to the position of SK-OV-3 on 
the score plot, although only in the DNA-free case; SK-OV-3 overexpresses erbB-2.40  
TO1-8 and DNATO1-8, which contain the AGL motif selected for binding to 
MDA-MB-231, both contribute to the classification of MDA-MB-231 on the PCA plot. 
The response of DNATO1-8 results in a positive delta percent for MDA-MB-231, while 
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TO1-8 alone results in a negative delta percent. However, this delta percent value is the 
least negative for MDA-MB-231 compared to the other cell lines, which means it bound 
better to the cell line it was selected for than the others tested. The greater response when 
the peptide is intercalated into DNA may be due to the increased valency of the 
interaction with the cell surface. Other peptides for which MDA-MB-231 has a positive 
response are DNATO1-2 through 4, DNATO1-6 through 8, TO1-3, TO1-7, and TO1-9. 
The strongest response of the DNA-containing variables was to DNATO1-4, which 
contains the RGD-binding motif. MDA-MB-231 expresses αv, β5, and β1 integrins but 
does not express αvβ3 and does not adhere well to collagen.41 The presence of β5 
integrins may explain why the RGD motif elicited a positive fluorescence response. This 
effect was only seen in the context of the multivalent receptor, indicating that multiple 
ligands may be necessary to target integrins. The absence of αvβ3 and low adherence to 
collagen explains why, with or without DNA, the fluorescence response to the DGR 
peptide was low. The other DNA-containing receptors that have positive responses were 
expected to bind other cell lines, which indicates that the peptides are promiscuous. This 
is also the case for the non-DNA variables TO1-3 and TO1-7. TO1-9 contains the erbB 
binding motif and MDA-MB-231 overexpresses EGFR, like many other breast cancers, 
but does not express erbB-2.42  
The responses of DNATO1-1, DNATO1-3, DNATO1-5, DNATO1-7, 
DNATO1-9, TO1-3, TO1-7, and TO1-9 determine the position of A-549 on the score 
plot. A-549 overexpresses CD44,43 and high CD44 is associated with high HA levels in 
NSCLCs.44 TO1-1 contains a hyaluronan-binding sequence; therefore, this characteristic 
of A-549 may be why it has a response to DNATO1-1 that contributes to its PCA 
classification. This peptide may only be able to significantly bind to the multivalent HA 
when presented in the context of a multivalent receptor, which is why TO1-1 without 
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DNA did not result in a fluorescence signal enhancement. Although the RGS sequence of 
TO1-3 showed strong responses to SK-OV-3 and HCT-15 and weak binding to A-549 in 
Kolonin’s phage display assay, this peptide contributes to the classification of A-549. 
SK-OV-3, HCT-15, and A-549 are all adenocarcinomas, which are epithelial cancers of 
glandular tissues. The RGS sequence, in the context of our receptor design, may interact 
with cell surface features that are common to this type of cancer. The RSS motif of TO1-
7 also shows a fluorescence increase with A-549. Although this motif was selected for 
MOLT-4/786-O, it differs from the RGS motif by only one amino acid, so it is 
unsurprising that this peptide binds to A-549 as well. The response to TO1-5 was 
positive, although not as strong as that of SK-OV-3. A-549 has been shown to bind well 
to laminin,45 which may explain its positive response to the DGR motif in TO1-5. TO1-9 
contains the GXRC motif for binding erbB-family receptors and A-549 has been shown 
to have elevated erbB-2 expression46 that coincides with elevated, growth-dependent 
EGFR expression.47 The TO1-2 peptide was expected to bind to A-549, but its 
fluorescence was not enhanced. However, analysis of the loading plot shows that the 
placement of TO1-2 without DNA is correlated with the placement of A-549 on the score 
plot. Interestingly, intercalation of this peptide into DNA seems to remove the expected 
response to the peptide bearing the cell-line binding motif. 
3.2.5 Patterning of Cancer Cell Lines with a 9-Peptide Array 
After initial patterning of three cell lines using the array confirmed some of the 
expected response of peptides to known motifs on the tested cell surfaces, the analytes 
tested were expanded to include more cell lines of different tissue types. 
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3.2.5.1 Initial Attempts at Patterning Adherent Cells 
In an initial experiment, all cells were plated simultaneously at the same seed 
density and allowed to grow for the same amount of time, 24 hrs. Each cell line has a 
different growth rate, therefore the number of cells were counted for each plate and 
averaged for each cell line. It was observed that some of the cell lines, such as A-549 and 
U-87 MGΔVIII, had grown more confluent than the others. Many of the cell counts were 
extremely low, which resulted in decreased signal and increased scatter for the low count 
and/or low confluency cell types (Table 3.4). This is evident in the PCA score plot 
(Figure 3.27) which shows the best clustering for U-87 MGΔVIII and A-549, which are 
the two cell lines which were observed to have retained the most attached cells after the 
experiment. Interestingly, the LDA score plot is able to reduce this noise significantly, 
illustrating the power of prior knowledge of classes to improved classification (Figure 
3.28). LDA was determined to be the best method of classification as the assumption that 
the within-class covariance matrices are equal was found to be valid using Box’s test. 
Most of the classification by LDA is explained by the first factor axis, and the cross-
validation routine resulted in 87.5% classification, with only A-549, U-87 MG VIII, and 
MDA-MB-231 correctly classified 100% of the time (Table 3.5). 
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Cell Line Average Cell Count 
Average Cells Per 
Well 
A-549 109.5 13687.5 
U-87 
MGΔVIII 20.5 2562.5 
DU-145 28.7 3587.5 
HCT-15 106.8 13350 
SK-MEL-28 12.0 1500 
786-O 5.7 2850 
SK-OV-3 4.5 562.5 
MDA-MB-
231 1.3 162.5 
Table 3.4 Cell counts for the 8 adherent cell lines. Counts are extremely low for some cell 
lines. 
 
Figure 3.27 PCA on adherent cell response to the 9-peptide array. Cells had become 
significantly detached over the course of the experiment. 
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Figure 3.28 Linear Discriminant Analysis (LDA) on highly scattered cell responses to the 
9-peptide array. 
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from \ to 786O A549 DU 145 
HCT
15 MDA 
SK 
MEL 
SKO
V3 
U87
MG Total 
% 
correct 
786O 7 0 0 0 0 0 2 0 9 77.78 
A549 0 9 0 0 0 0 0 0 9 100.00 
DU145 0 0 7 0 0 1 1 0 9 77.78 
HCT15 0 0 0 8 0 1 0 0 9 88.89 
MDA 0 0 0 0 9 0 0 0 9 100.00 
SKMEL 0 0 0 0 0 8 1 0 9 88.89 
SKOV3 2 0 0 0 0 1 6 0 9 66.67 
U87MG 0 0 0 0 0 0 0 9 9 100.00 
Total 9 9 7 8 9 11 10 9 72 87.50% 
Table 3.5 Cross-validation of cell types according to the LDA model built from prior 
knowledge of the classes. 
These results led to the development of experimental conditions where, instead of 
plating cells simultaneously and allowing them to grow for the same period of time, cells 
were tested once they had reached confluency. The eight adherent cell lines were each 
plated at n=6 and allowed to grow until a uniform monolayer was present in each well. 
Additional wells were grown for cell counts; cells were counted for each plate and 
averaged over 15,000 cells/well per cell line. 
Figure 3.29 shows the 3D PCA plot of the response of each cell line to the 9-
peptide array. It is clear that there is a large amount of scatter present for some cell lines, 
in particular HCT-15 and A-549 and to a lesser extent DU-145. On the first PC, which 
accounts for 31% of the variance in the data, on average U-87 MGΔVIII and MDA-MB-
231 have the highest scores. As seen in the loading plot of the first two PCs (Figure 3.30), 
the responses of TO1-2, TO1-1, TO1-3, and DNATO1-5 are highly positively correlated 
with this PC. From the loading plot, the response of TO1-5 is highly negatively 
correlated with PC1; this peptide has a DGR motif for binding collagen and laminin 
receptors, but the peptide TO1-5 may be interacting non-specifically without assembly 
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on DNA. Although they are not highly negatively correlated, DNATO1-3 and DNATO1-
7 are both negatively correlated with PC1 (<-0.45); these two peptides were chosen to 
bind to the cells with the lowest scores on this PC: HCT-15 and 786-O.  
 
Figure 3.29 Three-dimensional PCA plot of the response of eight adherent cell lines to 
the 9-peptide array. 
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Figure 3.30 Loading plot of the PCA on the eight adherent cell lines grown to confluency 
and exposed to the 9-peptide array. 
Although there are some promising correlations between the responses of some of 
the peptides with their expected behavior, the negative effects of the experimental 
procedure on analyte integrity were observable. For both initial eight cell line 
experiments, cell detachment associated with washing and incubation was observed. 
Addtionally, when cells were treated with DNA-peptides they detached to a greater 
extent compared to those that were treated with peptide only or DPBS. This indicates that 
the peptides are much better at binding to cell surfaces in a way that interferes with their 
adhesion properties when assembled onto DNA, creating a dynamic multivalent receptor. 
Unfortunately, such detachment when using the variable set containing DNA results in a 
lower fluorescence response, increased scatter, and a loss of analyte that cannot be 
accounted for. In order to eliminate this confounding variable, cells were grown on cell 
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culture treated plates coated with poly-D-lysine. This polycationic coating enhances the 
attachment of cells to the growth surface. 
3.2.5.2 Patterning of Nine Cell Lines with a 9-Peptide Array 
Cells were grown to confluency on poly-D-lysine plates and once again exposed 
to the 9-peptide array with or without DNA. Classification of the cells according to cell 
line was achieved using both LDA (Figure 3.31) and PCA (Figure 3.32). For LDA, 75% 
of the classification occurs on two factors with 61% of the classification on the first 
factor (F1). In a cross-validation routine, the replicates were correctly classified 
according to the model 100% of the time.  
 
Figure 3.31 LDA score plot (left) and loading plot (right) for classification of nine cell 
lines using a 9-peptide array. 
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Figure 3.32 PCA plots in two dimensions (left) and three dimensions (right) of nine 
cancer cell lines exposed to the 9-peptide array. Three dimensions account 
for 57.4% of the variance in the data set. 
Classification was also achieved using the unsupervised method PCA, which 
indicates that the variance in response of the array is diagnostic for each cell line. 
Analysis of the PCA loading plots (Figure 3.33) in conjunction with the score plots 
reveals several contributions to the classification model. From the loading plots it is 
evident that several variables contribute to each principal component to varying extents 
and have loadings on multiple components. This means that the array was behaving in a 
cross-reactive manner. In two dimensions, there is overlap of the responses of SK-MEL-
28, DU-145, U-87 MGVIII, and HCT-15 (Figure 3.32). These groups are better classified 
with the addition of a third principal component. Classification continues on the fourth 
and fifth PCs; however, the scatter increases as these PCs account for less variance and 
thus include more relative error (Figure 3.34). Over 70% of the variance in the data is 
accounted for with the inclusion of the first five components of the model, further 
supporting the cross-reactivity of the array response. 
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Figure 3.33 Loading plots of array variables on the first four PCs, accounting for 68% of 
the variance in the data set. 
 
Figure 3.34 PCA score plot of nine cell lines on the third, fourth, and fifth principal 
components. Addition of PC5 accounts for 74% of variance in the data set. 
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MOLT-4 and A-549 have the most negative scores. The positions of SK-OV-3 and A-
549 on the score plot were previously shown to be influenced by their responses to TO1-
6 and DNATO1-1, respectively. DNATO1-2, TO1-8, and DNATO1-8 are also 
positively correlated with PC1, although not as strongly as TO1-2 and TO1-6. The 
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former peptides were chosen to bind to particular cell lines, A-549/SK-MEL-28 and DU-
145/MDA-MB-231, respectively. Although the response of these cell lines to the two 
peptides does not result in pairing of the cell lines on this axis, both SK-MEL-28 and 
DU-145 have positive scores. TO1-6 was selected to act as a mimic of the sugar 
mannose, but it is also the most hydrophobic of the peptides. Cell lines that score 
positively on PC1 may display receptors for binding mannose, or may have an abundance 
of other receptors that provide hydrophobic contacts. 
The loading of TO1-1 onto PC1 indicates that cells that have negative scores on 
PC1 may display hyaluronan or a similar feature that binds the peptide sequence 
VVKLK. This sequence also has the most positive charge directed away from the site of 
intercalation, indicating that cell lines that score negatively on PC1 may have more 
negatively charged surfaces. TO1-4 and TO1-5 are also negatively correlated with PC1; 
both peptides were designed to bind to integrins. As discussed earlier, A-549 binds 
laminin and its negative score on PC1 may be due to binding of TO1-5. MDA-MB-231 
and 786-O display integrins that bind to the RGD motif of TO1-4,48 and part of the 
invasiveness of these cells comes from the expression of α5β1 integrin.49  
On PC2, DNATO1-9 is highly positively correlated and DNATO1-4 is highly 
negatively correlated. MOLT4 and MDA-MB-231 have the highest scores, while A-549 
has the lowest. The TO1-9 peptide was designed to target erbB receptors. Breast cancers, 
such as MDA-MB-231, overexpress erbB receptors,42 which indicates that cell lines that 
score positively on PC2 may express erbB receptors to a greater extent than those that 
score negatively. TO1-4 targets the surface adhesion protein integrins. This PC may be 
indicative of the adherent properties of the cell lines, as it was observed in cell culture 
that A-549 was the hardest to enzymatically detach from the growth surface. MOLT-4 is 
a suspension cell line, and it was observed that MDA-MB-231 frequently detached 
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during initial experiments. Additionally, MDA-MB-231 is highly metastatic and altered 
adhesion properties of metastatic cells have been shown to contribute to their motility and 
invasive potential. 
On PC3, MDA-MB-231 and SK-MEL-28 have the highest scores, while DU-145 
has the lowest. TO1-3 is highly positively correlated with this PC, and DNATO1-5 is 
also positively correlated. TO1-7 and TO1-8 are negatively correlated. TO1-8 was 
chosen to bind to both MDA-MB-231 and DU-145, but as seen on PC1, the response of 
TO1-8 significantly contributes to the classification of DU-145 but not MDA-MB-231. 
This PC also helps to separate the cell lines that are not well classified along the first two 
PCs; both SK-MEL-28 and U-87 MGVIII have positive scores on PC3, while HCT-15 
and DU-145 have negative scores. On this axis, the DNA-peptides and peptides alone 
generally display the same direction but different magnitudes, with the peptides alone 
having larger magnitudes. 
Despite an increase in scatter, groupings are still observed on PC4 and PC5. 
DNATO1-6, DNATO1-8, and TO1-9 are the most positively associated variables with 
PC4, while TO1-7, DNATO1-7, and DNATO1-3 are the most negatively associated. On 
average, SK-MEL-28 has the most positive score, while SK-OV-3 has the most negative 
score. These cell lines are more closely associated on the first three PCs; the variance 
described by PC4 is able to better separate them. U-87 MGVIII, DU-145, and MDA-MB-
231 also score positively on this PC, and TO1-8 contains the motif designed to bind the 
latter two cell lines. Here the response of this peptide contributes to their grouping, unlike 
on previous axes. The TO1-3 peptide was designed to bind SK-OV-3 and HCT-15, and 
these two lines score negatively on this PC. It appears that on axes which describe 
smaller, yet still significant, amounts of the variance, the hypothesized responses of the 
cell-targeting peptides contribute to cell classification. 
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The variables containing TO1-2, TO1-4, TO1-5, and TO1-6 are highly 
associated with the PCA classification of SK-MEL-28. TO1-2 was included as a peptide 
expected to bind to this cell line. SK-MEL-28 expresses αvβ3, α2β1, and α2β1 integrins 
that should bind to peptides TO1-4 and TO1-5.50 The response of mannose mimic TO1-6 
could indicate mannose receptors present on this cell line or other surface features that 
are capable of interactions with the most hydrophobic peptide in the array.  
The classification of DU-145 is highly associated with responses to peptides 
containing TO1-8, TO1-6, and to a lesser extent TO1-4 and TO1-9. The motif in TO1-8 
was included to bind to DU-145. This cell line expresses α5β1 integrin and binds to 
fibronectin, explaining its response to TO1-4.51 ErbB receptor overexpression, especially 
erbB-2, is highly associated with negative clinical outcome in prostate cancers, like the 
metastatic, androgen resistant DU-145 that expresses high levels of erbB1-3.52 Again the 
response of mannose mimic TO1-6 contributes to the classification of this cell line, 
indicating the presence of receptors capable of binding this peptide. 
Although no peptides were selected specifically to bind U-87 MG VIII, several 
peptides are correlated with this cell line’s classification, indicating the promiscuity of 
the array receptors. In particular, TO1-9 is correlated with classification on PC1, PC2, 
and PC4, and this peptide binds erbB receptors of the type (αvβ3) that are overexpressed 
on gliomas. Peptide TO1-8, chosen to bind MDA-MB-231, is also correlated with 
classification of this cell line. Both cell lines are highly metastatic and overexpress erbB, 
which indicates that the peptide may be targeting erbB or other malignancy-associated 
receptors on these cell lines. 
The classification of A-549 by PCA is correlated with the response of many of the 
array peptides. On PC1-PC3, the axes with the most variance, TO1-2, TO1-4, TO1-5, 
TO1-6, and TO1-9 are correlated with classification.  As noted in section 3.2.4, A-549 
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binds to laminin and expresses erbB receptors, explaining the correlation of classification 
with the loadings of TO1-4 and TO1-5.46,47 As observed in initial experiments, TO1-1 
and TO1-3 are correlated with A-549 classification. The peptide chosen to bind A-549, 
TO1-2, also contributes to classification on axes that carry less variance (PC4 and PC5).  
A variety of peptides are correlated with the classification of MOLT-4. These 
include TO1-1, TO1-3, TO1-5, TO1-7, and TO1-9. TO1-7 is the peptide chosen to bind 
MOLT-4. The response of the other peptides to classification indicates that MOLT-4 
expresses hyaluronan (TO1-1),53 collagen- and/or laminin-binding integrins (TO1-5),54 
surface features similar to SK-OV-3 and HCT-15 (TO1-3), or other surface features that 
are capable of recognizing these sequences. 
PCs that classify 786-O have high correlation with TO1-9. ErbB receptors are 
crucial to renal cell development and homeostasis.55 Additionally, for classification of 
this cell line, TO1-3, TO1-4, and TO1-5 are correlated on PCs that describe higher 
variance. The latter two peptides likely bind to cell surface integrins, whose assembly is 
modified in 786-O cells.48 TO1-7 and TO1-8 are correlated with PCs describing lower 
variance. TO1-7 was selected to bind 786-O, while TO1-8 was selected for binding other 
cell lines. 
TO1-2, TO1-3, TO1-5, TO1-6, TO1-8, and TO1-9, contribute to classification of 
SK-OV-3. The response of these peptides to classification of this cell line is in agreement 
with the initial three cell line experiment. TO1-3 was selected to bind SK-OV-3, TO1-9 
binds erbB-2 that is overexpressed by SK-OV-3, TO1-5 binds integrin receptors that are 
expressed to a greater extent on this cell line compared to other ovarian cancers.38 
The variables that contribute to the classification of MDA-MB-231 are also in 
agreement with initial experiments. TO1-8, the peptide selected to bind MDA-MB-231, 
is correlated with the classification of this cell on three out of five PCs. As expected, the 
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integrin binding peptides TO1-4 and TO1-5 respond to this cell line, which 
overexpresses erbB. The rather promiscuous peptide TO1-3 also contributes to 
classification of this cell line. This cell line also has a strong response to TO1-1, 
indicating it may express hyaluronan; hyaluronan synthase is associated with breast 
cancer cell invasion.56 
Classification of the nine cancer cell lines tested was achieved using the 
differential array composed of nine peptide conjugates with and without DNA. 
Classification was observed over five principal components, which described 74% of the 
variance in the data set. Several peptide receptors were associated with each of the 
principal components, and the major contributors to each component were variable. 
Peptide sequences that had been selected to bind particular cell lines and known cell 
surface receptors generally responded as hypothesized. These sequences also responded 
to other cell lines that they were not hypothesized to bind, indicating that the receptors 
behave in a cross-reactive manner.  
3.2.5.3 Reproducibility 
Eight cell lines were grown from frozen stocks and again passaged to poly-D-
lysine plates. The response of each cell line to the 9-peptide array was measured and 
analyzed using PCA. These results can be compared to PCA performed on the original 
data set, omitting the ninth cell line, MDA-MB-231.  Comparison of the loading plots 
shows that both models capture similar amounts of variance on the first two PCs (Figure 
3.35) Although the variables have different magnitudes, many of the variables that are 
positively associated with PC1 in the original experiment are also positively associated 
with PC1 in the reproduction. These are DNATO1-6, TO1-7, TO1-8, DNATO1-8, and 
DNATO1-9. This is also true for many variables that are negatively associated with PC1: 
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TO1-1, DNATO1-1, TO1-3, DNATO1-3, and TO1-9. Similar congruencies are 
observed on PC2; in both experiments, TO1-4, TO1-6, TO1-8, and DNATO1-5 are 
positively associated, while DNATO1-1, TO1-5, DNATO1-8, and DNATO1-9 are 
negatively associated. It is clear that the models generated from the two data sets are not 
exactly the same, as the responses of some of the peptides were found to have different 
contributions to the variance in the two models generated. 
   
Figure 3.35 Comparison of PCA loading plots of the original experiment (left) and 
experiment reproduction (right) for eight cell lines. 
The score plots of the first two PCs for both experiments are shown in Figure 
3.36. It is clear that in both experiments cells can be classified according to cell line. 
There are major similarities between the reproduction and the original experiment in 
terms of placement on the score plot; this is likely due to the similarities of variable 
contributions in the model generated for each data set. This is an indication that, to some 
extent, the array is responding similarly each time it is exposed to an analyte. For 
example, in both experiment sets, MOLT-4 scores negatively on the first and second PCs. 
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Additionally, HCT-15, U87MGVIII, and DU-145 are closely associated in both score 
plots. 
 
Figure 3.36 Comparison of two dimensional PCA score plots of the original experiment 
(left) and experiment reproduction (right) for eight cell lines. 
As is apparent from the differences in the loading plots (Figure 3.35), there are 
observable differences in the scores of analytes between the two experiments (Figure 
3.36). On the first PC, 786-O and SK-OV-3 have switched responses. Originally, SK-
OV-3 had a high positive score and 786-O had a small negative score, while in the 
reproduction SK-OV-3 has a medium negative score and 786-O has a high positive score. 
Although both SK-MEL-28 and A-549 both score positively on PC2, the magnitude of 
their responses is switched between the two experiments 
The score plot with a third PC is shown in Figure 3.37. Differences in the scores 
along PC3 are observed between the two experiments. However, it is shown in Table 3.6 
that the sign of the majority of the variables is switched on this axis. The manner in 
which variables are chosen to positively or negatively correlate with a PC depend on the 
program algorithms used and are essentially arbitrary. Therefore, it is possible that cell 
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lines that had a high positive score on PC3 in the original experiment would have a high 
negative score on PC3 in the reproduction, due to the opposite signs of the correlations of 
a majority of the variables on this axis. For example, both MOLT-4 and SK-MEL-28 
have negative scores on PC3 in the reproduction, but positive scores in the original 
experiment. DU-145 has a positive score in the reproduction, but a large negative score in 
the original experiment. The ordering of cell lines along this axis differs between 
experiments, likely due to the differences in magnitudes of the contribution of each 
variable to PC3 for the two data sets. Nevertheless, the third PC carries a significant 
amount of the variance in the data set (>10%) and contributes to classification of the cell 
lines in both experiments. 
 
 
Figure 3.37 Comparison of three-dimensional PCA score plots of the original experiment 
(left) and experiment reproduction (right) for eight cell lines. 
 
 
 
 128 
 Original Repeat DNApep1 -0.374 0.374409 
DNApep2 -0.125 0.655486 
DNApep3 -0.222 -0.19253 
DNApep4 0.268 -0.53816 
DNApep5 0.575 -0.18678 
DNApep6 0.247 0.175707 
DNApep7 0.069 0.353574 
DNApep8 -0.034 0.132327 
DNApep9 -0.117 0.326137 
pep1 -0.094 0.439931 
pep2 0.260 0.324185 
pep3 0.799 -0.53936 
pep4 0.468 0.100267 
pep5 -0.237 -0.35808 
pep6 0.313 -0.35334 
pep7 -0.604 0.185345 
pep8 -0.512 0.317246 
pep9 -0.489 0.123915 
Table 3.6 Correlations between variables and PC3 in the original and reproduction data 
sets. Green values are inverted between the two experiments. 
3.2.6 Fluorescence and MS Patterning of Cancer Cell Lines Using a Peptide Mixture 
3.2.6.1 Titrations of Peptides and Mixture with 2 kb dsDNA 
In order to assemble more intercalator peptides along the DNA backbone, a 
longer dsDNA strand consisting of about 2.5 kilobases was used. Titrations with each 
peptide were performed to determine the equivalents required for fluorescence saturation. 
As observed with the 1 kb strand, variable equivalents were needed to reach saturation of 
the fluorescence signal and different peptide sequences resulted in different emission 
intensities. A mixture of the nine peptides at the individual saturation concentrations was 
prepared and titrated with the 2.5 kb strand (Figure 3.38). Maximum fluorescence was 
seen at about two peptides per DNA base pair, which corresponded to a 1/10 
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concentration of the nine peptide mixture. For further experiments, such a dilution of the 
peptide mixture was used. 
 
Figure 3.38 Titration of 2.5 kb dsDNA with a nine-peptide mixture at individual peptide 
concentrations corresponding to fluorescence saturation upon intercalation 
with DNA. 
3.2.6.2 Fluorescence Classification 
Cancer cells of different tissue type were grown to confluency on 12-well plates. 
The peptide mixture was exposed at the same concentration with and without 2.5 kb 
dsDNA to plates of each cell type and the fluorescence response of 10 replicates was 
measured. Fluorescence values of the mixture exposed to cells were expressed as ratios 
over the solution fluorescence. The plot of the fluorescence values with DNA versus 
those without DNA shows that the mixtures are able to classify the cell line replicates 
(Figure 3.39). Differences in the fluorescence values for the cell lines arise from either 
differential binding of sequences, binding of sequences with different emission 
intensities, or both. The different fluorescence properties of the peptides therefore lead to 
the differential fluorescence responses that are responsible for the cell line classification. 
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Figure 3.39 Fluorescence responses of peptide mixtures with and without DNA to cells of 
different tissue origins. 
3.2.6.3 Mass Spectrometric Analysis 
In order to identify the sequences of the peptides in the mixture that bound to each 
cell line, cell lines were washed with DPBS, detached, and bound sequences were eluted 
into water. The supernatant of the elution solution was analyzed using ESI mass 
spectrometry. Although fluorescence values were measured on concentrated supernatant, 
masses corresponding to the peptides could not be identified in these solutions. 
Elimination of the DPBS wash did allow for identification of one peptide bound to DU-
145, TO1-6 (Figure 3.40). This peptide is the most hydrophobic of those in the mixture. 
However, it was found to contribute to the classification of DU-145 in the nine-peptide 
array. Further experiments will be conducted to analyze other cell lines under similar 
low-wash conditions. 
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Figure 3.40 Mass spectrum of peptide indentified as present in DU-145 cell supernatant. 
Expected mass is 457.68070 for (M+2H)2+. 
 
3.3 CONCLUSION 
A dynamic, DNA-templated array of differential intercalator-peptide receptors 
was created to pattern multivalent biological analytes. Derivatives of thiazole orange, a 
fluorescent DNA intercalator, were prepared, and their interactions with dsDNA were 
studied. Although it was hypothesized that supercoiled DNA would be able to 
accommodate a larger amount of thiazole orange derivatives, it was concluded that long, 
linear dsDNA of 1000 bp was the best scaffold for assembling peptide recognition units. 
Cancer cells of different tissue origin were chosen as exemplar multivalent biological 
analytes due to their surface complexity and the strength of differential array sensing with 
complex mixtures. Instead of choosing recognition units of simple functionality, a variety 
of peptide conjugates of thiazole orange were synthesized. These peptides were chosen to 
target analytes by incorporating sequences that bind to known cell surface features and 
sequences that were previously shown to have high association with particular cell lines. 
These receptors were hypothesized to behave in a cross-reactive manner and bind to 
many of the cell lines to varying extents because each peptide sequence targets shared 
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surface features or multiple cell lines. The array was hypothesized to produce a unique 
pattern for each cell line resulting from a differential response from many peptides 
binding to each cell line but to different extents. Using chemometric techniques, unique 
patterns of receptor responses can be used for analyte classification. 
Receptor assemblies of dsDNA and nine peptides of variable sequence were 
prepared and incubated with nine cancer cell lines. The nine peptides were 
simultaneously exposed to the cancer cell analytes without DNA. The receptor assembly 
containing DNA displayed the ability to detach the cells from the growth surface, which 
indicated that the receptors were targeting cell surface features that contribute to 
adhesion. Detachment of cells occurred to a much greater extent when the peptides were 
exposed as the DNA-assembled receptors, compared to the free peptides. This indicated 
that the receptor assembly was better at binding to the cell surface, likely due to 
multivalent interactions, and therefore behaved as hypothesized. 
Fluorescence measurements of the response of the peptide array, with and without 
DNA, to each cell line were input into chemometric routines for analysis. Both linear 
discriminant analysis and principal component analysis were able to successfully classify 
nine replicates of each cell line on score plots by using the fluorescence pattern of the 
array. Such classification indicated that the fluorescence patterns for each cell line were 
unique, as hypothesized for a differential array. Analysis using PCA indicated that the 
classification arose from the data structure, and that the variance in the data set was 
diagnostic for cell type.  
Analysis of the contributions of each peptide to the variance captured and to cell 
line classification showed that many of the peptides responded as designed. The variable 
sequences bound to cells that express epitopes for which the peptides were designed to 
bind and/or showed binding to cell lines for which they were hypothesized to have 
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affinity. The peptides behaved promiscuously, as each peptide was capable of responding 
to multiple cell lines. Not all peptides bound to each cell line, but the pattern of receptor 
response was diagnostic of the cell type. These combined responses allowed for 
discrimination of cell lines using the differential array. 
Investigation into reproducibility of the array classification showed that cell lines 
were again successfully classified. The array response, as analyzed using PCA, was 
found to not be exactly reproduced. Many of the peptides responded in a similar manner 
and had congruent contributions to the variance, as shown in their correlations with the 
principal components. The scores of cell lines on the score plot, however, were 
significantly different for some cell lines. This may be due to the difference in the 
contribution of some variables to the PCs, or due to significant differences in the 
response of the array to cell lines between the two experiments. Even though the cell 
lines are successfully classified, the pattern of response for each cell line is subtly 
different, and any small changes can lead to differences in variable loading and analyte 
scores, resulting in differences in the appearance of PCA plots. Additionally, the array 
may be capable of responding to subtle changes in expression of cell surface receptors on 
the analytes that are associated with growth for different experiments. In such a case, the 
response may not be exactly the same as a previous pattern, but the surface features 
would be unique to each cell line and the array response to each analyte would therefore 
still be unique. 
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3.4 EXPERIMENTAL 
3.4.1 Synthesis 
Chemicals were purchased from Sigma-Aldrich, Fisher Scientific, or Acros 
Organics and used without further purification. All solvents were of at least reagent grade 
and purchased from Fisher Scientific. NMR spectra were collected on a Varian 400MHz 
NMR using isotope-enriched solvents from Cambridge Isotopes. Mass spectrometry was 
performed in water/methanol or water/acetonitrile mixtures on an Agilent instrument. 
3.4.1.1 Synthesis of a Carboxylic Acid Thiazole Orange Derivative 
Synthesis of 3-methyl-2-(methylthio)-benzothiazolium tosylate (3.3) 
3.7 g (20 mmol) of 2-methylthiobenzothiazole and 4.5 g (24 mmol) of methyl p-
toluene sulfonate were added to a dry 100 mL round bottom flask and heated under Ar 
gas to 130°C. After 1 hour, the solution turned yellow and the temperature was reduced 
to 70°C. Acetone was added to the mixture through the condenser until a yellow solid 
appeared, and the solid was heated for an additional half-hour then cooled to RT. White 
crystals were isolated by vacuum filtration and washed with acetone, then dried under 
high vacuum overnight, yielding 5.71 g of 3.3 (76% yield). 
1H-NMR (400 MHz, CD3OD): δ 2.34 (s, 3H), 3.11 (s, 3H), 4.13 (s, 3H), 7.18 (d, J=7.9, 
2H), 7.66 (d, J=8.2, 2H), 7.71 (td, J=1.0, 8.2, 1H), 7.83 (td, J=1.2, 8.5, 1H), 8.06 (d, 
J=8.5, 1H), 8.21 (d, J=8.2, 1H). 
13C-NMR (100 MHz, CD3OD): δ 18.64, 21.44, 37.00, 116.60, 124.77, 127.03 (2C), 
128.63, 129.89, 130.02 (2C), 130.85, 141.68, 143.86, 144.21, 183.35. 
 
Synthesis of 1-(3-carboxypropyl)-4-methylquinolin-1-ium chloride (3.8c) 
1.4 g of lepidine (9.8 mmol) and 2.2 g of 4-bromobutyrate (11.2 mmol) were 
added to a dry 5 mL microwave tube equipped with a stirbar and microwaved for 40 
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minutes at 82°C. The microwave tube was rinsed with MeOH, and the resulting purple 
liquid was poured into 100 mL of Et2O and stirred until the ether became clear, then the 
ether was decanted. Upon combining the purple liquid with 50 mL of H2O in a 100 mL 
rbf, the solution turned burnt orange. Then 2 mL of 48% HBr was added to the water and 
the solution was refluxed overnight. The solution volume was reduced by evaporation, 
and a solution of saturated KPF6 was added by pipet until the remaining liquid became 
cloudy. After precipitation in the fridge overnight, an off-white solid, 3.8b, was obtained 
from vacuum filtration. The product was dissolved in 3:1 MeCN:H2O and passed down 
an Amberlite® 402 Cl ion exchange column and lyophilized. A white fluffy solid was 
isolated but turned into a taupe hard solid upon exposure to moisture. Yield of 3.8c was 
0.171g (7%). 
3.8b: 1H-NMR (400MHz, CD3CN): δ 2.27 (m, 2H), 2.53 (t, 2H), 3.00 (d, 3H), 4.92 (m, 
2H), 7.85 (d, 1H), 8.02 (m, 1H), 8.48 (m, 2H), 8.90 (d, 2H). 
19F-NMR (400 MHz, CD3CN): δ -74.58, -72.02. 
13C-NMR (100 MHz, CD3CN): δ 20.85, 25.89, 30.84, 58.18, 120.28, 124.02, 128.50, 
131.06, 131.12, 136.79, 138.78, 149.00, 161.16, 174.50. 
MP: 100-105°C dec. 
3.8c: 1H-NMR (400MHz, CD3CN): δ 2.57 (t, 3H), 2.99 (s, 3H), 4.95 (2H), 7.86 (d, 1H), 
7.99 (t, 1H), 8.21 (t, 1H), 8.47 (d, 1H), 8.54 (d, 1H), 8.98 (d, 1H). 
MP: 196-198°C dec.  
 
Synthesis of TO1 
The thiazolium tosylate salt 3.3 (0.735 g, 2.0 mmol) and quinolinium chloride 
3.8c (0.534 g, 2.0 mmol) were both weighed into a dry 100 mL rbf. After adding dry 
CH3CN (40 mL), the flask was equipped with a condenser, and the mixture heated to 
82°C. 600 uL (0.44 g, 4.3 mmol) Et3N was injected into the mixture, causing the orange 
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solution to immediately change to a dark red. The solution was heated under Ar for three 
hours; after forty-five minutes, orange solid was present in the flask, and it emitted a bad 
odor (methyl sulfide). The flask was cooled and 100 mL Et2O added into the suspension. 
The solid was vacuum filtered and rinsed with Et2O and then recrystallized from 
MeOH/H2O. The orangey red solid weighed 0.442g (54% yield).  
1H-NMR (400 MHz, DMSO-d6): δ 1.07 (t, J=7.0, 1H), 2.11-2.01 (m, 2H), 2.41 (t, J=7.1, 
2H), 3.37 (dd, J=7.0, 14.0, 3H), 3.98 (s, 3H), 4.55 (t, J=7.6, 2H), 6.88 (s, 1H), 7.34 (d, 
J=7.2, 1H), 7.40 (t, J=7.6, 1H), 7.59 (t, J=7.8, 1H), 7.73 (t, J=7.1, 2H), 7.98 (dd, J=7.8, 
17.2, 2H), 8.16 (d, J=8.6, 1H), 8.55 (d, J=7.2, 1H), 8.75 (d, J=8.2, 1H). 
13C-NMR (150 MHz, DMSO-d6): δ 24.11, 30.30, 33.70, 53.41, 88.03, 107.87, 112.88, 
117.83, 122.74, 123.77, 124.11, 124.45, 125.68, 126.74, 128.11, 133.20, 136.96, 140.31, 
144.17, 148.50, 159.98, 173.69. 
HRMS-ESI (m/z): [M]+ calcd for (C22H21N2O2S)+ 377.1324; found: 377.1324. 
MP: 237-239°C dec. 
3.4.1.2 Peptide Coupling 
Synthesis of all peptides was undertaken using an automated peptide synthesizer 
(Protein Technologies) using Fmoc chemistries and Wang resins. All deprotection and 
coupling steps were repeated twice. Resins and protected amino acids were obtained from 
NovaBioChem. HPLC-grade solvents were purchased from Sigma-Aldrich and prepared 
by addition of 0.1% TFA (v/v), filtration through a 0.2 micron filter, and then degassed 
using sonication. HPLC purification was performed on a Shimadzu with a preparative C-
18 column using water and acetonitrile as the mobile phase. 
General Procedure 
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For a 200 umol scale reaction, an Fmoc-protected Wang resin (100-200 mesh) 
coupled to the C-terminal residue was swelled in DMF. The resin was deprotected with a 
20% piperidine solution then washed sequentially with DMF and DCM. A DMF solution 
of the next peptide in the sequence (100 mM), with appropriate protecting groups, was 
added to the reaction vessel for coupling between the amine and carboxylic acid. The 
coupling reagent used was PyBOP (300 mM) with DIPEA (1.2 M) in DMF. After 
coupling to the final residue in the peptide sequence, the resin was washed with DMF and 
DCM and removed from the synthesizer. The resin was manually deprotected using 20% 
piperidine until a positive Kaiser test resulted. At this point, a solution of TO1 in 
HOBT/HBTU (300 mM each) with1.2 M DIPEA in DMF was added, and the resin 
shaken until a negative Kaiser test resulted. The resin turned blood red and retained a red 
stain after washing with 20 mL DMF, 20 mL DCM, and 20 mL MeOH. The resin was 
rinsed with 15 mL acetic acid and vacuum dried overnight. Peptides were cleaved from 
the resin using a TFA cleavage cocktail (95% TFA, 2.5% TIPS, 1.5% EDT, 1% H2O) and 
shaking for 4 hours. The TFA solution was separated from the resin by filtration under 
aspirator pressure, the resin was washed with TFA, and the filtrate collected. TFA was 
removed from the filtrate on a rotavap. Precipitation of the peptides using cold ether 
resulted in an orange solid. 
HPLC Purification and Isolation 
 Solid peptides were taken up in a mixture of 50/50 DMSO/H2O and purified using 
preparative HPLC. The method was as follows: 
0-35 min 5-30% MeCN in H2O, 35-45 min 30% MeCN, 45-60 90% MeCN. The 
absorbance at 500 nm was monitored and only fractions containing this absorbance were 
analyzed. 
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Fractions containing the desired peptide were verified using LC/MS then 
combined, rotavaped to remove acetonitrile, and lyophilized to remove water. Low 
resolution mass spectrometry was used for each peptide (Table 3.7) 
 
 
TO1-peptide 
Expected Mass (m/z) 
Found (m/z) 
(M+2H)3+ (M+H)2+ (M+) 
TO1-1 315.5 472.7 944.5 315.6, 472.6, 944.1 
TO1-2 282.8 423.7 846.4 282.9, 423.7, 846.3 
TO1-3 292.8 438.7 876.4 292.9, 438.7, 876.3 
TO1-4 310.8 465.7 930.4 310.9, 465.7, 930.3 
TO1-5 292.8, 438.7 876.4 292.9, 438.4, 876.3 
TO1-6 305.4 457.7 914.3 457.6, 914.0 
TO1-7 302.6 453.7 906.4 302.8, 453.6, 907.1 
TO1-8 273.1 409.2 817.4 409.2 
TO1-9 298.1 446.7 892.4 298.2, 446.6, 892.0 
Table 3.7 FIA-ESI + MS (low-res) on HPLC purified peptides 
3.4.2 DNA Isolation and Amplification 
3.4.2.1 General Procedures 
All oligonucleotides were ordered from Integrated DNA Technologies (IDT), 
were dissolved in nuclease-free water to a concentration of 100 μM, and stored at -20C. 
Polymerase chain reaction (PCR) was performed under one of two following conditions. 
Using Taq Polymerase from NEB: 2.5U enzyme per 50ß uL reaction, 1X ThermoPol 
buffer, 0.2 mM dNTPs, 4 μM primers, 0.1 ng/uL template or 10 ng/uL template 
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(genomic) were added. Thermal cycling steps were 1) 98 °C 2 min, 2) 98C - 30 sec, 3) 
Annealing T - 30 sec, 4) 68 °C 1 min/kb, 5) hold at 4 °C, and steps 2-4 were repeated for 
as many cycles as necessary to yield optimal amplification. Using Q5 high fidelity 
polymerase from NEB 1X buffer, 0.2 mM dNTPs, 4 μM primers, 1.25 U/25 uL 
polymerase, and 0.1 ng/uL template were added to 50 or 100 uL reactions. Thermal 
cycling steps were 1) 98 °C – 30 sec, 2) 98 °C – 10 sec, 3) Annealing T – 30 sec, 4) 72 
°C – 25 sec/kb, 5) 72 °C – 2 min, 6) 4 °C – hold, with steps 2-4 repeated as needed. 
Concentrations of dsDNA were estimated from absorbance values measured at 
260 nm on a nanodrop. Sequences of dsDNA were input into the spreadsheet provided 
from Tautarov et al. in order to estimate the sequence and length-dependent molar 
absorptivity of each strand at 260 nm.57 The concentrations of each dsDNA solution were 
calculated using the absorbance values at 260 nm and the estimated molar absorptivity. 
Gel electrophoresis was performed using agarose gels of variable concentration 
(3-4% for less than 100 bp, 1-2% for 1000 bp or higher) in 1x TAE buffer. Samples were 
loaded with glycerol loading dyes and run against a Fermentas GeneRuler DNA Ladder 
Mix or O’RangeRuler 10 bp DNA ladder (<150 bps) (Figure 3.41). Ethidium bromide 
was added to the gels upon preparation in order to stain the DNA. Gels were run at 
15V/cm until appropriate loading dyes ran at least half the length of the gel, and then gels 
were imaged with UV illumination. 
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Figure 3.41 DNA ladders used to size PCR products on agarose gels. 
3.4.2.2 dsDNA strands 
53-mer 
An oligonucleotide consisting of 53 base pairs of the sequence:  
5’-
TGCTGCAGATGCAACGTCATGTATTATCAGCAGTAACTAGCGACTGGGTCCG-
3’ 
was designed to have close to 50% GC content and a linear structure. Primers specific to 
this sequence were also designed using Primer-3. After a temperature gradient and cycle 
course, the optimal annealing temperature was found to be °C with X cycles of 
amplification. The absorbance value of purified PCR product at 260nm (A260) of the DNA 
suspended in DPBS was measured by nanodrop and the concentration calculated from ε = 
84,2003 M-1cm-1.  
152- and 202-mers 
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These strands of DNA are the double-stranded templates for aptamers, and were 
donated by Sara Stewart.  
1000-mer 
Genomic DNA was isolated from buccal cells collected after rinsing the mouth 
with 0.1 M saline for 2 minutes. The buccal cells were lysed and extracted following the 
procedures of the Sigma-Aldrich GenElute™ miniprep kit. Isolated genomic DNA was 
stored at -20°C. Gel electrophoresis showed that the DNA had not been sheared to 
smaller than 15,000 bps (Figure 3.42). Concentration of the genomic DNA was measured 
as 58.4 ng/uL on a nanodrop.  
 
 
Figure 3.42 Genomic DNA isolated from buccal cells run against GeneRuler ladder on 
1% agarose in 1X TAE. 
A search through the NIH genome database Nucleotide identified a highly 
conserved genomic sequence of 2500 bps that codes for the β2 adrenergic receptor. 
Primers for a 1000 bp product from the gene were developed using Primer-3 and 
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crosschecked in the Primer-BLAST program from NIH. Primer-BLAST showed that the 
only product that the primers would give from a genomic template was the intended 1000 
bp sequence: 
5’CACCAACTACTTCATCACTTCACTGGCCTGTGCTGATCTGGTCATGGGCCTG
GCAGTGGTGCCCTTTGGGGCCGCCCATATTCTTATGAAAATGTGGACTTTTGG
CAACTTCTGGTGCGAGTTTTGGACTTCCATTGATGTGCTGTGCGTCACGGCCA
GCATTGAGACCCTGTGCGTGATCGCAGTGGATCGCTACTTTGCCATTACTTCA
CCTTTCAAGTACCAGAGCCTGCTGACCAAGAATAAGGCCCGGGTGATCATTC
TGATGGTGTGGATTGTGTCAGGCCTTACCTCCTTCTTGCCCATTCAGATGCAC
TGGTACCGGGCCACCCACCAGGAAGCCATCAACTGCTATGCCAATGAGACCT
GCTGTGACTTCTTCACGAACCAAGCCTATGCCATTGCCTCTTCCATCGTGTCC
TTCTACGTTCCCCTGGTGATCATGGTCTTCGTCTACTCCAGGGTCTTTCAGGA
GGCCAAAAGGCAGCTCCAGAAGATTGACAAATCTGAGGGCCGCTTCCATGTC
CAGAACCTTAGCCAGGTGGAGCAGGATGGGCGGACGGGGCATGGACTCCGC
AGATCTTCCAAGTTCTGCTTGAAGGAGCACAAAGCCCTCAAGACGTTAGGCA
TCATCATGGGCACTTTCACCCTCTGCTGGCTGCCCTTCTTCATCGTTAACATTG
TGCATGTGATCCAGGATAACCTCATCCGTAAGGAAGTTTACATCCTCCTAAAT
TGGATAGGCTATGTCAATTCTGGTTTCAATCCCCTTATCTACTGCCGGAGCCC
AGATTTCAGGATTGCCTTCCAGGAGCTTCTGTGCCTGCGCAGGTCTTCTTTGA
AGGCCTATGGGAATGGCTACTCCAGCAACGGCAACACAGGGGAGCAGAGTG
GATATCACGTGGAACAGGAGAAAGAAAATAAACTGCTGTGTGAAGACCTCC
CAGGCACGGAAGACTTTGTGGGCCATCAAGGTACTGTGCCTAGCGATAACAT
TGAT-3’ 
Primers were ordered from IDT and dissolved in nuclease-free water to a 
concentration of 100 μM. The conditions for PCR were optimized by running a 
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temperature gradient to find the ideal annealing temperature of the primers to the 
genomic sequence, 58.5°C. The product band at 1000 bp was gel-extracted and purified, 
and the number of cycles for this template optimized for use in further PCR reactions 
(Figure 3.43). For amplification with NEB Taq, the annealing temperature was 58.5 °C; 
for NEB Q5, the annealing temperature was the recommended 3 °C above the lower 
primer Tm. 56 °C. PCR products were purified using a QIAquick PCR purification kit, 
and the A260 of the resulting DNA measured by nanodrop and its concentration calculated 
from ε=15791142 M-1 cm-1. 
 
Figure 3.43 PCR amplified 1 kb dsDNA after optimization of annealing temperature and 
cycles. Samples were run on a 1.5% agarose gel in 1X TAE against 
GeneRuler ladder.  
2.5 kb 
The template for this strand was donated from the Ellington lab. It is a mutant of the 
pKD3 plasmid that consists of 2645 base pairs. This sequence was amplified using Q5 
with an annealing temperature of 63 °C and 30 cycles.  
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3.4.3 Titrations 
All fluorescence spectral values were measured on a PTI Fluorimeter with an 814 
photomultiplier detection system using a 75W xenon short arc lamp at λex = 498 nm and 
λem= 508-620 nm with 4 nm slit widths. Absorbance measurements were taken on a 
Beckmann Coulter DU 800 UV/Vis Spectrophotometer. Well plates were measured on a 
BioTek Synergy 2 Multimode Microwell-plate reader, with fluorescence filters as 
follows: excitation – 485/20, emission – 528/20. Well plates for the cell-patterning 
reproduction were measured on a BioTek Cytation3 Microwell-plate reader, using 
monochromators set for excitation at 485 nm and emission at 528 nm. 
Titrations were undertaken in Dulbecco’s phosphate buffered saline without 
calcium or magnesium (Gibco® Life Technologies). The formulation is 200 mg/L KCl, 
200 mg/L KH2PO4, 8 g/L NaCl, and 2.16 g/L Na2HPO4  7H2O which results in a 10 mM 
phosphate buffer with 150 mM NaCl at pH = 7.4.  
3.4.3.1 Initial Titrations 
A 1 mM stock solution of TO1 in DMSO was prepared by weighing 0.0420 g in a 
100 mL volumetric flask and diluting to volume with DMSO. This solution was diluted 
to 100 μM by adding 1 mL by syringe into a 10 mL volumetric half filled with DPBS and 
then filling to volume with DPBS. 
Titration of TO1 into DNA 
A solution of TO1 (typically 5 μM) was prepared by diluting the appropriate 
volume of a 1 mM stock solution in DMSO in a volumetric flask ¾ filled with DPBS and 
diluting to volume. The concentration of TO1 was verified by UV/Vis spectrophotometry 
using A501 = 63,000 M-1 cm-1.14d A solution of DNA (typically 250 nM) was prepared by 
adding a DNA stock solution in H2O into a 1 mL volumetric ¾ filled with DPBS and then 
diluted to volume. 750 uL of the DNA solution was added into a fluorescence cuvette, 
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and aliquots of TO1 were added by microsyringe. For the titration where the 
concentration of DNA was held constant, an aliquot of DNA stock was added to the TO1 
solution before diluting to volume, such that the concentration was the same as the 
titrand. The fluorescence was monitored with two averages taken for each titration point. 
 
 
 
Titration of DNA into TO1 
A solution of TO1 (typically 250 μM) was prepared by diluting the appropriate 
amount of a 1 mM stock in DMSO into a volumetric flask ¾ filled with DPBS and 
diluting to volume. A solution of DNA (typically 1 μM) was prepared by diluting the 
appropriate amount of a DNA stock in H2O into a 1 mL volumetric ¾ filled with DPBS, 
then adding the appropriate volume of a 1 mM stock of TO1 in DMSO such that its 
concentration was the same was the titrand. A fluorescence cuvette was filled with 750 
uL of TO1, and aliquots of DNA containing TO1 were added by microsyringe. The 
fluorescence was recorded with two averages taken for each titration point. 
Continuous Variation Analysis 
 4.5 μM solutions of 53 bp DNA and TO1 were prepared in DPBS by diluting the 
appropriate volumes of stock solutions in water and DMSO, respectively, into DPBS. 
Variable amounts of each solution were added into 10 glass vials, such that the total 
concentration of the two components was equal to 4.5 μM, but the mole fraction of each 
varied from 0-1. The solutions were diluted to 800uL with DPBS, giving a final total 
concentration of 700 nM, and transferred to a cuvette and the fluorescence monitored. 
 Solutions of 4 μM base pair concentration 1 kb DNA (5 nM DNA strand) and 5 
μM TO1 were prepared as above. These solutions were dispensed into a 384-well plate 
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by micropipette, such that the total volume was 100 uL, the total concentration of the two 
components held constant at 4 μM, and the mole fraction of each component varied from 
0-1. The fluorescence was measured on the well-plate reader with the sensitivity 
referenced to the wells with the highest fluorescence after an initial reading at the default 
sensitivity. 
ESI-Mass Spectrometry Titrations 
Using 14 base pair duplex, d(GGCGTCGGCGTCGC/CCGCAGCCGCAGCG), 
time dependent intercalation studies were carried out using a 1:1 solution of DNA-to-dye 
at 5 μM in 30 mM ammonium acetate. Aliquots of the solution were taken every 0.5 
hours over the course of two hours and a reaction time of 1 hour was determined to yield 
sufficient intercalation at detectable levels and was used for all subsequent experiments. 
Concentration dependent studies were conducted using the same duplex by 
varying the molar ratio of duplex-to-dye for a fixed reaction time of 1 hour. The 
concentration of duplex was maintained at 5 μM in solution, while the dye concentration 
was varied from 5 – 25 μM. 
3.4.3.2 Peptide-Intercalator Titrations 
A stock solution of dsDNA was diluted to give a final concentration of 4 nM (1 
kb strand) or 2 nM (2.5 kb strand) in appropriate wells of 96-well black, clear bottom 
plates (Costar® 3631) filled with DPBS. Stock solutions of peptides were added to each 
well at different volumes in order to provide different concentrations and thus 
equivalents. Fluorescence emission was measured and subtracted from DPBS blank with 
dsDNA in order to give a delta emission value for each well. 
1 kb dsDNA 
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Figure 3.44 Fluorescence emission of titration of 1kb dsDNA (4 nM) with TO1-1 in 
DPBS, pH = 7.4. Maximum fluorescence is seen beyond 2300 equivalents, 
or 9.2 μM, TO1-1. 
 
 
Figure 3.45 Fluorescence emission of titration of 1kb dsDNA (4 nM) with TO1-2 in 
DPBS, pH = 7.4. Maximum fluorescence is seen at 200 equivalents, or 0.8 
μM, TO1-2. 
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Figure 3.46 Fluorescence emission of titration of 1kb dsDNA (4 nM) with TO1-3 in 
DPBS, pH = 7.4. Fluorescence saturation is seen at 1500 equivalents, or 6 
μM, TO1-3. 
 
Figure 3.47 Fluorescence emission of titration of 1kb dsDNA (4 nM) with TO1-5 in 
DPBS, pH = 7.4. Maximum fluorescence is seen beyond 2300 equivalents, 
or 9.2 μM, TO1-5. 
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Figure 3.48 Fluorescence emission of titration of 1kb dsDNA (4 nM) with TO1-6 in 
DPBS, pH = 7.4. Maximum fluorescence is seen beyond 2300 equivalents, 
or 9.2 μM, TO1-6. 
 
 
Figure 3.49 Fluorescence emission of titration of 1kb dsDNA (4 nM) with TO1-8 in 
DPBS, pH = 7.4. Maximum fluorescence is seen at 1900 equivalents, or 7.6 
μM, TO1-8. 
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Figure 3.50 Fluorescence emission of titration of 1kb dsDNA (4 nM) with TO1-9 in 
DPBS, pH = 7.4. Maximum fluorescence is seen beyond 2300 equivalents, 
or 9.2 μM, TO1-9. 
 
2.5 kb dsDNA 
A mixture of nine peptides was titrated into 2.5 kb dsDNA. The relative concentrations of 
each peptide were determined by the fluorescence response of a peptide alone to the same 
strand (Table 3.8). 10.44 μM of peptide mixture were needed to reach maximum 
fluorescence, which is a little lower than average peptide concentration (12.88 μM) 
(Figure 3.51). 
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TO1-peptide Concentration (μM) 
TO1-1 30 
TO1-2 7.5 
TO1-3 6 
TO1-4 10 
TO1-5 6 
TO1-6 15 
TO1-7 4 
TO1-8 12.5 
TO1-9 25 
total 116 
Table 3.8 Concentrations of peptides used in the peptide mixture, as determined from 
previous titrations of each peptide with 2 nM 2.5 kb dsDNA in DPBS. 
 
Figure 3.51 Titration of 2 nM 2.5 kb dsDNA with 9-peptide mixture in DPBS. Maximum 
fluorescence is seen at a dilution of 9 uL into 100 uL total volume. 
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3.4.4 Cell Culture 
Cells were obtained from ATCC (Manassas, VA) and cultured in the 
recommended growth media supplemented with 10% fetal bovine serum (FBS) and 1x 
penicillin-streptomycin antibiotic (100 IU/mL and 100 ug/mL, respectively). The 
Ellington lab provided line U87MGvIII. This line was cultured with an additional 
antibiotic, G418, which was used in the selection of the cell line transfected with the gene 
encoding for the EGFRvIII mutant often observed in glioblastomas.  
HCT-15, MOLT-4, and 786-O cells were cultured in RPMI-1640 medium, SK-
MEL-28, DU-145, and U87MGvIII were cultured in EMEM, A-549 was cultured in F-
12K medium, MDA-MB-231 was cultured in DMEM, SK-O-V3 was cultured in 
McCoy’s 5A Medium. Cells were grown in T-25 tissue culture treated flasks (Corning® 
canted neck 0.2 μM vent cap) until n=4, at which point they were passaged into T-75 
tissue culture treated flasks and grown to confluency. 
3.4.5 Cancer Cell Patterning 
3.4.5.1 Array Generation 
Stock solutions of peptides were prepared by dissolving solid peptide into DPBS. 
For TO1-6, a mixture of methanol and DMSO was required to solubilize the peptide. 
Stocks were diluted to final concentrations of TO1-peptides as determined by titrations 
with 1 kb dsDNA (Table 3.X). These solutions were prepared in DPBS pH = 7.4 with and 
without 4 nM dsDNA and allowed to incubate at 4 °C overnight.  
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TO1-peptide Concentration (μM) 
TO1-1 10.0 
TO1-2 0.8 
TO1-3 5.8 
TO1-4 7.8 
TO1-5 10.0 
TO1-6 10.0 
TO1-7 3.7 
TO1-8 7.8 
TO1-9 10.0 
Table 3.9 Concentrations of peptides used in cell patterning experiments, as determined 
by titration with 4 nM 1 kb dsDNA. 
After five passages, cells of one type were passaged from T-75 flasks into three 
clear-bottom black polystyrene tissue culture treated (costar 3603) or poly-D-lysine 
treated (Corning® BioCoat) 96-well plates and allowed to grow to confluency for at least 
24 hours. Growth medium was removed, and 200 uL DPBS heated to 37°C was used to 
wash each well. Solutions of nine peptides warmed to 37 °C, with or without DNA, were 
added to appropriate wells, and three repeats of the same solution on each plate provided 
nine total repeats over the three plates. Solutions of cells with DPBS and peptides without 
cells were also prepared on each plate. The well plates were incubated at 37°C with 5% 
CO2 for 40 minutes. The peptide solutions were removed and each well with cells was 
again washed with warm DPBS. Fluorescence emission of each well plate was measured 
three times and the fluorescence response was averaged over the three measurements.  
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3.4.5.2 Chemometric Analysis 
Fluorescence responses of each peptide were expressed as a percentage compared 
to the total fluorescence of all of the peptides in the array. This was accomplished by 
summing the fluorescence values of one repeat of each peptide, dividing one repeat by 
the sum, and then multiplying by 100. Such values were calculated for the nine repeats of 
peptides exposed with DNA and the nine repeats of peptides without DNA, as well as for 
the samples not exposed to cells. The latter percentage values were subtracted from those 
of the replicates in order to provide a delta % value that showed how each peptide’s 
contribution to the total fluorescence changed before and after exposure to cells. 
The delta % values for the nine repeats of each cell line were used as input for 
chemometric analysis. Using the XLSTAT 2011 program for Microsoft Excel 
(Addinsoft), Discriminant Analysis and Principal Component Analysis were performed 
on the data sets. DA was performed using linear functions (assumption that the within 
class covariance matrices are equal), taking into account the prior probabilities, and using 
a 5% significance level. Box’s test using the Fisher F asymptotic approximation showed 
that this assumption was valid. PCA was used to reduce the dimensionality of the 
multivariate data set using the correlation matrix (Pearson’s n), and the components that 
described at least 70% of the variance were retained for further analysis. Three-
dimensional score plots were created using the Statistica software package (Dell, 
formerly StatSoft). 
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Chapter 4: Glycoform Discrimination of Cell Surfaces 
4.1 BACKGROUND 
The cell surface is covered in a fuzzy, glycoprotein-polysaccharide coating known 
as the glycocalyx. Carbohydrates on glycolipids and glycoproteins contribute to cell-cell 
recognition, and the glycocalyx is important for organisms to distinguish healthy 
endogenous cells from diseased or exogenous cells. Changes in the glycocalyx of cancer 
cells that result in the presence of bulky glycoproteins help to increase integrin adhesion 
and signaling.1 Large glycoproteins are expressed on circulating tumor cells in patients 
with advanced disease, indicating that such glycocalyx changes are associated with 
cancer cell mobility and metastasis. The increase in size of tumor cell glycopeptides can 
be explained in part by the increase in β-1,6 branching of N-linked glycans.2 Other glycan 
changes that are associated with cancer include altered mucin glycosylation in 
carcinomas, increase in sialylation, overexpression of sialyl Lewis structures, and high 
expression of hyaluronan. 
Antibodies, lectins, aptamers, and small molecules have been developed as 
carbohydrate sensors. Small molecule synthetic molecular receptors have been developed 
that recognize carbohydrates through hydrogen bonding. These interactions are disrupted 
in aqueous media due to competition from solvent. However, in aqueous media boronic 
acids form reversible covalent bonds with hydroxyl groups, forming cyclic boronic or 
boronate esters with 1,2- and 1,3-diols, polyols, catechols, and α-hydroxyacids (Figure 
4.1).3 The covalent nature of the interaction allows for analyte binding in competitive 
media, and carbohydrates display many hydroxyls that are available for bonding with 
boronic acids. The binding of a monoboronic acid to sugars in solution is on the order of 
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102-103 M-1.4 The interaction of boronic acids with diols is dependent on the pKas of the 
boronic acid and of the diol, the pH of the solution, and sterics.5 1,2-diols that form 5-
membered rings react preferentially over the 6-membered ring forming 1,3-diols, and cis-
diols are preferred due to their more favorable complex conformation (see Figure 4.1). 
Increases in acidity of boronic acids can increase the association with diols. Electron 
withdrawing groups lower the pKa of boronic acids and therefore increase the affinity 
towards diols. The pKa of phenylboronic acid is 8.8, while the pKas of 3-
aminophenylboronic acid and 3-nitrophenylboronic acid are about 9 and 7, respectively. 
ortho-Aminomethylphenylboronic acid has a pKa value that is lower than expected based 
on the electron withdrawing ability of the substituents; this is due to the formation of a 
zwitterionic, ion paired species. Generally, ligands with higher acidity have more 
favorable association constants with boronic acids, but solution pH affects affinities of 
boronic acids for diols variably. The optimal binding does not necessarily occur at a pH 
above the pKa of the boronic acid, but instead usually occurs at a pH between the pKas of 
the boronic acid and the diol. Lowering the pKa of the boronic acid therefore should 
enhance the binding affinity for non-acidic carbohydrates at neutral pH.  
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Figure 4.1 Formation of boronic esters (A) and boronate esters (B) from 1,2- and 1,3-
diols. 
In general, monoboronic acid receptors display carbohydrate selectivity on the 
order of fructose > galactose > glucose > mannose.3 However, sugars are capable of 
forming a variety of structures in solution; pyranose, furanose, and open chain structures 
exist in equilibrium in aqueous solution as well as their α- and β-anomers. The preferred 
mode of boronic acid binding to sugars is not necessarily the preferred conformation in 
solution. For example, aromatic boronic acids have been shown to bind D-glucose in its 
furanose form,6 even though pyranose is largely (>99%) preferred in solution (Figure 
4.2). Glucose is able to form two boronate esters with two monoboronic acids in its α-
furanose form via bidentate interaction with the cis-hydroxyls at the 1,2-positions and 
tridentate interaction with the 3,5,6-hydroxyls, and this effect is achieved with only two 
equivalents of boronic acid. 
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Figure 4.2 The forms of glucose and their preferences at aqueous equilibrium (A) and the 
structure of a boronic acid complex with D-glucose, preferentially formed 
with the α-furanose form (B).6 
Both aryl boronic acids and alpha-amido boronic acids have been used to bind 
sugars in aqueous media, though the former sometimes suffer from low water solubility. 
On cell surfaces, sugars exist primarily in the pyranose form. Nevertheless, boronic acid-
based receptors have been developed to target saccharides on cells; the most effective of 
these are multivalent. The first instance of a such a receptor targeting cell surface sugars 
was a diboronic acid developed by Hageman et al. that was capable of agglutinating 
erythrocytes and therefore hypothesized to have functionality similar to a lectin.7 The 
Wang group reported the development of a different diboronic acid receptor that was 
selective for cell surface sialyl Lewisx.8 Although mannose and galactose display cis-
vicinal diols ideal for boronic acid complexation, arylboronic acids do not bind well to 
sugars in their pyranose form, and instead prefer the furanose form. Benzoboroxole-based 
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repectors have shown affinity for pyranosides in aqueous solutions at physiological pH 
due to their high Lewis acidity and hydrogen bonding capability.9 
 
4.2 INDICATOR DISPLACEMENT ASSAY FOR BORONIC ACID BINDING TO CELLS 
An array consisting of boronic acids of varying structure and pH indicators was 
developed for the discrimination of cancer cell glycocalyces. It was hypothesized that 
interaction of the cell surface with boronic acids would result in disturbance of the 
equilibrium of boronic acid-indicator complexes, resulting in a color change indicative of 
cell binding. The different boronic acids were hypothesized to have variable affinity for 
cell surfaces based on the boronic acid and glycocalyx structures and respective 
complementarity. Variable response of each boronic acid-indicator pair would provide a 
unique fingerprint for each cell type. 
Six commercially available boronic acids (4.1-4.6) displaying a variety of 
functionalites were chosen for the array (Figure 4.3). These boronic acids were combined 
with three commercially available indicators that contain catechols for binding boronic 
acids: Alizarin Red S (ARS), Pyrocatechol Violet (PV), and 4-methylesculetin (4ME). 
Benzoboroxole 4.5 was chosen because this type of boronic acid has been shown to bind 
pyranoside carbohydrates, like those on cell surfaces, in aqueous solutions. Other phenyl 
boronic acids have functional groups that contribute variably to the pKa, such as pKa 
elevating electron-donating groups (4.2, 4.6) and pKa lowering groups (4.1, 4.3). The 
non-aromatic 4.4 was chosen to provide hydrophobic contacts with the cell surface, 
despite its lower acidity (pKa 10.4).  
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Figure 4.3 The boronic acids and indicators selected for the glycocalyx-patterning array. 
4.2.1 Boronic Acid-Indicator Complexes 
Titrations of each of the catechol indicators with increasing equivalents of boronic 
acid were undertaken. The indicator concentrations were chosen such that their 
absorbance values fell within the range of 0.4 – 2.0 absorbance units in order to provide 
sufficient signal-to-noise ratios. Increasing equivalents of boronic acid resulted in a 
decrease in the free indicator peak and a simultaneous increase in the absorbance of the 
boronic acid-indicator complex. The presence of an isosbestic point was indicative of two 
absorbing species in solution. For ARS, this manifested as an increase at 460 nm, a 
decrease at 510 nm, and an isosbestic point at 480 nm (Figure 4.4). 
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Figure 4.4 Changes in the absorbance spectrum upon titration of 4.5 (0–1 mM) into ARS 
(200 μM) in 10 mM HEPES 0.1 M NaCl, pH = 7.4 (left). The free indicator 
and complex absorbances are plotted as a function of equivalents of boronic 
acid relative to indicator (right). 
Fitting of the absorbance increase at 460 nm and the absorbance decrease at 510 
nm using a 1:1 binding model lead to an estimation of the association constant between 
4.5 and ARS on the order of 2×103 M-1. The magnitude of this binding constant is in 
agreement with literature values for association of monoboronic acids with diols in 
neutral aqueous solution. 
4.2.2 Indicator Displacement 
Increasing numbers of cells were added to boronic acid-indicator complexes in 
order to investigate the displacement of indicator upon binding of boronic acids to cell 
surfaces. The absorbance values for the displacement were compared to those of cells 
added to free indicator. Addition of cells to free indicator resulted in a uniform increase 
in absorbance associated with the cell density (Figure 4.5). This is due to the light 
scattering of the cell suspension. The same effect was observed when cells were added to 
the boronic acid-indicator complex (Figure 4.6). 
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Figure 4.5 Increase in absorbance of free ARS (200 μM) upon addition of increasing 
number of cells in 10 mM HEPES 0.1 M NaCl, pH = 7.4. 
 
Figure 4.6 Increase in absorbance of boronic acid-indicator complex of 4.5 (800 μM) 
with ARS (200 μM) upon addition of increasing cells in 10 mM HEPES 0.1 
M NaCl, pH = 7.4. 
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The extent of scatter and absorbance increase differed by cell line for the same 
number of cells added. This resulted in unique absorbance intensities of indicators for 
each of the cell lines. The absorbance values of the boronic acid-indicator complexes also 
displayed intensity differences for each cell line. Although the intensities were perhaps 
diagnostic, these differences were not due to the expected indicator displacement. The 
ratio of absorbance intensity of the free indicator and the boronic acid indicator at their 
respective λmax was plotted for each cell line and compared to the values without cells 
(Figure 4.7). The intensity of the free indicator peak should increase relative to that of 
bound indicator if indicator displacement occurs. This would manifest as an increase in 
the ratio of the λmax intensities. It was clear from Figure 4.7 that displacement of the 
indicator was not occurring as the ratio of intensities actually decreased across all cell 
lines. Such an observation may be due to differential changes in molar absorptivites of 
the free indicator and the indicator-boronic acid complex in the presence of cells, such 
that the boronic-acid indicator complex shows a larger change in molar absorptivity. It is 
also likely that indicator displacement does not occur because interaction of the 
monoboronic acid with cell surface sugars in competitive media is much weaker than 
indicator complexation. 
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Figure 4.7 Ratio of the λmax intensities of ARS and ARS complexed with 4.5 in 10 mM 
HEPES 0.1 M NaCl pH= 7.4 with cells of different tissue type added. Error 
bars show the standard deviation of the ratios of three measurements on cell-
free solutions, which are indicative of the errors associated with the 
absorbance measurements. 
It was hypothesized that increasing the concentration of cells relative to the 
boronic acid indicator complex would make boronic acid binding to the cell surfaces 
more favorable compared to indicator complexation, despite the differences in affinity. 
Therefore, an indicator uptake experiment was undertaken at low indicator and boronic 
acid concentrations. Indicator solutions were added to solutions of boronic acids and cells 
or free boronic acid. The absorbance intensity changes of these two titrations were 
compared. It was hypothesized that the uptake of indicator, measured by the appearance 
of boronic acid-indicator complex, would be different in the presence of cells if boronic 
acid binding to cell surfaces was occurring. Even using experimental conditions that 
favored cell binding, there was no appreciable difference in the indicator uptake in the 
presence of cells, as evidenced by similar absorbance values with and without cells 
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(Figure 4.8). Indicator uptake did not result in appreciable formation of boronic acid-
indicator complex in either case. 
 
Figure 4.8 Indicator uptake of PV with 100 μM 4.5 in the presence or absence of 50,000 
MOLT-4 cells in 10 mM HEPES 0.1 M NaCl, pH = 7.4. 
 
4.3 FLUORESCENCE RESPONSE OF CANCER CELLS TO A LYSINE-LINKED AROMATIC 
BORONIC ACID  
The synthesis-free array of commercially available boronic acids with indicators 
developed above could not produce reliable signals of hypothesized boronic acid binding 
to cell glycocalyces. A more synthetically intense route, where a boronic acid was 
conjugated to a fluorescent indicator, is presented below. Conjugation of ortho-
bromomethylboronic acid to a derivative of the DNA intercalator thiazole orange, TO1, 
allows for assembly of the boronic acid onto a DNA scaffold that can present multiple 
binding units that should increase the association with cell surfaces compared to 
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monoboronic acids. Additionally, signals can be generated by measuring fluorescence 
emission upon association of the boronic acid with cell surfaces. 
TO1 was conjugated to an Mtt-protected lysine Wang resin, then deprotected and 
reacted with ortho-bromomethylboronic acid (Scheme 4.1). Cleavage from the resin and 
HPLC purification produced BALysTO1. The amino acid conjugate was used in 
combination with 1 kb dsDNA and incubated with cancer cells of different tissue type at 
37°C for 40 minutes. The fluorescence response of the bound boronic acid was recorded 
for each cell type, and normalized to the starting fluorescence of the free solution (Figure 
4.9).  
 
 
Scheme 4.1 Solid phase synthesis of BALysTO1 using Fmoc chemistry and a Wang 
resin. 
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Figure 4.9 The average fluorescence response of BALysTO1 (30 μM) with and without 1 
kb dsDNA (4 nM) to seven different cell lines in DPBS pH=7.4. 
The cell line that exhibited the greatest fluorescence response was 786-O, a renal 
carcinoma. Other cell lines resulted in similar responses to each other. Plotting the 
relative emission with and without DNA showed some cell classification ability based on 
response to the boronic acid conjugate (Figure 4.10). 
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Figure 4.10 Classification of cells from their fluorescence response to BALysTO1 with 
or without 2.5 kb dsDNA. Inset: Classification of the six cell lines with 
more similar responses. 
 
4.4 FLUORESCENCE ACTIVATED CELL SORTING OF ENZYME-TREATED CELLS 
4.4.1 Titrations with 50 base DNA single strands 
Single strands of DNA were randomly generated to have 50% GC content, and 
two fifty-base sequences were chosen that displayed high and low self-complementarity 
(Figure 4.11). The intercalation of BALysTO1 into each of these strands was studied. As 
expected, the fluorescence emission from the high double-strand sequence was higher 
than that of the less self-complementary sequence, due to greater intercalation (Figure 
4.12).  
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Figure 4.11 High double stranded and low double stranded 50-base ssDNA. 
 
Figure 4.12 Titration of ssDNA sequences of high and low double stranded character 
with BALysTO1 in DPBS, pH=7.4. 
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4.4.2 Glycosidase treatment of cells 
It was hypothesized that boronic acid binding to cell surfaces would be modulated 
by cell surface sugar expression. Glycosidases are enzymes that remove carbohydrates 
from glycoproteins. Two types of glycosidases exist that either remove oligosaccharides 
conjugated to proteins or lipids (endoglycosidases) or remove monosaccharides from a 
terminal residue or non-reduced end (exoglycosidases). O-glycosidases remove sugars 
that are linked to proteins through the hydroxyl of a threonine or serine residue, while N-
glycosidases remove sugars that are linked via asparagine. 
In order to test the effect of sugar density on boronic acid receptor binding, four 
enzymes were chosen to remove sugars from cell surface glycans: neuraminidase, O-
glycosidase, PNGase F, and mannosidase. Neuraminidase is an exoglycosidase that has 
specificity for hydrolysis of terminal sialic acid residues that have α-linkages with any 
sugar hydroxyls at the 2-, 6-, or 8-position. Sialic acids are overexpressed on metastatic 
cancer cell surfaces, resulting in increased negative surface charge. They are the terminal 
residues on sialyl Lewisx; this tetrasaccharide is overexpressed on cancer cells and found 
on both N- and O-linked glycans. O-glycosidase is an endoglycosidase that hydrolyzes 
core 1 and core 3 O-linked disaccharides, detaching polysaccharides from proteins by 
hydrolyzing the bond to a threonine or serine residue. Core 1 linked saccharides are 
attached to protein-linked N-acetylgalactosamine (GalNAc) via a β-1,3 linkage to 
galactose (Figure 4.13). Core 3 linked saccharides are attached to GalNAc via a β-1,3 
linkage to N-acetylglucosamine (GlcNAc). O-glycosidase is used in conjuction with 
neuraminidase because sialic acid residues must be removed for the enzyme to function. 
PNGase F catalyzes the hydrolysis of N-linked glycans by cleaving between GlcNAc and 
asparagine (Figure 4.14). This enzyme can be used with high mannose, hybrid, and 
complex oligosaccharides. High mannose oligosaccharides have branching of additional 
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terminal mannose residues linked from the mannotriose. Hybrid oligosaccharides contain 
terminal mannose branches as well as further substituted branches from GlcNAc 
antennae attached to the α-1,3 and α-1,6 mannoses. Complex oligosaccharides do not 
contain terminal mannose residues but instead display a variety of monosaccharides 
branched from GlcNAc antennae; these oligosaccharides usually terminate with sialic 
acid residues. Mannosidase is an exoglycosidase that catalyzes hydrolysis of mannose on 
glycoproteins. The mannosidase used in these studies is capable of hydrolyzing α-1,2 and 
α-1,3 linked mannose on high mannose and hybrid oligosaccharides. 
 
Figure 4.13 Core 1 and core 3 linked residues targeted by O-glycosidase. 
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Figure 4.14 N-linked glycans contain a core trimannose linked to a GlcNAc dimer.  
4.4.3 FACS response of cells to BALysTO1 
Cells were treated with enzymes and then incubated with BALysTO1 intercalated 
into high double-stranded (high ds) or low double-stranded (low ds) ssDNA. 
Fluorescence measurements were made on individual cells using flow cytometry and the 
population fluorescence plotted and compared for each enzyme treatment and each 
receptor incubation condition. The fluorescence response of the receptors changed the 
most when incubated with mannosidase-treated cells, when compared to their 
fluorescence with DPBS-treated cells, resulting in a fluorescence increase (Figure 4.15). 
The response of low ds ssDNA, high ds ssDNA, and DNA-free BALysTO1 to the two 
cell lines was variable. The positively charged free dye exhibited the highest 
fluorescence, while the presence of DNA lead to decreased binding likely due to the 
negative charge of the strands. The low ds sequence showed a higher fluorescence than 
the high ds sequence for MOLT-4 and this response was switched for SK-OV-3. SK-OV-
3 also showed a greater fluorescence increase with BALysTO1-based receptors than 
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MOLT-4. SK-OV-3 cells have been shown to exhibit a large amount of high-mannose N-
glycans, implicating these structures as potential markers for ovarian cancer.10  
  
Figure 4.15 Cumulative density function (CDF) of fluorescence response of BALysTO1 
with MOLT-4 (left) and SK-OV-3 (right) cells treated with mannosidase.  
Hydrolyzing native proteins on cell surfaces can require increased reaction times 
and enzyme concentrations. When MOLT-4 cells were treated with higher concentrations 
of the least responsive enzymes, neuraminidase, O-glycosidase, and PNGase F, new 
fluorescence responses were observed. For the high double-stranded DNA, 
neuraminidase gave a slight decrease in fluorescence compared to the DPBS treated 
sample (Figure 4.16) O-glycosidase, PNGase F, and mannosidase all resulted in 
fluorescence increases compared to non-enzyme treated cells. Increase in the 
concentration of PNGase F resulted in the death of all sample cells, which exhibit large 
emissions with TO1 derivatives. The fluorescence increase of live cells was larger for 
mannosidase than that of O-glycosidase. 
 180 
 
Figure 4.16 CDF plots of MOLT-4 cells treated with different enzymes and incubated 
with BALysTO1 and high ds ssDNA. 
 Treatment of cells with neuraminidase removes sialic acid residues that lead to a 
negatively charged cell surface. This may be the reason why the positively charged 
BALysTO1 exhibits a slight decrease in fluorescence when incubated with 
neuraminidase treated cells. However, this receptor is intercalated into a negatively 
charged DNA scaffold. It is therefore more likely that this boronic acid has affinity for 
sialic acid residues, which contain free 1,2 diols that can bind to boronic acid receptors. 
Removal of these sugars would result in lower binding and thus lower fluorescence. The 
negative change in fluorescence with this enzyme treatment group is small, and could 
therefore be insignificant; however, it was observed both with high ds and low ds 
ssDNAs. 
Treatment with O-glycosidase should result in the removal of oligosaccharides to 
reveal a free serine or threonine hydroxyl. It was hypothesized that removal of sugars 
would lead to decreased boronic acid binding and decreased fluorescence. The increase in 
fluorescence when cells are treated with O-glycosidase does not support this hypothesis, 
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but instead indicates that removal of O-linked glycans increases the affinity of the 
receptor for cells. Removal of O-linked oligosaccharides could give the boronic acid 
access to cell surface features for which it has higher affinity. 
Removal of α-1,2 and α-1,3 linked mannose from high-mannose and hybrid 
glycans was also hypothesized to result in decreased affinity of the boronic acid receptor 
for the cell surface and decreased fluorescence. The fluorescence increase observed could 
be due to easier access of the receptor to mannose residues as the enzyme should remove 
branching that may cause hindrance to boronate ester formation.  
 
4.5 CONCLUSION 
An array of commercially available boronic acids and indicators was tested for 
responsiveness to cell surface sugars. Boronic acid indicator complexes did not exhibit 
absorbance changes in the presence of cells. This is likely due to the weaker association 
of monoboronic acids with cell surface sugars in competitive media compared to the 
association with catechol indicators at the concentrations necessary to observe indicator 
absorbance. 
Receptor assemblies of a boronic acid conjugated to a lysine derivative of 
fluorescent intercalator TO1, BALysTO1, were better at signaling binding to cells. 
Intercalation of BALysTO1 into a 1 kb dsDNA was used to assemble a multivalent 
receptor for patterning cell surface glycocalyces. The fluorescence response with and 
without DNA was used to classify cell lines. 
The response of two cell lines tested, SK-OV-3 and MOLT-4, to receptor 
assemblies composed of ssDNA and boronic acid-derived intercalators was shown to be 
differential in initial cytometry experiments. Although enzyme treatment did not result in 
 182 
the hypothesized fluorescence responses based on theorized interactions of boronic acid-
based receptors with cell surface glycans, the response of the receptors in initial 
experiments has the potential to be diagnostic of cell type. Using the boronic acid-based 
receptor assemblies, such glycocalyx patterning can be undertaken on whole cells instead 
of cell lysates. This gives the advantage of measuring cell surface properties while the 
cells are still alive. Further cytometry experiments will be undertaken on additional cell 
lines. 
 
4.6 EXPERIMENTAL 
4.6.1 IDA 
Cells were grown as detailed in chapter 3. Cells in the growth phase (n=5-15) 
were detached, if necessary, and counted on a hemacytometer. Appropriate numbers of 
cells for each experiment were pelleted and their growth media removed. The cells were 
then washed with DPBS and again pelleted. After DPBS removal, cells were taken up in 
10 mM HEPES with 0.1 M NaCl at pH = 7.4. 
Boronic acids and indicators were procured from various sources (Sigma-Aldrich, 
Acros, TCI America) and used without further purification.  
Absorbance measurements were made on a Cytation3 Microwell Plate Reader 
from BioTek measuring 300 – 700 nm at 10 nm intervals. Clear-bottomed black well 
plates were procured from Grenier (384-well) and Costar (96-well). 
4.6.1.1 Boronic Acid and Indicator Titrations 
Stock solutions of indicators were prepared in 10 mM HEPES 0.1 M NaCl at a pH 
= 7.4. These solutions were diluted in the same buffer to a concentration of 500 μM and 
used for titrations. Stock solutions of boronic acids were prepared at concentrations 
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greater than 2 mM in the same buffer as indicators, with DMSO added as needed for 
solubility. These solutions were diluted to 2 mM for use in titrations. 
Increasing equivalents of boronic acid were added to indicator solutions at 250 
μM (ARS), 200 μM (PV), or 75 μM (4ME) and absorbance values were recorded. 
Plotting the absorbance changes of the free indicator and the indicator-boronic acid 
complex allowed for determination of binding equivalents for each boronic acid-indicator 
pair. These equivalents were used for indicator displacement studies with cells. 
Titrations with ARS 
 
Figure 4.17 Titration of 4.1 into ARS in 10 mM HEPES 0.1 M NaCl pH = 7.4. 
 
Figure 4.18 Titration of 4.2 into ARS in 10 mM HEPES 0.1 M NaCl pH = 7.4. 
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Figure 4.19 Titration of 4.3 into ARS in 10 mM HEPES 0.1 M NaCl pH = 7.4. 
 
Figure 4.20 Titration of 4.4 into ARS in 10 mM HEPES 0.1 M NaCl pH = 7.4. 
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Figure 4.21 Titration of 4.6 into ARS in 10 mM HEPES 0.1 M NaCl pH = 7.4. 
Titrations with PV 
  
Figure 4.22 Titration of 4.1 into PV in 10 mM HEPES 0.1 M NaCl pH = 7.4. 
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Figure 4.23 Titration of 4.2 into PV in 10 mM HEPES 0.1 M NaCl pH = 7.4. 
 
Figure 4.24 Titration of 4.3 into PV in 10 mM HEPES 0.1 M NaCl pH = 7.4. 
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Figure 4.25 Titration of 4.4 into PV in 10 mM HEPES 0.1 M NaCl pH = 7.4. 
 
 
Figure 4.26 Titration of 4.5 into PV in 10 mM HEPES 0.1 M NaCl pH = 7.4. 
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Figure 4.27 Titration of 4.6 into PV in 10 mM HEPES 0.1 M NaCl pH = 7.4. 
Curve Fitting of 4.5 with ARS 
Titration data were expressed as delta absorbance values at 460 nm and 510 nm. 
The absorbance change at 510 nm was negative, so these values were multiplied by -1 in 
order to generate positive numbers. These values were plotted against the concentration 
of boronic acid in mM. Curve fitting was undertaken using OriginLab® 8.1 with a 
custom parameterized equation derived from 1:1 binding thermodynamics (equation 
4.1).11 
dA = de*(Rt*10-3)/(2/(K*(It*10-6)-1-K*(Rt*10-3)+((1-K*(It*10-6)+K*(Rt*10-
3))^2+4*K*(It*10^-6))^0.5)+1)     (equation 4.1) 
In this equation, dA are the delta absorbance values (y-values), Rt are the host 
concentrations at a particular dA (x-values). The parameters that can be fit are the molar 
absorptivity (de), the guest concentration (It), and the binding constant (K). Any of these 
parameters can also be fixed, provided the values are known.  
The indicator concentration was input in μM and not allowed to vary, while the 
indicator or indicator-boronic acid complex molar absorptivity and the binding constant 
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were allowed to freely vary. Convergence was reached when the Chi-squared tolerance 
was less than 1×10-9. The curve fit and parameter results are shown in Figure 4.28. 
 
 
de K It 
Adj. R-
Square 
460 
nm 803±87 
2431±63
1 200 0.98194 
510 
nm 
1337±15
2 
1367±29
8 200 0.99059 
Figure 4.28 Iterative curve fitting of titration of ARS (200 μM) with 4.5 (0-1 mM) in 
10mM HEPES 0.1 M NaCl pH=7.4 at 460 nm and 510 nm using a 
parameterized equation. 
4.6.1.2 Titration of Boronic Acid-Indicator Complexes with Cells 
Using the results of the boronic acid-indicator titrations, boronic acid-indicator 
complexes were prepared at approximately 90% saturation so that the cells and indicators 
could compete for boronic acid binding. Stock solutions of 400 uM ARS or PV with 1 
mM boronic acids 3.1-3.6 were prepared in 10 mM HEPES 0.1 M NaCl pH=7.4. These 
solutions were added to 384-well plates and increasing volumes of a cell suspension 
solution (5000 cells/uL) were added. Each well was filled with HEPES buffer to a 
volume of 50 uL such that the final concentration of dye was 200 uM. Cells were added 
to boronic acid-free solutions for comparison. 
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Figure 4.29 ARS and boronic acid-bound ARS without any cells. 
 
Figure 4.30 Responses of increasing SK-OV-3 to 4.2-ARS (left) and 4.5-ARS (right). 
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Figure 4.31 Responses of increasing MOLT-4 to 4.2-ARS (left) and 4.5-ARS (right). 
 
Figure 4.32 Responses of increasing DU-145 to 4.2-ARS (left) and 4.5-ARS (right). 
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indicator uptake was therefore prepared with 50,000 cells per well at a concentration of 
100 uM BA. Indicator concentrations again ranged from 0-250 uM. 
4.6.2 Fluorescence of BALysTO1 
4.6.2.1 Synthesis 
BALysTO1 was synthesized manually using an Fmoc Wang resin of lysine, 
protected with methyl trityl (Mtt). The resin, 282.8 mg, was swelled in DMF overnight. A 
20% piperidine solution in DMF (5 mL) was added to the resin to deprotect the Fmoc. 
The resin was deprotected for 30 mins, then washed 3x DMF, 2x DCM, 2x MeOH (10 
mL each). A coupling solution containing TO1 (130.85 mg, 2.1 equivs), DIPEA (80.5 
mg, 4.1 equivs), and PyBOP (165 mg, 2.1 equivs) in DMF was added to the deprotected 
resin and allowed to react overnight. The coupling solution was removed, the resin was 
washed as above, and the lysine Mtt protection group was removed by shaking the resin 
in a solution of 5% TFA and 5% TIPS (v/v) in DCM. The deprotection solution turned 
yellow after 10 minutes and was removed. Two more aliquots of deprotection solution 
were reacted in this manner. The deprotected resin was again washed and a coupling 
solution containing o-bromomethylboronic acid (130.68 mg, 4.1 equivs), DIPEA (78.75 
mg, 3.99 equivs) in DMF was added and the resin was shaken overnight. The boronic 
acid coupling solution was removed, the resin was washed, and then dried overnight 
under high vacuum. A cleavage cocktail of 95% TFA, 2.5% TIPS, 2.5% H2O was used 
to cleave BALysTO1 from the Wang resin by shaking for four hours. The liquid was 
separated from the resin, rotavaped to remove TFA, and BALysTO1 was precipitated by 
adding cold ether.  
Prep HPLC was performed on a Shimadzu instrument on a C-18 column. 
BALysTO1 was dissolved in MeOH and separated using a gradient of acetonitrile and 
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water as follows: 0-30 min, 5-75% MeCN in H2O; 30-40 min 95% MeCN. The peak with 
absorbance at 500 nm was collected and analyzed using LC/MS. ES-APCI + showed a 
masses at m/z 621.8, 320.0, and 311.2. These correspond to expected m/z 621.3 (M-
H2O)+, 320.1 (M+H)2+, and 311.1 (M-OH)2+. 
4.6.2.2 Titration of BALysTO1 into 1 kb dsDNA 
1 kb dsDNA was prepared as outlined in section 3.4. Increasing volumes of a 
stock solution of BALysTO1 (50 uM in DPBS) were added to 1 kb dsDNA and diluted 
with DPBS to a final volume of 100 uL in each well such that the dsDNA concentration 
was 4 nM. The BALysTO1 concentration varied from 0 – 30 uM.  
 
Figure 4.33 Titration of BALysTO1 into 1 kb dsDNA (4 nM) in DPBS at pH = 7.4 
4.6.3 FACS 
4.6.3.1 Solution Preparation and Enzyme Digestion 
Stock solutions of ssDNA were prepared by diluting oligonucleotides ordered 
from IDT to a concentration of 100 μM in ddH2O. A stock solution of 357.85 μM 
BALysTO1 was prepared by diluting the solid amino acid conjugate with 2 mL DPBS. 
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Solutions of ssDNA and BALysTO1 were prepared using the stocks at 1 μM each in 
DPBS and incubated at 4°C overnight.  
An aliquot of suspension cells was removed from the culture flask after aspiration 
and counted on a hemacytometer. Cells were stained with 2X trypan blue to identify 
viability. The hemacytometer provides four replicates of measurements in a 10 uL sample 
of cells by measuring the cells in 1 mm2 and a volume of 0.1 uL. The amount of cells in 1 
cm3 (1 mL) is calculated after averaging the cell counts, multiplying for the dilution 
factor, and multiplying by 10,000. For adherent cells, T-75’s grown to confluency were 
trypsinized with 2 mL 0.25% trypsin/EDTA. 3 mL appropriate growth media was added, 
the cell suspension aspirated, and an aliquot of cells counted on a hemacytometer. 
Appropriate volumes of cells were removed from suspension such that each enzyme 
treatment group would have 1×106 cells. Cells were pelleted at 175 × g and then taken 
into DPBS and split into 2 mL DNA LoBind eppendorf tubes such that each tube 
contained 1×106 cells. Cells were again pelleted, DPBS removed, and the appropriate 
amount of recommended enzyme buffer added to the solution, along with the following 
amounts of enzymes (Table 4.1): 
 
Enzyme Low (U) High (U) 
Neuraminidase 50 400 
O-glycosidase 40,000 400,000 
PNGase F 500 3,000 
α-1-2,3-mannosidase 160 128 
Table 4.1 Enzyme concentrations per 1×106 cells used in low enzyme and high enzyme 
experiments. 
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Solutions of cells and enzymes, along with a DPBS control solution, were 
incubated at 37°C for four hours. After incubation, cells were pelleted, taken up into 
DPBS and split into equal volumes for incubation with receptor. These aliquots were 
pelleted and 100 uL of BALysTO1 receptor solutions were added. The receptor was 
incubated with cells for 30 min at 37°C. Each enzyme treatment group was also 
incubated with a DPBS control and a dead cell stain (LIVE/DEAD® Fixable Red Dead 
Cell Stain, Life Technologies). After incubation cells were pelleted and taken up into 500 
uL DPBS, transferred to FACS tubes (BD Falcon 352052), and fluorescence values 
measured.  
4.6.3.2 Flow Cytometry 
Flow cytometry measurements were made using a BD LSRFortessa™ cell 
analyzer with laser excitation at 488 nm and emission recorded at 519 nm (FITC) and 
695 nm (PerPE Cy 5.5) for TO1 and dead cell stain, respectively. Flow cytometry 
solutions were prepared in DPBS without calcium and magnesium. A minimum of 1,000 
cells was recorded per experiment, but most experiments used 5,000-10,000 cells per 
sample. Voltages for FSC, SSC, FITC, and PerPE Cy 5.5 were adjusted to place the 
sample population appropriately on the dot plot. FSC and SSC values had to be adjusted 
for each cell line. FITC was adjusted so that the DPBS-only treated sample had an 
emission at 0, while PerPE Cy 5.5 voltage was adjusted so that both dead and live cell 
populations appeared on the fluorescence dot plot. 
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